Colorectal endoscopic submucosal dissection at a low-volume centre: tips and tricks, and learning curve in a district hospital in Hong Kong

Hong Kong Med J 2016 Jun;22(3):256–62 | Epub 6 May 2016
DOI: 10.12809/hkmj154736
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
ORIGINAL ARTICLE
Colorectal endoscopic submucosal dissection at a low-volume centre: tips and tricks, and learning curve in a district hospital in Hong Kong
Deon HM Chong, FRCSEd; CM Poon, FRCSEd; HT Leong, FRCSEd
Department of Surgery, North District Hospital, Sheung Shui, Hong Kong
 
Corresponding author: Dr HT Leong (lamyn@ha.org.hk)
 
 Full paper in PDF
 
Click here to watch a video clip showing colorectal endoscopic submucosal dissection
 
Abstract
Introduction: Colorectal endoscopic submucosal dissection is not a widely adopted procedure due to its technical difficulties. This study aimed to share the experience in setting up this novel procedure and to report the learning curve for such a procedure at a low-volume district hospital in Hong Kong.
 
Methods: This case series comprised 71 colorectal endoscopic submucosal dissections that were performed by a single endoscopist without experience in gastric or colorectal endoscopic submucosal dissection. Lesion characteristics, procedure time per unit area of tumour, en-bloc resection rate, R0 resection rate, complications, and length of stay were recorded prospectively. Results were compared for two consecutive periods to study the learning curve.
 
Results: Overall, 41 (57.7%) tumours were located in the right colon, 21 (29.6%) in the left colon, and nine (12.7%) in the rectum. The median tumour area was 4 cm2 (range, 0.25-16 cm2). The median operating time was 105 (range, 47-342) minutes. The median procedure time per unit area of tumour was 24.9 min/cm2. There was one instance of intra-operative bleeding that required conversion to laparoscopic colectomy. There was no postoperative haemorrhage. The overall perforation rate was 15.5%, in which one required conversion to laparoscopic colectomy. The overall morbidity rate was 16.9% and there was no mortality. The median hospital stay was 1 day (range, 0-11 days). The overall en-bloc resection rate and R0 resection rate was 81.2% and 58.0%, respectively. Comparison of the two study periods revealed that procedure time per unit area of tumour decreased significantly from 31.5 min/cm2 to 21.5 min/cm2 (P=0.032). The en-bloc resection rate improved from 78.8% to 83.3% (P=0.15). The R0 resection rate improved significantly from 39.4% to 75.0% (P<0.01).
 
Conclusion: Untutored colorectal endoscopic submucosal dissection is feasible with acceptable clinical outcomes at a low-volume district hospital in Hong Kong.
 
New knowledge added by this study
  • Untutored colorectal endoscopic submucosal dissection (ESD) has an acceptable clinical outcome after 35 procedures at a low-volume centre.
Implications for clinical practice or policy
  • ESD can be safely performed at a low-volume centre.
  • ESD can be started at the colorectum instead of the stomach.
 
 
Introduction
For many years, conventional endoscopic mucosal resection (EMR) and surgery were the only options for treating a large (>20 mm) sessile or flat colorectal lesion. Conventional EMR, however, often results in piecemeal removal and there is a significant local recurrence rate ranging from 7.4% to 17%.1 2 3 Full histological evaluation is also difficult.
 
Endoscopic submucosal dissection (ESD), pioneered in Japan for treating early upper gastro-intestinal malignancy, was introduced in the late 1990s by Yamamoto et al4 and Fujishiro et al5 to treat colorectal lesions. The technique has an advantage over EMR in that its effectiveness is not limited by size or shape of the lesion. In the past decade, colorectal ESD has been shown to be superior to EMR, in terms of higher en-bloc resection rate and lower recurrence rate.6 Colorectal ESD can be applied not only to adenoma, but also to intramucosal carcinoma and low-risk submucosal carcinoma, as defined by the Paris classification7 and the Japanese Society for Cancer of the Colon and Rectum.8 Recently, a large-scale multicentre study has shown that ESD alone is adequate in the management of patients with low-risk submucosal carcinoma and achieves an excellent 5-year recurrence-free survival of 98% and 5-year overall survival of 94%.9
 
Despite the growing evidence to support the use of colorectal ESD, it is not established as a standard treatment outside Japan. The drawbacks of colorectal ESD include longer operating time6 and higher complication rates, especially perforation. Although the perforation rate of ESD is much higher than that of EMR, most ESD perforations can be treated conservatively by clip closure during endoscopy.10 11 In a multicentre study of iatrogenic perforations in Japan, the respective EMR and ESD perforation rate was 0.58% and 14% in 15 160 therapeutic colonoscopies.12 Endoscopic clipping failed in 43.5% of ESD perforations and surgical intervention was necessary.12
 
Perhaps one of the major hurdles to its general application is that it is a technically demanding procedure that is difficult to set up at a low-volume district hospital. We would like to share our experience of applying this novel technique in a district hospital in Hong Kong.
 
Methods
Case selection
North District Hospital was a district hospital serving 700 000 population with a case volume of 15 to 20 cases of ESD per year. Since the introduction of the ESD technique at the hospital in 2009, all lateral spreading tumours larger than 2 cm or those unable to be resected en bloc by conventional polypectomy were referred to a single endoscopist to determine the appropriateness of ESD. Colonoscopy was repeated by a single endoscopist to determine the location, size, and nature of each tumour by white-light and narrow band imaging (NBI). Benign polyps not amendable to removal by EMR were triaged to ESD. Target biopsy was performed on Sano III lesions that were triaged to conventional laparoscopic colectomy. No tumours were excluded based on location.
 
Preoperative evaluation of the depth of invasion
Evaluation of the depth of invasion is important to determine the treatment strategy. To predict the depth of invasion, we used NBI colonoscopy, based on Sano’s capillary pattern classification. The underlying principle is that angiogenesis is critical for transition of a premalignant lesion to a malignant one and the microcapillary pattern changes in this process. Sano et al13 focused on this microcapillary difference based on their histopathological findings and devised three classifications: types I, II, and III. Type III was further subdivided into IIIA and IIIB.14
 
The diagnostic accuracy of NBI colonoscopy in differentiating a neoplastic from non-neoplastic lesion is superior to conventional colonoscopy and equivalent to chromoendoscopy using indigocarmine.15 For estimation of the depth of invasion, the sensitivity, specificity, and diagnostic accuracy of capillary pattern type III for differentiating pM-ca (intramucosal) or pSM1 (superficial) from pSM2-3 (deep) was 84.8%, 88.7% and 87.7%, respectively.14 We preferred NBI colonoscopy because it is fast and easy to use, without the need to spray dye as in chromoendoscopy.
 
Preparation
The procedure was performed in the operating theatre with the patient under conscious sedation. All patients were assessed by an anaesthetist in a preoperation clinic.
 
Patients were instructed to eat a low-residue diet 2 days before the procedure and a fluid diet on the day before ESD. Bowel preparation with 4 L polyethylene glycol solution was given on the day before ESD. Prophylactic antibiotics were not prescribed.
 
Setting
All procedures were performed in the operating theatre. This ensured that all equipment was on hand should conversion to an open procedure be required, for example, if there was full-thickness perforation that could not be closed endoscopically.
 
Endoscopic system
In our hospital, ESD was performed using a single-channel colonoscope (CF-H180AL; Olympus, Tokyo, Japan). This colonoscope was a high-density television compatible with a wide angle of 170°, 3.7-mm instrument channel, and auxiliary water jet. A short transparent hood was fitted to the tip of the endoscope so that the whole ring could be seen in endoscopic view. Carbon dioxide was used for insufflation to decrease patient discomfort. We used a high-frequency electrosurgical generator (ESG-100; Olympus, Tokyo, Japan) with a peristaltic pump (AFU-100; Olympus, Tokyo, Japan). The energy setting used for incision and dissection was “forced coagulation 2” 30W, whereas “soft coagulation” 100W was used for haemostasis.
 
Cutting devices
In our initial practice, we used the Flex Knife (KD-630L; Olympus, Tokyo, Japan) to perform the procedure. It had a loop-shaped tip that allowed easy control in any direction, as it was soft and flexible. Nonetheless, we found it difficult to adjust the length of the tip and there was frequent accumulation of debris around the tip. We then changed to Dual Knife (KD-650L; Olympus, Tokyo, Japan) with a fixed length (1.5 mm) and hence a more stable knife movement. More recently, we have used Flush Knife BT (DK2618JB/DK2618JN; Fujifilm, Saitama, Japan) for dissection. It has a ball tip of fixed length that touches a wider part of tissue and enhances haemostasis. The knife has a water jet channel and achieves two purposes: (1) it can wash away any tissue that accumulates around the tip, thereby maintaining the sharpness of the knife; and (2) submucosal normal saline injection can be performed without the need to change the instrument for further hyaluronate injection.
 
Injecting agent
We used a mixture of 10% sodium hyaluronate (LG Chemical, South Korea) and 1:200 000 adrenaline saline at a ratio of 1:1.5. This solution was chosen for three reasons: the addition of adrenaline can produce a haemostasis effect; dilution of sodium hyaluronate made it less viscous and thus easier to inject; and it reduced the amount used of the relatively more expensive sodium hyaluronate.
 
Endoscopist
All ESD procedures were performed by a single experienced endoscopist who had performed more than 500 therapeutic colonoscopic procedures and more than 200 laparoscopic colectomies. The ESD procedure was implemented by the endoscopist following completion of training on an animal model in the Second Master Workshop on Novel Endoscopic Technology & Endoscopic Submucosal Dissection in 2009 at Prince of Wales Hospital in Hong Kong, which was organised by the Department of Surgery, The Chinese University of Hong Kong (http://www.surgery.cuhk.edu.hk/events/2009-07-22-ESD.pdf). The workshop included both lecture sessions and hands-on sessions to perform ESD in a pig. The endoscopist had no experience in gastric or colorectal ESD. He received further overseas training in ESD in 2011 at Osaka Medical Center for Cancer and Cardiovascular Diseases in Japan as a clinical observer with hands-on animal model training.
 
Procedure
With the patient initially lying in the left lateral position, a full colonoscopy was first performed to confirm and locate the site of pathology. Patients were then re-positioned such that the lesion was at an anti-gravitational position in the endoscopic view at 6 o’clock. This could be easily achieved by seeing the injected water pooling opposite to the lesion. In this position, the gravitational force aided in retracting the lesion away from the submucosal plane during dissection. We then injected 1:100 000 adrenaline saline at 1 cm distal to the lesion, aiming at the submucosal layer. This could be ascertained by seeing the formation of a dwell. With the injecting needle still in situ, the solution was then changed to the mixture of adrenaline saline and sodium hyaluronate to provide a precipitous elevation of sufficient height. After elevating the lesion, a mucosal incision was made proximal to the lesion. The mucosal incision was started at the proximal two thirds of the lesion. After mucosal incision, the submucosal plane was dissected with the submucosa dissected away from the muscle layer. Care was taken to manipulate the dissection plan parallel to the intestinal wall to prevent perforation. When a more than 1-mm diameter vessel was detected, it was coagulated using haemostasis forceps (Radial Jaw 4; Boston Scientific, US). When the flap was sufficient for retraction, the mucosal incision was completed. In case of perforation, the defect was closed with endoscopic clipping (EZ Clip; Olympus, Tokyo, Japan). The resected area was not closed as healing usually occurred in a few weeks without complications.16
 
Histological assessment
All specimens were pinned on a piece of foam and fixed in formalin. Histological type, depth of invasion, as well as lateral and vertical resection margins were recorded. En-bloc resection was defined as one-piece resection of an entire lesion as observed endoscopically. R0 resection was defined as clear lateral and vertical resection margin.
 
Post–endoscopic submucosal dissection
All patients were allowed to resume a full diet on the same day. We performed no routine blood tests or imaging and patients were discharged the next day if there were no signs of perforation or haemorrhage. Postoperative haemorrhage was defined as clinical evidence of bleeding manifested by melena or haematochezia that required endoscopic haemostasis within 0 to 14 days of the procedure.11
 
Follow-up
All patients were followed up in clinic 2 weeks later to review the pathology report. Additional surgery would be offered in case of carcinoma with one of the following criteria: (1) margin involved; (2) >1 mm submucosal invasion; (3) positive lymphovascular permeation; (4) poorly differentiated adenocarcinoma, signet ring cell carcinoma, or mucinous carcinoma; or (5) high-grade tumour budding.17 Surveillance colonoscopy was performed 1 year after ESD.
 
Statistical analysis
All continuous variables were described as median and range. To study the learning curve, all patients were grouped chronologically into two periods: group 1 with cases 1 to 35; and group 2 with cases 36 to 71. Comparisons between non-parametric data were done with Mann-Whitney U test, while Chi squared test was used for categorical variables. A P value of <0.05 was considered statistically significant.
 
Results
From March 2009 to December 2013, a total of 71 ESDs were performed. Characteristics of the patients are shown in Table 1.
 

Table 1. Characteristics of patients undergoing endoscopic submucosal dissection
 
There was one conversion to laparoscopic colectomy due to intra-operative bleeding that could not be controlled endoscopically (40 mm x 15 mm tumour at the transverse colon). For perforation, there were 11 (15.5%) perforations: eight in the colon and three in the rectum, all were noticed during the ESD. Endoscopic clipping was successful in 10 of the perforations. The median number of clips used was 2 (range, 1-6). One perforation required conversion to laparoscopic colectomy (30 mm x 5 mm tumour at the sigmoid colon). Both laparoscopic operations were uneventful and patients were discharged without any surgical complications. The overall morbidity rate was 16.9% including bleeding and perforation and there was no mortality. The median postoperative stay was 1 day (range, 0-11 days).
 
Of the 69 patients who completed the endoscopic procedure, en-bloc resection was successful in 56 (81.2%) patients, of whom 19 (27.5%) required additional snare (SD-210U-25, Snare Master; Olympus, Tokyo, Japan) to complete the en-bloc resection. Conversion to piecemeal resection by snare occurred in 14 (20.3%) patients.
 
In these 69 patients, the resection margin was unclear in 15 patients as it was too close to the cauterised edge. These, together with piecemeal resection, were classified as R1 (29 patients in total). R0 resection was achieved in 40 (58.0%) patients. The histopathological diagnosis was tubular adenoma for 26 (36.6%) tumours, tubulovillous adenoma for 28 (39.4%), villous adenoma for two (2.8%), serrated adenoma for six (8.5%), carcinoid for one (1.4%) with involved margin, intramucosal carcinoma for two (2.8%), and carcinoma with submucosal invasion for six (8.5%). The ESD procedure was considered curative for the two patients with intramucosal carcinoma. One patient who had submucosal carcinoma refused further treatment because of a subsequent diagnosis of primary lung cancer. All other patients with submucosal carcinoma had curative interval laparoscopic surgeries. There was no residual tumour and no lymph node involvement found in the surgical specimen for any of these patients. The patient with rectal carcinoid also underwent subsequent interval laparoscopic total mesorectal excision: the pathology was well-differentiated carcinoid with invasion to the muscularis propria. There was one lymph node metastasis out of 11 lymph nodes retrieved.
 
Recurrence and surveillance colonoscopy
After excluding the six interval surgeries and two conversions to laparoscopic colectomy, the remaining 63 patients were offered colonoscopy surveillance of whom four refused and one defaulted from follow-up. Until August 2014, 51 patients had undergone surveillance colonoscopy and seven were awaiting colonoscopy. Recurrence of polyp occurred in seven (13.7%) out of 51 patients: three recurrences occurred after piecemeal resection, another three recurrences occurred after additional snare to complete the en-bloc resection. All three cases had uncertain margin due to proximity to the cauterised edge. In one patient, recurrence occurred after successful en-bloc resection by ESD, in which the deep margin was clear but the circumferential margin was not certain.
 
Learning curve between the two chronological groups
All patients were grouped chronologically into two periods: group 1 with cases 1 to 35; and group 2 with cases 36 to 71. The comparison between the two groups is shown in Table 2. The median procedure time per unit area of tumour improved significantly from 31.5 min/cm2 to 21.5 min/cm2 (P=0.032).
 

Table 2. Comparison between the two chronological groups
 
There were three (8.6%) perforations in group 1; one of them required conversion to laparoscopic colectomy. There were eight (22.2%) perforations in group 2; all managed successfully by endoscopic clipping. There was no significant difference in perforation rate (P=0.054). The intra-operative bleeding that required a conversion to laparoscopic colectomy also belonged to group 1.
 
For the 33 patients in group 1 who completed the endoscopic procedure, en-bloc resection was successful in 26 (78.8%), while 30 (83.3%) out of 36 patients in group 2 had successful en-bloc resection. This trend of improvement, however, did not reach statistical significance (P=0.15). Among these successful en-bloc resections, 15 (57.7%) out of 26 patients in group 1 and four (13.3%) out of 30 patients in group 2 required additional snare to complete the en-bloc resection (P<0.01).
 
R0 resection rate had improved significantly in group 2 despite a lower rate of snare application: 13 (39.4%) of 33 patients in group 1 had R0 resection, whereas in group 2, 27 (75.0%) of 36 patients had R0 resection (P<0.01).
 
The median postoperative stay was 1 day in both groups and was not significantly different (P=0.25). The median postoperative stay in patients with perforation in group 1 and group 2 was 1 day (range, 1-7 days) and 2 days (range, 1-11 days), respectively (P=0.73).
 
Discussion
Colorectal ESD has been shown to be feasible and safe when performed at expert centres in Japan. In a recent prospective multicentre cohort study involving 1111 patients in Japan, the reported en-bloc resection rate was 88% and R0 resection rate was 89%.11 The total perforation rate was only 5.3% and postoperative bleeding was 1.5%.11 Nonetheless, these excellent results are largely reported from Japan. Colorectal ESD is technically difficult, as the lumen is narrow and angulated and the very thin wall presents a high risk of perforation. In Japan, endoscopists are first required to gain experience in gastric ESD, which is technically less demanding, before they move on to colorectal ESD.18 This is not possible in western and Asian countries outside Japan, where early gastric cancer is much less prevalent. In a recent review of 82 rectosigmoid ESD from a tertiary centre in Germany, the en-bloc resection rate and R0 resection rate was only 81.6% and 69.7%, respectively.19 This reflects the difficulty in generalising this novel procedure in other counties outside Japan, and an even greater challenge to low-volume district centres that lack local expertise.
 
The low case volume and the absence of expertise in western countries leads to the development of untutored colorectal ESD when it is impossible to have a step-up approach in ESD training starting from the stomach before proceeding to colon. The reported learning curve for untutored colorectal ESD has an acceptable outcome, however. Berr et al20 reported a case series of 48 colorectal ESDs with 76% en-bloc resection, 14% perforation, and 4% requirement for surgical intervention. This compared favourably with results in Japan.11 Another learning curve study of colorectal ESD found procedure time could be significantly shorter after 25 procedures.21
 
With a similar situation in Hong Kong, this study showed that untutored colorectal ESD is safe and feasible. Results demonstrated obvious improvement after 35 procedures, as evidenced by the significant reduction in combined ESD and EMR with snare from 45.5% to 11.1%. Procedure time per unit area of tumour as well as R0 resection rate also significantly improved after 35 cases. Although there were more perforations in group 2, it did not determine adverse outcome. None of the perforations in group 2 required conversion to laparoscopic colectomy. There was no significant impact on hospital stay. The higher perforation rate in group 2 may reflect a second learning curve to perform a complete ESD procedure without the assistance of a hybrid technique to achieve a reasonable R0 resection rate. A perforation rate comparable with the Japanese series11 is expected in the third tranche of 35 patients.
 
Contrary to perforations in traditional therapeutic colonoscopies, all perforations in ESD were only 1 to 2 mm in size and were noticed intra-operatively, thus immediate endoscopic repair was possible. No patient required surgical intervention solely for treatment of perforation. The only conversion to laparoscopic colectomy in the initial learning curve aimed to offer one-stop treatment rather than treating perforations. In a multicentre review of colonoscopic perforations by Teoh et al,22 43 (0.113%) perforations were found in 37 971 colonoscopies. Only seven (43.8%) out of 16 therapeutic colonoscopic perforations were noticed during the endoscopic procedure. The mean size of perforation was 0.98 cm. The overall 30-day morbidity and mortality rate was 48.7% and 25.6%, respectively and the stoma rate was 38.5%. This showed clearly that surgical outcome was much worse in conventional colonoscopic perforations compared with perforations in ESD, despite a much higher perforation rate of 15.7% in ESD group.22
 
After implementation of the ESD service, the following were noted:
(1) Venue of procedure—operating theatre was chosen instead of an endoscopic unit to enable conversion to conventional laparoscopic colectomy without the need to change location as well as the ready availability of an anaesthetist to give conscious sedation.
(2) Mode of anaesthesia—in the first few patients, we performed ESD under general anaesthesia for patient comfort and in the event conversion to laparoscopic colectomy was necessary. Positioning of patients was clumsy particularly when a prone position was needed to perform the procedure. Subsequently conscious sedation by an anaesthetist was used instead. Patients could follow instructions for positioning and deeper sedation could be achieved if necessary. There were no complaints from patients about any discomfort during the procedure.
(3) Choice of injecting agents—albumin 20% (Albumex 20; CSL, Australia) was used as submucosal injecting agent in the first few patients when sodium hyaluronate was not available. Albumin 20% has both a good cushioning effect without any inflammatory effect and the cost was much cheaper at HK$2.7/mL compared with commercially available sodium hyaluronate at HK$68/mL.23 Yet sodium hyaluronate has the longest lasting cushioning effect among all injecting agents. We recommend its use whenever available.
(4) A mixture of adrenaline saline and sodium hyaluronate was favourable for the assistant to inject and a lesser volume of sodium hyaluronate was required. Moreover, there were no instances of postoperative haemorrhage, although it was difficult to conclude whether this was due to the addition of adrenaline saline.
(5) Endoscopic technique—in our initial practice, we performed a full circumferential mucosal incision before submucosal dissection. We noticed it was technically more difficult compared with a two-third circumferential incision, because firstly, the submucosal elevation was lost quickly due to faster leakage of injecting agent, and secondly, it was difficult to retract the lesion at the end of dissection, and we had to complete the en-bloc resection with snare. After changing to two-third circumferential incision in the second period of the study, the need for additional snare to complete the en-bloc resection was significantly decreased (from 57.7% to 13.3%).
(6) Postoperative management—it was feasible and safe to resume diet immediately after the procedure and discharge patients the day following ESD without the need for routine blood taking or imaging. In one study from Japan, abdominal computed tomography was performed on day 1 and blood tests were carried out for 2 consecutive days. Oral intake was gradually stepped up and patients were discharged 5 days after ESD.10 In contrast, we allowed full diet on the same day after ESD and did not perform computed tomography or blood tests routinely. Our overall median postoperative stay was 1 day. Further development of ESD as a day procedure can be explored.
 
There are a number of limitations in this study. First, this was the learning curve of a single endoscopist and 35 procedures may not be a typical number required for such a learning curve. Second, the inclusion criteria for colorectal ESD were less strict than those in Japan. Lesion less than 2 cm that could not be removed en bloc would be subjected to ESD instead of piecemeal resection. These kinds of lesion were expected to be easier with shorter operating time. Third, this was a retrospective comparison of two chronological groups which might not have been directly comparable. Lastly, the 7.9% patient default rate may lead to underestimation of recurrence in this series.
 
Conclusion
Untutored colorectal ESD at a low-volume centre was an option in the absence of enough experts to supervise the procedure. Training on an animal model and clinical observation of real-time demonstrations was useful to start ESD without supervision. A cut-off at 35 procedures showed an acceptable R0 resection rate at a significantly improved procedure time per unit area. There was a second learning curve to achieve a complete ESD procedure without EMR at a higher perforation rate. Colorectal ESD performed by a colorectal surgeon enables any complications to be managed by the same operator, or any lesion unresectable by ESD to be surgically removed. It was not necessary to first perform gastric ESD as the start of ESD training. When more endoscopists have gained experience in colorectal ESD, a structured training programme with accreditation can be established.
 
Declaration
All authors have disclosed no conflicts of interest.
 
References
1. Tanaka S, Haruma K, Oka S, et al. Clinicopathological features and endoscopic treatment of superficially spreading colorectal neoplasms larger than 20 mm. Gastrointest Endosc 2001;54:62-6. Crossref
2. Walsh RM, Ackroyd FW, Shellito PC. Endoscopic resection of large sessile colorectal polyps. Gastrointest Endosc 1992;38:303-9. Crossref
3. Uraoka T, Fujii T, Saito Y, et al. Effectiveness of glycerol as a submucosal injection for EMR. Gastrointest Endosc 2005;61:736-40. Crossref
4. Yamamoto H, Kawata H, Sunada K, et al. Successful en-bloc resection of large superficial tumors in the stomach and colon using sodium hyaluronate and small-caliber-tip transparent hood. Endoscopy 2003;35:690-4. Crossref
5. Fujishiro M, Yahagi N, Kakushima N, et al. Outcomes of endoscopic submucosal dissection for colorectal epithelial neoplasms in 200 consecutive cases. Clin Gastroenterol Hepatol 2007;5:678-83. Crossref
6. Saito Y, Fukuzawa M, Matsuda T, et al. Clinical outcome of endoscopic submucosal dissection versus endoscopic mucosal resection of large colorectal tumors as determined by curative resection. Surg Endosc 2010;24:343-52. Crossref
7. The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc 2003;58(6 Suppl):S3-43.
8. Watanabe T, Itabashi M, Shimada Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol 2012;17:1-29. Crossref
9. Yoda Y, Ikematsu H, Matsuda T, et al. A large-scale multicenter study of long-term outcomes after endoscopic resection for submucosal invasive colorectal cancer. Endoscopy 2013;45:718-24. Crossref
10. Yoshida N, Wakabayashi N, Kanemasa K, et al. Endoscopic submucosal dissection for colorectal tumors: technical difficulties and rate of perforation. Endoscopy 2009;41:758-61. Crossref
11. Saito Y, Uraoka T, Yamaguchi Y, et al. A prospective, multicenter study of 1111 colorectal endoscopic submucosal dissections (with video). Gastrointest Endosc 2010;72:1217-25. Crossref
12. Taku K, Sano Y, Fu KI, et al. Iatrogenic perforation associated with therapeutic colonoscopy: a multicenter study in Japan. J Gastroenterol Hepatol 2007;22:1409-14. Crossref
13. Sano Y, Muto M, Tajiri H, et al. Optical/digital chromoendoscopy during colonoscopy using narrow-band image system. Dig Endosc 2005;17(Suppl):S43-8. Crossref
14. Ikematsu H, Matsuda T, Emura F, et al. Efficacy of capillary pattern type IIIA/IIIB by magnifying narrow band imaging for estimating depth of invasion of early colorectal neoplasms. BMC Gastroenterol 2010;10:33. Crossref
15. Machida H, Sano Y, Hamamoto Y, et al. Narrow-band imaging in the diagnosis of colorectal mucosal lesions: a pilot study. Endoscopy 2004;36:1094-8. Crossref
16. Iguchi M, Yahagi N, Fujishiro M, et al. The healing process of large artificial ulcers in the colorectum after endoscopic mucosal resection [abstract]. Gastrointest Endosc 2003;57:AB226.
17. Asano M. Endoscopic submucosal dissection and surgical treatment for gastrointestinal cancer. World J Gastrointest Endosc 2012;4:438-47. Crossref
18. Tanaka S, Tamegai Y, Tsuda S, Saito Y, Yahagi N, Yamano HO. Multicenter questionnaire survey on the current situation of colorectal endoscopic submucosal dissection in Japan. Dig Endosc 2010;22 Suppl 1:S2-8. Crossref
19. Probst A, Golger D, Anthuber M, Märkl B, Messmann H. Endoscopic submucosal dissection in large sessile lesions of the rectosigmoid: learning curve in a European center. Endoscopy 2012;44:660-7. Crossref
20. Berr F, Wagner A, Kiesslich T, Friesenbichler P, Neureiter D. Untutored learning curve to establish endoscopic submucosal dissection on competence level. Digestion 2014;89:184-93. Crossref
21. Białek A, Pertkiewicz J, Karpińska K, Marlicz W, Bielicki D, Starzyńska T. Treatment of large colorectal neoplasms by endoscopic submucosal dissection: a European single-center study. Eur J Gastroenterol Hepatol 2014;26:607-15. Crossref
22. Teoh AY, Poon CM, Lee JF, et al. Outcomes and predictors of mortality and stoma formation in surgical management of colonoscopic perforations: a multicenter review. Arch Surg 2009;144:9-13. Crossref
23. ASGE Technology Committee, Kantsevoy SV, Adler DG, Conway JD, et al. Endoscopic mucosal resection and endoscopic submucosal dissection. Gastrointest Endosc 2008;68:11-8. Crossref

Diagnostic accuracy of spot urine protein-to-creatinine ratio for proteinuria and its association with adverse pregnancy outcomes in Chinese pregnant patients with pre-eclampsia

Hong Kong Med J 2016 Jun;22(3):249–55 | Epub 6 May 2016
DOI: 10.12809/hkmj154659
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
ORIGINAL ARTICLE
Diagnostic accuracy of spot urine protein-to-creatinine ratio for proteinuria and its association with adverse pregnancy outcomes in Chinese pregnant patients with pre-eclampsia
HC Cheung, MB, BS, MRCOG1; KY Leung, FRCOG, FHKAM (Obstetrics and Gynaecology)1; CH Choi, FHKCP, FHKAM (Medicine)2
1 Department of Obstetrics and Gynaecology, Queen Elizabeth Hospital, Jordan, Hong Kong
2 Department of Medicine, Queen Elizabeth Hospital, Jordan, Hong Kong
 
Corresponding author: Dr HC Cheung (chc670@ha.org.hk)
 
 Full paper in PDF
Abstract
Introduction: International guidelines have endorsed spot urine protein-to-creatinine ratio of >30 mg protein/mmol creatinine as an alternative to a 24-hour urine sample to represent significant proteinuria. This study aimed to determine the accuracy of spot urine protein-to-creatinine ratio in predicting significant proteinuria and adverse pregnancy outcome.
 
Methods: This case series was conducted in a regional obstetric unit in Hong Kong. A total of 120 Chinese pregnant patients with pre-eclampsia delivered at Queen Elizabeth Hospital from January 2011 to December 2013 were included. Relationship of spot urine protein-to-creatinine ratio and 24-hour proteinuria; accuracy of the ratio against 24-hour urine protein at different cut-offs; and relationship of such ratio and adverse pregnancy outcome were studied.
 
Results: Spot urine protein-to-creatinine ratio was correlated with 24-hour urine protein with Pearson correlation coefficient of 0.914 (P<0.0001) when the ratio was <200 mg/mmol. The optimal threshold of spot urine protein-to-creatinine ratio for diagnosing proteinuria in Chinese pregnant patients (33 mg/mmol) was similar to that stated in the international literature (30 mg/mmol). A cut-off of 20 mg/mmol provided a 100% sensitivity, and 52 mg/mmol provided a 100% specificity. There was no significant difference in spot urine protein-to-creatinine ratio between cases with and without adverse pregnancy outcome.
 
Conclusions: Spot urine protein-to-creatinine ratio had a positive and significant correlation with 24-hour urine results in Chinese pre-eclamptic women when the ratio was <200 mg/mmol. Nonetheless, this ratio was not predictive of adverse pregnancy outcome.
 
New knowledge added by this study
  • Spot urine protein-to-creatinine ratio (uPCR) had a positive and significant correlation with 24-hour urine results in Chinese pre-eclamptic women when uPCR was <200 mg/mmol.
  • uPCR was not predictive of adverse pregnancy outcome in Chinese pre-eclamptic women.
Implications for clinical practice or policy
  • The optimal threshold for diagnosis of proteinuria in the local Chinese population was similar to the 30 mg/mmol suggested by international guidelines.
  • When uPCR is <20 mg/mmol (significant proteinuria very unlikely) or >52 mg/mmol (significant proteinuria very likely), early clinical management can be facilitated without awaiting results of 24-hour urine protein.
  • When uPCR is ≥200 mg/mmol, 24-hour urine is needed for an accurate quantification as correlation between these two tests is low above this level.
 
 
Introduction
Pre-eclampsia, or de-novo proteinuric hypertension after 20 weeks of pregnancy,1 is a major cause of maternal and perinatal morbidity and mortality due to eclampsia, cerebrovascular events, preterm delivery, and fetal growth restriction. In industrialised countries, the incidence has been reported to be 3% to 5% of pregnancies.2 3 In a territory-wide study in China, hypertensive disorders complicated 5.2% of all pregnancies, with more than 50% of them being pre-eclampsia.4
 
The gold standard for diagnosis of proteinuria is the presence of >300 mg of protein in a 24-hour urine sample.1 This test, however, is cumbersome and time-consuming for women, has cost implications, can cause a delay in diagnosis and hence management because of its turnaround time, and can lead to inaccurate results from incomplete collection or varying use of assays.
 
International guidelines have endorsed spot urine protein-to-creatinine ratio (uPCR) of >30 mg protein/mmol creatinine as an alternative to a 24-hour urine sample to represent significant proteinuria.1 5 6 Meta-analyses in 2012 and 2013 revealed that maternal uPCR showed promising diagnostic value for significant proteinuria in suspected pre-eclampsia.7 8 The optimal threshold to detect significant proteinuria varied from 0.30 to 0.35, and considerable heterogeneity existed in the diagnostic accuracy at most thresholds across studies.7 Moreover, there were few studies of the diagnostic value of uPCR in a Chinese population. Since Chinese women generally have a lower muscle mass than their western counterparts, the former may have a lower urinary creatinine excretion that may alter their uPCR level9 and consequent diagnostic accuracy of uPCR.
 
While some studies10 11 12 have suggested that proteinuria is related to adverse pregnancy outcome, others have not.1 13 In the 2012 meta-analysis, there was insufficient evidence that uPCR could predict adverse pregnancy outcome.7 The latest guidelines on hypertension in pregnancy from the National Institute for Health and Care Excellence have recommended research to identify diagnostic thresholds of proteinuria that can accurately predict clinically important outcomes.5
 
The aims of this study were to determine the accuracy of uPCR in predicting significant proteinuria in our local population, and adverse maternal or neonatal outcomes. If uPCR can accurately predict significant proteinuria and adverse pregnancy outcomes, it will be a quick, acceptable, and potentially cost-effective alternative to 24-hour urine for protein analysis. The clinical management of suspected proteinuric hypertension in pregnancy can then be modified to facilitate an early diagnosis or exclusion of pre-eclampsia.
 
Methods
All Chinese pregnant women with a diagnosis of pre-eclampsia (new-onset proteinuric hypertension after 20 weeks of gestation) and who delivered at Queen Elizabeth Hospital in Hong Kong from January 2011 to December 2013 (36 months) were eligible for initial inclusion in this retrospective study. Hypertension was defined as blood pressure of ≥140/90 mm Hg. Significant proteinuria was defined as 24-hour urine total protein of ≥300 mg/day or uPCR of ≥30 mg/mmol (local laboratory reference) if the former was not available. Test of uPCR has been available for a long period and has been widely used in our department since January 2011. The diagnosis of proteinuria was mostly based on 24-hour urine testing rather than uPCR before January 2011. Women were excluded from the study if they had pre-existing renal disease, chronic hypertension, or co-existing urinary tract infection (defined by a positive mid-stream urine culture). The study was approved by the hospital research and ethics committee as a registered study (Ref.: KC/KE-15-0025), with the requirement of patient informed consent waived because of its retrospective nature.
 
In this study, uPCR was collected as a random urine sample at any time of the day. It was collected in the presence of a positive urine dipstick for protein or in women who presented with hypertension (even dipstick negative) to confirm or exclude proteinuria. For 24-hour urine, women were provided with a bottle and instructions to collect all urine within a 24-hour period. All collections were sent to the laboratory within 1 day of completion. Urine total protein was measured using a turbidimetric method based on benzethonium chloride reaction. Urine creatinine was measured using a kinetic colorimetric assay based on the Jaffé method. Both tests were performed with a Roche/Hitachi cobas c501 analyser (cobas 6000 system; Roche Diagnostics GmbH, Mannheim, Germany). The imprecision (coefficient of variation) of the urine protein assay was 3.7% at 0.18 g/L and 1.9% at 0.54 g/L. The imprecision of the urine creatinine assay was 6.9% at 7.0 mmol/L and 2.2% at 20.8 mmol/L.
 
For the primary outcome analysis, women who had both uPCR and adequate 24-hour urine results collected within 24 hours were identified. 24-Hour urine collection was often inaccurate (due to over- or under-collection), even though patients have been provided with a standard instruction. It has been reported that 13% to 54% of 24-hour urine collections were inaccurate, with 24.8% of patients having a difference of ≥25% in the results between collections, exceeding the analytical and biological variation.14 Completeness of a 24-hour urine collection was assessed by urinary creatinine excretion. The normal range for urinary creatinine excretion was 7 to 14 mmol/day in our laboratory as recommended by the vendor of the test. Considering a mean body weight of 70 kg during pregnancy and understanding that urinary creatinine excretion remains unchanged in pregnancy, this reference range was compatible with general nephrology references of 133 to 177 µmol/kg/day of lean body mass.15 The two urine tests should be collected within 1 day to avoid the effect of day-to-day variation on the amount of protein in urine.
 
For the secondary outcome analysis, adverse maternal outcomes were represented by severe hypertension (blood pressure ≥160/110 mm Hg), raised liver enzyme (alanine aminotransferase or aspartate aminotransferase ≥70 IU/L), renal insufficiency (serum creatinine ≥80 µmol/L), thrombocytopenia (platelet count <100 x 109 /L), admission to intensive care unit (ICU), eclampsia, or maternal mortality. Adverse neonatal outcomes were represented by prematurity (delivery at <37 weeks’ gestation), low birth weight (<2500 g), small-for-gestational age based on local population data, low Apgar score (<7) at 1 minute and 5 minutes of birth, admission to the neonatal intensive care unit (NICU), stillbirth, or early neonatal death. Data for maternal and neonatal outcomes were obtained from the hospital’s Clinical Data Analysis and Reporting System and individual medical records. To minimise the effect of multiple pregnancy on the clinical outcome, only singleton pregnancies were included for secondary outcome analysis. If more than one sample of uPCR were collected during the pregnancy, the first uPCR at the onset of proteinuria was used to determine the association with adverse outcomes.
 
Data were analysed using the Statistical Package for the Social Sciences (Windows version 22.0; SPSS Inc, Chicago [IL], US). For the primary outcome analysis, the relationship between uPCR and 24-hour urine was assessed by Pearson correlation coefficient after taking logarithm as the data distribution of these two parameters were not nominal. Sensitivity, specificity, and positive and negative predictive values of uPCR were calculated. The sensitivity and specificity of uPCR at different cut-offs were analysed by receiver operating characteristics (ROC) curve. For the secondary outcome analysis, Mann-Whitney U test was used to determine the difference in proteinuria level between cases with or without an adverse pregnancy outcome.
 
Results
Of 432 cases of pre-eclampsia identified during the 36-month study period, 175 (40.5%) had uPCR analysed after excluding cases without collection of uPCR before delivery or ordering because of individual clinician’s preference or because immediate delivery was expected. Of these 175 cases, 55 (31.4%) were excluded after review of medical records, including 28 non-Chinese patients, 24 cases with pre-existing hypertension or pre-existing renal disease, one woman with active urinary tract infection, one with missing information, and one who did not deliver at our hospital. Urine samples collected from the remaining 120 women, who ranged from 24 weeks to 41 weeks of gestation, were analysed. The general characteristics of the study population are shown in Table 1.
 

Table 1. General characteristics of the study population (n=120)
 
Spot urine protein-to-creatinine ratio and 24-hour urine protein
Of these 120 cases, 98 pairs of urine samples were collected, of which 12 were inadequate and 20 were collected more than 1 day apart. The remaining 66 pairs with both uPCR and adequate 24-hour urine collection available within 1 day were used for the primary outcome analysis. The median body weight of these 66 women was 72.1 kg (range, 56.5-97.0 kg).
 
The two tests were correlated with a Pearson correlation coefficient (r) of 0.914 (P<0.0001). From Figure 1, it is clear that a positive and linear correlation between uPCR and 24-hour urine protein was evident up to a uPCR of 200 mg/mmol. On subgroup analysis, the correlation coefficient was high (0.875) and significant (P<0.0001) for uPCR of <200 mg/mmol, but low (0.389) and non-significant (P=0.152) for uPCR of ≥200 mg/mmol.
 

Figure 1. Individual 24-hour urine protein versus spot urine protein-to-creatinine ratio (uPCR) values (n=66)
 
With the local laboratory reference of uPCR set at 30 mg/mmol, as suggested by international guidelines,1 5 6 the positive predictive value of significant proteinuria (defined by 24-hour urine total protein ≥300 mg/day) was 96%, sensitivity 96%, negative predictive value 87%, and specificity 87%. Two false-positive cases and two false-negative cases were found. For the two false-positive cases, the 24-hour urine results were 0.28 g/d and 0.26 g/d and corresponding uPCR results were 44 mg/mmol and 31 mg/mmol. Although these 24-hour urine results were negative, these women subsequently developed proteinuria and were confirmed to have pre-eclampsia. For the two false-negative cases, their 24-hour urine results were 0.31 g/d and 0.38 g/d and corresponding uPCR results were 26 mg/mmol and 21 mg/mmol.
 
The area under ROC curve was 0.981 (95% confidence interval [CI], 0.954-1.000; Fig 2). The optimal threshold of uPCR for diagnosing proteinuria was 33 mg/mmol. This gave the same sensitivity but a slightly higher specificity when compared with the suggested threshold of 30 mg/mmol,1 although there was a large overlap of 95% CIs (Table 2). A lower cut-off of 20 mg/mmol rather than the local laboratory reference of 30 mg/mmol on the uPCR would give 100% sensitivity. A higher cut-off of 52 mg/mmol would have 100% specificity (Table 2).
 

Figure 2. Receiver operator characteristics analysis (n=66)
Diagonal segments are produced by ties
 

Table 2. Comparison of accuracy of uPCR against 24-hour urine protein at different cut-offs (n=66)
 
Spot urine protein-to-creatinine ratio and adverse pregnancy outcomes
We excluded 25 multiple pregnancies for this secondary outcome analysis. Of the remaining 95 singleton pregnancies with pre-eclampsia, the median gestation age of onset of proteinuria was 35 weeks and 64% were preterm (<37 weeks) at the onset.
 
For maternal outcome, 47% of women developed severe hypertension, 6% developed raised liver enzymes, 6% renal insufficiency, and 2% thrombocytopenia. Admission to the ICU was required by 16%. There was no case of eclampsia or maternal mortality. Substantial differences in uPCR were observed in cases with and without raised liver enzymes and thrombocytopenia, although the differences were not statistically significant due to the small number of cases (Table 3).
 

Table 3. Proteinuria determined by uPCR in pre-eclamptic patients with and without adverse maternal complications (n=95)
 
For the neonatal outcome of all singleton pregnancies, 60% were born with low birth weight, 21% with low Apgar score at 1 minute, 6% with low Apgar score at 5 minutes of birth, and 54% required admission to the NICU. There was no case of stillbirth or early neonatal death. On the other hand, uPCR was significantly greater in newborns who required admission to the NICU than in those who did not. Nonetheless, if only women with onset of proteinuria before 34 weeks were included, there was no difference in uPCR between newborns with and without neonatal complications (Table 4).
 

Table 4. Proteinuria determined by uPCR in pre-eclamptic patients with and without adverse neonatal complications
 
Discussion
Consistent with previous studies,7 8 our present study has shown a positive and significant correlation of uPCR with 24-hour urine result. This correlation was low and insignificant if uPCR was ≥200 mg/mmol. This is similar to the finding of another study that reported a lower positive predictive value between 24-urine protein excretion and uPCR for the greater degree of proteinuria (>1 g/day).16
 
In the present study, the optimal threshold of uPCR for diagnosing proteinuria was 33 mg/mmol. This gave a similar predictive value when compared with the suggested threshold of 30 mg/mmol (Table 2).1 The area under ROC curve in the present study was 0.981 and was comparable with the result of a meta-analysis that included 24 trials with 3186 participants in which the area under summary ROC curve was 0.90, with pooled sensitivities and specificities of 91% and 86.3%, respectively.8
 
Using a cut-off of 20 and 52 mg/mmol had 100% sensitivity and 100% specificity, respectively (Table 2). Similar findings for the cut-off value were noted in a systematic review of seven studies with 1717 patients.17 Random uPCR determinations are helpful primarily when they are <150 mg/g (17 mg/mmol) as ≥300 mg proteinuria is unlikely to be below this threshold. Nonetheless, for uPCR >600 mg/g (67.8 mg/mmol), significant proteinuria could be established.
 
In clinical practice, there are three scenarios. First, if uPCR is >52 mg/mmol (66% of cases in the present study), significant proteinuria will be highly likely and the positive predictive value of a composite adverse neonatal outcome will be high (78.7% in the present study). Second, if uPCR is <20 mg/mmol (13% in the present study), significant proteinuria will be very unlikely. In either scenario, an earlier clinical decision can be made without ordering or completion of 24-hour urine collection or awaiting results. 24-Hour urine collection can be omitted in the majority of cases, therefore shortening the time to diagnose or exclude pre-eclampsia. Third, if uPCR is 20 to 52 mg/mmol (21% in the present study), 24-hour urine results will be required to confirm or exclude significant proteinuria. Although 24-hour urinary protein of ≥300 mg/day is the gold standard for diagnosing abnormal proteinuria in pregnancy, this is more a time-honoured value than one with high scientific proof.1 Having said that, in cases of gestational hypertension with proteinuria of <300 mg/day, attention should still be warranted if the uPCR is >30 mg/mmol, particularly if it shows a rising trend.
 
If uPCR is ≥200 mg/mmol, correlation with 24-hour urine analysis will be low. In such cases, proteinuria should be confirmed with 24-hour urine protein measurement. It is probable that nephrotic range proteinuria exists above this threshold, thus necessitating prophylaxis against thromboembolism.1
 
It is controversial whether uPCR can predict clinical outcome. Some studies10 11 12 have suggested that proteinuria is related to adverse pregnancy outcomes, for example, severe hypertension, renal insufficiency, liver disease, preterm delivery, small-for-gestational age, and transfer to NICU. Nonetheless, the latest ISSHP (International Society for the Study of Hypertension in Pregnancy) guideline suggests that the degree of proteinuria provides very little additional risk stratification in cases of pre-eclampsia, and does not include it when defining the severity of the disease.1 The recent multicentre PIERS (Pre-eclampsia Integrated Estimate of Risk) study demonstrated that neither uPCR nor 24-hour urine protein output was predictive of adverse perinatal outcome and hence concluded that the amount of proteinuria should not be used in isolation for decision making in women with pre-eclampsia.13 In the present study that focused on Chinese pre-eclamptic women, uPCR was significantly greater in cases that required admission to the NICU. This difference was no longer evident if only cases with early-onset proteinuria were included in the analysis. This shows that the observed difference in uPCR was related to the management strategy of preterm delivery in cases with early-onset pre-eclampsia rather than to the severity of proteinuria itself.
 
The study provides an insight into the accuracy of uPCR and its relationship with pregnancy outcomes in a local Chinese population. Nonetheless, the present study was small and retrospective. Only those with a valid spot urine sample were included in the study and women with severe pre-eclampsia who required immediate treatment and delivery were excluded. The results would therefore be affected by such selection bias. The precision of the ROC curve is limited by the small sample size. Further research by a prospective study with timed urine collection and larger sample size is suggested to validate the findings of the present study.
 
Conclusions
There was a positive and significant correlation of uPCR with 24-hour urine protein result in Chinese pre-eclamptic women when uPCR was <200 mg/mmol. Significant proteinuria can probably be excluded in the presence of uPCR of <20 mg/mmol, but it should be considered when uPCR >52 mg/mmol. Significant proteinuria should be confirmed by 24-hour urine collection when uPCR is 20 to 52 mg/mmol, and uPCR was not significant in predicting adverse pregnancy outcomes.
 
Acknowledgements
The authors would like to thank Dr CC Shek from the Department of Pathology of Queen Elizabeth Hospital for his valuable assistance for providing information on the laboratory tests. We would also like to thank Ms Janice Yung for her kind clerical assistance in the preparation of this manuscript.
 
Declaration
All authors have disclosed no conflicts of interest.
 
References
1. Tranquilli AL, Dekker G, Magee L, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens 2014;4:97-104. Crossref
2. Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol 2011;25:391-403. Crossref
3. Tan KH, Kwek K, Yeo GS. Epidemiology of pre-eclampsia and eclampsia at the KK Women’s and Children’s Hospital, Singapore. Singapore Med J 2006;47:48-53.
4. Ye C, Ruan Y, Zou L, et al. The 2011 survey on hypertensive disorders of pregnancy (HDP) in China: prevalence, risk factors, complications, pregnancy and perinatal outcomes. PLoS One 2014;9:e100180. Crossref
5. Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. NICE Clinical Guidelines, No. 107. London: RCOG Press; 2010.
6. Lowe SA, Bowyer L, Lust K, et al. SOMANZ guidelines for the management of hypertensive disorders of pregnancy 2014. Aust NZJ Obstet Gynaecol 2015;55:e1-e29. Crossref
7. Morris RK, Riley RD, Doug M, Deeks JJ, Kilby MD. Diagnostic accuracy of spot urinary protein and albumin to creatinine ratios for detection of significant proteinuria or adverse pregnancy outcome in patients with suspected pre-eclampsia: systematic review and meta-analysis. BMJ 2012;345:e4342. Crossref
8. Sanchez-Ramos L, Gillen G, Zamora J, Stenyakina A, Kaunitz AM. The protein-to-creatinine ratio for the prediction of significant proteinuria in patients at risk for preeclampsia: a meta-analysis. Ann Clin Lab Sci 2013;43:211-20.
9. James GD, Sealey JE, Alderman M, et al. A longitudinal study of urinary creatinine and creatinine clearance in normal subjects. Race, sex, and age differences. Am J Hypertens 1988;1:124-31. Crossref
10. Chan P, Brown M, Simpson JM, Davis G. Proteinuria in pre-eclampsia: how much matters? BJOG 2005;112:280-5. Crossref
11. Thornton CE, Makris A, Ogle RF, Tooher JM, Hennessy A. Role of proteinuria in defining pre-eclampsia: clinical outcomes for women and babies. Clin Exp Pharmacol Physiol 2010;37:466-70. Crossref
12. Bouzari Z, Javadiankutenai M, Darzi A, Barat S. Does proteinuria in preeclampsia have enough value to predict pregnancy outcome? Clin Exp Obstet Gynecol 2014;41:163-8.
13. Payne B, Magee LA, Côté AM, et al. PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can 2011;33:588-97. Crossref
14. Côté AM, Firoz T, Mattman A, Lam EM, von Dadelszen P, Magee LA. The 24-hour urine collection: gold standard or historical practice? Am J Obstet Gynecol 2008;199:625.e1-6. Crossref
15. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 1992;38:1933-53.
16. Demirci O, Kumru P, Arınkan A, et al. Spot protein/creatinine ratio in preeclampsia as an alternative for 24-hour urine protein. Balkan Med J 2015;32:51-5. Crossref
17. Papanna R, Mann LK, Kouides RW, Glantz JC. Protein/creatinine ratio in preeclampsia: a systematic review. Obstet Gynecol 2008;112:135-44. Crossref

The effect of anticonvulsant use on bone mineral density in non-ambulatory children with cerebral palsy

Hong Kong Med J 2016 Jun;22(3):242–8 | Epub 6 May 2016
DOI: 10.12809/hkmj154588
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
ORIGINAL ARTICLE
The effect of anticonvulsant use on bone mineral density in non-ambulatory children with cerebral palsy
SW Cheng, DPD (Cardiff), MRCPCH; CH Ko, FHKAM (Paediatrics), FRCP (Glasg); CY Lee, FHKAM (Paediatrics), FRCP (Edin)
Department of Paediatrics and Adolescent Medicine, Caritas Medical Centre, Shamshuipo, Hong Kong
 
Corresponding author: Dr SW Cheng (shirley.s.cheng@gmail.com)
 
 Full paper in PDF
Abstract
Introduction: Studies showed that use of anticonvulsants (antiepileptic drugs) might be associated with reduced bone mineral density. The primary objective of this study was to evaluate the effect of anticonvulsants on bone mineral density in non-ambulatory children with cerebral palsy. The secondary objective was to identify their risk factors for low bone mineral density.
 
Methods: This case series with internal comparisons was conducted in a paediatric residential rehabilitation centre in Hong Kong. Overall, 32 patients were enrolled. The study group comprised 18 patients (6 males, 12 females) aged 5.0 to 19.5 years (mean ± standard deviation, 13.8 ± 4.7 years); all were prescribed anticonvulsant therapy for more than 2 years. The comparison group comprised 14 patients (6 males, 8 females) aged 7.0 to 19.1 years (mean, 16.4 ± 3.0 years) who were concomitant non-ambulatory residents with cerebral palsy and were not prescribed any anticonvulsant therapy prior to study recruitment. Patients underwent a physical examination, blood tests, nutritional assessment, and dual-energy X-ray absorptiometry scan of the total body less head. Z-scores were calculated.
 
Results: There was no significant difference in Z-scores of total body less head between groups. Among children with low bone mineral density (Z-scores ≤–2.0) and normal bone mineral density, multivariate analysis revealed that higher weight-for-age Z-score (adjusted odds ratio=0.015) and presence of puberty (adjusted odds ratio=0.027) were independent factors for bone mineral density improvement. Hosmer-Lemeshow goodness of fit test (P=0.315) was not significant. Nagelkerke R2 was 0.677, signifying a relatively well-fitting model.
 
Conclusion: There was no evidence that anticonvulsant therapy has any detrimental effect on bone mineral density in non-ambulatory children with cerebral palsy. A low weight-for-age Z-score was associated with low bone mineral density. Early nutritional intervention to optimise body weight may help to increase bone mineral density.
 
New knowledge added by this study
  • Anticonvulsant use shows no significant and detrimental impact on bone mineral density (BMD) of non-ambulatory cerebral palsy children.
  • A low weight-for-age Z-score was found to be a significant independent risk factor predictive of low BMD.
Implications for clinical practice or policy
  • Optimal pharmacological treatment for epilepsy control can be pursued without jeopardising bone mineralisation in non-ambulatory cerebral palsy children.
  • Optimising nutritional status in this group of children is important in improving bone mineralisation and thus decreasing pathological fracture.
 
 
Introduction
Osteoporosis is a skeletal disorder characterised by low bone mass and micro-architectural deterioration of bone tissue that results in compromised bone strength and a predisposition to fracture.1 Childhood and adolescence are critical periods for bone mineralisation. Peak bone mineral density (BMD) achieved by early adulthood determines the risk of pathological fracture. Bone mass can be objectively measured by BMD and is correlated with risk of osteoporotic fracture.2
 
Dual-energy X-ray absorptiometry (DXA) scanning enables cost-effective quantitative measurement of BMD. Such methodology is the gold standard because it can detect bone mineral loss of 2% to 5%. Abnormal homeostasis of vitamin D, calcium, and phosphorous may lead to imbalanced osteoclastic and osteoblastic dynamics that will result in osteopenia and even osteoporosis. There have been reports from large- and small-scale studies of problems in bone mineralisation and vitamin D or calcium metabolism in patients with cerebral palsy (CP).3 4 Dietary restrictions, oromotor dysfunction, malabsorption, and limited sunlight exposure may lead to poor nutrition, low calcium intake, or altered vitamin D metabolism. These in turn contribute to poor mineralisation. Limited weight-bearing during the period of skeletal growth may also lead to reduced BMD. Chronic therapy with antiepileptic drugs (AEDs) may cause hypocalcaemia, hypophosphataemia, raised serum alkaline phosphatase, elevated serum parathyroid hormone, reduced biologically active vitamin D metabolites, rickets, and osteomalacia. The mechanism is unclear, however.5
 
A study revealed that AED use was associated with reduced BMD in 35 pairs of twin adults, and the effect was more marked in those prescribed enzyme-inducing AEDs, for example, phenytoin and phenobarbitone.6 A decrease in BMD (in g/cm2) of 6.4% and 4.6% at the lumbar spine and femoral neck respectively in their twin control pair was detected. For valproate, the effect was not consistently demonstrated.7 8
 
Chronic treatment with AEDs was observed to be significantly correlated with a lower BMD in 96 ambulatory children and young adults with epilepsy with a mean Z-score of -1.23 compared with 0.16 of a control group.9 In our retrospective study of 109 CP children in 2006, however, we could not demonstrate any association of AEDs with increased fracture rate in non-ambulatory CP children.10 In children with CP and a Gross Motor Function Classification System (GMFCS) level of 4 to 5 (bed-bound), the possible impact of anticonvulsants on BMD was not clearly demonstrated.
 
The primary objective of this study was to evaluate the effect of AEDs on BMD in non-ambulatory children with CP. The secondary objective was to identify the risk factors for low BMD in this group of children.
 
Methods
Subjects
Patients at the Developmental Disabilities Unit (DDU) of Caritas Medical Centre, Hong Kong were enrolled in the study from 1 October 2012 to 30 September 2013. The DDU is the largest long-term care facility for children with severe developmental disabilities and special health care needs in Hong Kong. Among the 100 residents, over 90% were non-ambulatory and over 50% had CP.
 
The inclusion criteria in this study were: (1) children and adolescents aged between 5 and 19 years; (2) GMFCS level 4 or 5; (3) the presence of spastic or mixed spastic dyskinetic CP; and (4) prescribed AED for more than 2 years.
 
The control group without anticonvulsant therapy comprised concomitant non-ambulatory DDU residents with CP who were not prescribed AEDs for more than 2 years prior to recruitment to the study.
 
The exclusion criteria included (1) GMFCS level of 1 to 3; (2) patients with underlying hepatic or renal disease; (3) presence of disease primarily involving bone metabolism or a family history of bone metabolic disorders; (4) known thyroid or parathyroid disease; (5) history of pathological long bone fracture; (6) history of chronic diarrhoea or malabsorption; (7) long-term intake of the following medications: non-physiological dose of glucocorticoid, anabolic steroid, vitamin A, non-steroidal anti-inflammatory drugs, bisphosphonates, thiazide diuretics, or calcitonin.
 
Sample size estimation
Coppola et al9 reported a mean BMD Z-score of -1.23 and 0.16 in 96 ambulatory epileptic patients and 63 controls, respectively. In 2012, the same group showed the mean Z-score to be -1.69 (n=47) and -0.83 (n=40) respectively in mentally retarded children with CP, with and without epilepsy.11 Based on these findings, we proposed a difference in Z-score of ≥1 to indicate a clinically significant reduction in BMD. In order to detect a Z-score difference of 1 with power of 0.8, 16 subjects were recruited in each group.12
 
Data collection and determination of bone mineral density
Upon entry, data were collected for age, gender, body weight, body height, body mass index (BMI), presence of contractures, skinfold thickness (triceps, lower biceps, and subscapular), and pubertal stage according to Tanner’s classification. Weight-for-age Z-score was calculated based on referenced data from a 1993 territory-wide growth survey of Hong Kong children.13 Blood taking was performed on the same day of DXA scan to evaluate calcium, phosphorous, alkaline phosphatase, transaminase, total protein, urea, creatinine, serum osmolality, and total cell count. A spot urine calcium-to-creatinine ratio (mmol/mmol) and urine calcium-to-osmolality ratio (mg/L:mosmo/kg) was also determined on the same day. Current dietary information was reviewed and daily calcium and vitamin D content were calculated by a dietitian.
 
In this study, BMD was determined by DXA of total body less head (TBLH) using a Lunar Prodigy Advance DXA bone densitometer (GE Healthcare, Madison [WI], US) with the latest Chinese children total BMD database installed.14 15 All subjects had BMD measured by the same validated densitometer to eliminate measurement error. Individual BMD value was expressed as g/cm2 and Z-score. Z-score is the number of standard deviations of the patient’s BMD above or below the average age- and sex-matched reference value. For the paediatric age-group, the current definition for osteoporosis includes BMD Z-score of ≤–2.0 adjusted for age, gender, and body size plus a clinically significant fracture defined in the International Society for Clinical Densitometry (ISCD) 2007 official positions.16 The head is disproportionately large in young children and may mask deficits at other skeletal sites, thus TBLH (subtotal/TBLH) BMD, which was recommended by ISCD 2007 official positions for the evaluation of child’s bone health, was used in this study. For children with CP, TBLH BMD is more feasible and provides a holistic picture for BMD estimation.
 
Statistical analyses
Effect of antiepileptic drugs on bone mineral density in non-ambulatory children with cerebral palsy
In bivariate analysis, normally and non-normally distributed data were analysed by independent sample t tests and Mann-Whitney U tests, respectively. Categorical data were compared using Chi squared and Fisher’s exact tests. Clinically relevant covariates (presence of puberty, daily calcium intake, and number of AED use) and the covariate (weight-for-age Z-score) approaching statistical significance (P<0.05) in bivariate analysis were entered into multivariable analysis (Enter Method). Statistical significance was defined as two-tailed probability below 0.05.
 
Risk factors for low bone mineral density in non-ambulatory children with cerebral palsy
Data of TBLH were split into low-BMD group versus normal-BMD group—those with TBLH Z-score of ≤–2.0 were considered to have low BMD. Baseline characteristics of the low- and normal-BMD groups were compared. Multivariable logistic regression analysis was used to examine the independent effect of puberty, weight-for-age Z-score (gender adjusted), number of AEDs, and daily calcium intake on TBLH Z-score.
 
All statistical analyses were performed using the Statistical Package for the Social Sciences (Windows version 13.0; SPSS Inc, Chicago [IL], US).
 
The study was approved by the Ethics Committee of Kowloon West Cluster of Hospital Authority, Hong Kong. Informed consent was obtained from respective parents or the legal guardians from the Social Welfare Department, Government of the Hong Kong Special Administrative Region.
 
Results
Effect of antiepileptic drugs on bone mineral density in non-ambulatory children with cerebral palsy
The subjects were enrolled from 1 October 2012 to 30 September 2013 in DDU. Sixty-two children with CP aged 5 to 19 years were identified. Informed consent was obtained from a legal guardian for 44 patients of whom 12 were excluded from study—four had a history of fracture, two had severe deformity making DXA technically difficult, one had poorly controlled asthma and required long-term steroid therapy, and five had deranged liver or renal function. Of the remaining 32 children and adolescents, 18 (6 males, 12 females) aged 5.0 to 19.5 (mean ± standard deviation, 13.8 ± 4.7) years comprised the study group. The control group consisted of 14 children and adolescents (6 males, 8 females) aged 7.0 to 19.1 (mean, 16.4 ± 3.0) years.
 
Among the 18 subjects in the study group, eight were prescribed one AED and 10 were prescribed two or more. Sodium valproate was prescribed to eight children, carbamazepine to three, topiramate to three, phenobarbitone to five, phenytoin to one, and lamotrigine to four. In view of the limited population size, the impact of individual anticonvulsants was not analysed.
 
The two groups showed no significant difference in age, gender, BMI, weight-for-age Z-score, CP type, daily calcium intake, or daily vitamin D intake (Table 1).
 

Table 1. Comparison of clinical characteristics and TBLH Z-score in children prescribed anticonvulsants (study group) and those not (control group)
 
Twelve (67%) patients in the study group were in puberty, compared with 13 (93%) patients in the control group (P=0.104). Sixteen (89%) patients in the study group were tube feeders compared with four (29%) in the control group (P=0.001). Among the oral feeders, all were reported by their caretaker to have a satisfactory dietary intake. Mean weight-for-age Z-score showed no significant difference between the study and control groups (P=0.226) [Table 1]. There was also no significant difference in the TBLH Z-scores (P=0.989; Table 1) or biochemical parameters of bone metabolism between the two groups (Table 2).
 

Table 2. Comparison of biochemical parameters of bone metabolism in children prescribed anticonvulsants (study group) and those not (control group)
 
Low BMD was defined as TBLH Z-score of ≤–2.0 and was evident in 18 (56%) patients. When comparing groups with low and normal BMD, there was no significant difference on univariate analysis in gender, age, CP, BMI, feeding mode, use of AEDs, puberty, or daily calcium and vitamin D intake (Table 3). Weight-for-age Z-score was significantly lower (-2.57 vs -1.12; P=0.001) in the low BMD group (Table 3).
 

Table 3. Comparison of clinical characteristics and use of anticonvulsants between children with low and normal BMD
 
When covariates including weight-for-age Z-score, presence of puberty, daily calcium intake, and number of AEDs used were analysed by multiple logistic regression, higher weight-for-age Z-score (adjusted odds ratio [OR]=0.015; 95% confidence interval [CI], 0.001-0.390) and presence of puberty (adjusted OR=0.027; 95% CI, 0.001-0.948) remained significant independent predictors for occurrence of a relatively normal BMD (ie TBLH Z-score >2.0). Hosmer-Lemeshow goodness of fit test (P=0.315) was non-significant, indicating a model prediction that was not significantly different to observed values. Nagelkerke R2 was 0.677, again signifying a relatively well-fitting model (Table 4).
 

Table 4. Multivariate analysis of potential factors affecting TBLH BMD Z-score
 
Discussion
In the present study, DXA evaluation in non-ambulatory children with CP, with or without AED use, revealed a low BMD in 56% of those who underwent DXA. This is concordant with the findings in previous studies4 17 18 19 with prevalence of low BMD ranging from 27% to 77%. Low BMD is the proximate cause of low-energy fracture in this group of children. Other factors such as stiff joints, poor balance leading to falls, and violent seizures may also contribute. Nearly 20% of such children have sustained a femoral fracture at some point.20
 
The impact of AED on BMD was unclear in non-ambulatory children with CP. The physician often faces a dilemma in optimising anticonvulsant treatment in this group of children who are already at high risk of developing osteoporotic long bone fracture.
 
Early studies revealed that treatment with enzyme-inducing anticonvulsants—for example, phenytoin and phenobarbitone—may induce catabolism of 25-hydroxyvitamin D, leading to rickets.21 22 Recent research on the effect of AED on BMD is inconclusive, and the results are often confounded by methodological flaws. In a cross-sectional study, Farhat et al5 measured the BMD in 71 ambulatory subjects who were prescribed AED for more than 6 months. Reduced BMD was found in adults (n=42) but not children (n=29). There was no control group and the findings were only compared with paediatric data from the manufacturer, rendering it difficult to detect any small but significant difference secondary to AED treatment. Ecevit et al23 measured femoral neck BMD in 31 healthy children and 33 subjects with idiopathic epilepsy treated with either carbamazepine (n=17) or valproate (n=16). Valproate but not carbamazepine monotherapy was associated with a significant reduction in BMD. In this study, however, more children had attained puberty in the control group (n=13, 93%) than in the AED group (n=12, 67%), which may have confounded the results. Coppola et al9 compared the BMD of 96 children with epilepsy alone or in association with CP and/or mental retardation against a control group of 63 healthy ambulatory subjects. While univariate analysis illustrated a reduced BMD Z-score in the AED group, no difference was found after adjustment for ambulatory status, mental retardation, lack of physical activity, and BMI in multivariate analysis.
 
In this study, we focused on non-ambulatory children with CP and severe mental retardation. This is the population most vulnerable to pathological long bone fracture, with a lifetime risk estimated to be 20%. This group of children is also prone to develop refractory epilepsy that requires multiple AEDs at high doses. By recruiting concomitant residents from the same facility as the control group, we minimised the confounding effect of factors that may contribute to low BMD, namely ambulatory status, physical activity, and nutritional status. Our findings support that long-term use of AED in this group of children does not have any significant adverse effect on BMD. Optimal pharmacological treatment can be pursued without jeopardising bone mineralisation.
 
In multivariable analysis, there was a significant association of BMD Z-score with the presence of puberty. This may be due to the physiology and time frame for bone mineralisation that surges in puberty and reaches a peak at 20 years of age. Variation in time of starting puberty was a confounding factor as BMD Z-score was adjusted for gender and age only.
 
This study was carried out in a single institution for disabled children in Hong Kong. Because of the need for sedation and exposure to radiation, guardians of children with more severe neurological disease tended not to consent for the study. Moreover, DXA could not be properly performed in patients with severe deformity. These children were not included in the study.
 
An inadequate number of patients in each group may have impacted the power of this study. Nevertheless, the result showed a strong association for weight-for-age Z-score with TBLH BMD. We believe the association was highly statistically significant.
 
Children with CP are at risk of malnutrition that has a significant impact on linear growth, wound recovery, motor function, and even survival. In addition to poor linear growth, malnourished children with severe CP are likely to have poor bone mineralisation leading to painful pathological fracture. In a retrospective study of 107 CP children (90 non-ambulatory), weight-for-age Z-score proved to be the best predictor of BMD Z-score.24 In the present study, we demonstrated a significant correlation of low weight-for-age Z-score with low BMD, with a relatively well-fitting model after adjusting for pubertal stage, calcium intake, and AED use. This is concordant with our previous findings in the same population in which there was a significant protective effect of increase in weight-for-age Z-score in reducing fracture risk (adjusted OR=0.41).10 A recent review of 32 cross-sectional, cohort, case-control, and randomised controlled trials suggested that reduced bone density, impaired bone growth, and vitamin D deficiency may be seen in children treated with anticonvulsants.25 In our study, individual vitamin D daily intake was calculated by dietitians. Sun exposure was limited in the institutional setting. Thus, we assumed that the calculated daily oral vitamin D intake correlated well with the serum vitamin D level. Although the daily vitamin D intake was similar in the low- and normal-BMD groups (P=0.297) as well as the study and control groups (P=0.702), 10 out of 32 subjects in the study consumed less than the recommended daily vitamin D intake (400 IU/day). To improve BMD and decrease fracture risk, regular nutritional assessment is necessary to identify malnourished children. Supplementation of vitamin D and calcium should be considered if the calculated daily need cannot be met. A nutritional rehabilitation programme should be implemented to optimise weight-for-age Z-score. Early gastrostomy tube placement should be considered in children with poor oral feeding. In children with weight-for-age Z score of ≤–2.0, serial BMD measurements can help to identify severe osteoporosis before fracture occurs. This window of time allows implementation of intensive nutritional rehabilitation, pharmacological intervention, and precautions in handling to prevent fracture occurrence.
 
Conclusion
Use of AED in non-ambulatory children with CP is unlikely to pose a detrimental impact on BMD. A low weight-for-age Z-score is a significant independent risk factor predictive of low BMD. Optimising nutritional status in this group of children is paramount to improving bone mineralisation and thus decreasing pathological fracture.
 
Acknowledgement
The authors would like to thank Ms Geraldine Ng, dietitian of Caritas Medical Centre, for her arduous effort to assess dietary calcium and vitamin D intake for our study patients.
 
Declaration
All authors have disclosed no conflicts of interest.
 
References
1. Houlihan CM, Stevenson RD. Bone density in cerebral palsy. Phys Med Rehabil Clin N Am 2009;20:493-508. Crossref
2. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-9. Crossref
3. Lee JJ, Lyne ED, Kleerekoper M, Logan MS, Belfi RA. Disorders of bone metabolism in severely handicapped children and young adults. Clin Orthop Relat Res 1989;245:297-302. Crossref
4. Henderson RC, Lark RK, Gurka MJ, et al. Bone density and metabolism in children and adolescents with moderate to severe cerebral palsy. Pediatrics 2002;110:e5. Crossref
5. Farhat G, Yamout B, Mikati MA, et al. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002;58:1348-53. Crossref
6. Petty SJ, Paton LM, O’Brien TJ, et al. Effect of antiepileptic medication on bone mineral measures. Neurology 2005;65:1358-65. Crossref
7. Sheth RD, Wesolowski CA, Jacob JC, et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr 1995;127:256-62. Crossref
8. Triantafyllou N, Lambrinoudaki I, Armeni E, et al. Effect of long-term valproate monotherapy on bone mineral density in adults with epilepsy. J Neurol Sci 2010;290:131-4. Crossref
9. Coppola G. Fortunato D, Auricchio G, et al. Bone mineral density in children, adolescents, and young adults with epilepsy. Epilepsia 2009;50:2140-6. Crossref
10. Ko CH, Tse PW, Chan AK. Risk factors of long bone fracture in non-ambulatory cerebral palsy children. Hong Kong Med J 2006;12:426-31.
11. Coppola G, Fortunato D, Mainolfi C, et al. Bone mineral density in a population of children and adolescents with cerebral palsy and mental retardation with or without epilepsy. Epilepsia 2012;53:2172-7. Crossref
12. Portney LG, Watkins MP. Foundations of clinical research applications to practice. 3rd ed. Upper Saddle River, NJ: Pearson/Prentice Hall; 2009: 832-47.
13. Leung SS, Lau JT, Tse LY, Oppenheimer SJ. Weight-for-age and weight-for-height references for Hong Kong children from birth to 18 years. J Paediatr Child Health 1996;32:103-9. Crossref
14. Xu H, Chen JX, Gong J, et al. Normal reference for bone density in healthy Chinese children. J Clin Densitom 2008;10:266-75. Crossref
15. Guo B, Xu Y, Gong J, Tang Y, Xu H. Age trends of bone mineral density and percentile curves in healthy Chinese children and adolescents. J Bone Miner Metab 2013;31:304-14. Crossref
16. Lewiecki EM, Gordon CM, Baim S, et al. International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone 2008;43:1115-21. Crossref
17. Hartman C, Brik R, Tamir A, Merrick J, Shamir R. Bone quantitative ultrasound and nutritional status in severely handicapped institutionalized children and adolescents. Clin Nutr 2004;23:89-98. Crossref
18. King W, Levin R, Schmidt R, Oestreich A, Heubi JE. Prevalence of reduced bone mass in children and adults with spastic quadriplegia. Dev Med Child Neurol 2003;45:12-6. Crossref
19. Ali O, Shim M, Fowler E, Cohen P, Oppenheim W. Spinal bone mineral density, IGF-1 and IGFBP-3 in children with cerebral palsy. Horm Res 2007;68:316-20. Crossref
20. Sturm PF, Alman BA, Christie BL. Femur fractures in institutionalized patients after hip spica immobilization. J Pediatr Orthop 1993;13:246-8.
21. Crosley CJ, Chee C, Berman PH. Rickets associated with long-term anticonvulsants therapy in a pediatric outpatient population. Pediatrics 1975;56:52-7.
22. Keck E, Gollnick B, Reinhardt D, Karch D, Peerenboom H, Krüskemper HL. Calcium metabolism and vitamin D metabolite levels in children receiving anticonvulsant drugs. Eur J Pediatr 1982;139:52-5. Crossref
23. Ecevit C, Aydoğan A, Kavakli T, Altinöz S. Effect of carbamazepine and valproate on bone mineral density. Pediatr Neurol 2004;31:279-82. Crossref
24. Henderson RC, Kairalla J, Abbas A, Stevenson RD. Predicting low bone density in children and young adults with quadriplegic cerebral palsy. Dev Med Child Neurol 2004;46:416-9. Crossref
25. Vestergaard P. Effects of antiepileptic drugs on bone health and growth potential in children with epilepsy. Pediatr Drugs 2015;17:141-50. Crossref

Mortality following primary total knee replacement in public hospitals in Hong Kong

Hong Kong Med J 2016 Jun;22(3):237–41 | Epub 6 May 2016
DOI: 10.12809/hkmj154712
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
ORIGINAL ARTICLE
Mortality following primary total knee replacement in public hospitals in Hong Kong
QJ Lee, FHKCOS, FHKAM (Orthopaedic Surgery); WP Mak, MPHC, FPHKAN; YC Wong, FHKCOS, FHKAM (Orthopaedic Surgery)
Joint Replacement Centre, Yan Chai Hospital, Tsuen Wan, Hong Kong
 
Corresponding author: Dr QJ Lee (leejasper@gmail.com)
 
 Full paper in PDF
Abstract
Introduction: More than 2000 total knee replacements are performed each year in Hong Kong and more than 10 000 patients are on the waiting list. How safe is total knee replacement, however? The aims of the study were to review the mortality of primary total knee replacement in public hospitals in Hong Kong and to identify risk factors for mortality in a high-volume hospital.
 
Methods: All primary total knee replacements performed in Hospital Authority hospitals and Yan Chai Hospital from October 2011 to September 2014 were reviewed. Case-control analysis was performed for risk factors of total all-cause mortality in total knee replacement at Yan Chai Hospital.
 
Results: There were 6588 patients in Hospital Authority hospitals and 1184 in Yan Chai Hospital (1095 unilateral and 89 bilateral total knee replacement). The mean follow-up time of patients in Yan Chai Hospital was 12.8 months. The mortality at 30 days, 90 days and 1 year was 0%, 0.08%, 0.34% for Yan Chai Hospital; and 0.1%, 0.2%, 0.7% for Hospital Authority hospitals, respectively. For Yan Chai Hospital, the mean operation-to-death interval was 21 months (range, 1-35 months). The mean age at death was 78 years and main causes were malignancy (50%) and pneumonia (21%). Predictors of mortality included age at surgery, American Society of Anesthesiologists class 3, and preoperative range of motion. Hospital surgery volume, preoperative co-morbidities, and postoperative deep vein thrombosis were not significant factors.
 
Conclusions: Mortality after primary total knee replacement was low in public hospitals in Hong Kong. Patients of older age or poorer general well-being in terms of poor range of motion or American Society of Anesthesiologists class 3 should be in optimal health before surgery and counselled about the higher mortality rate. A citywide joint replacement registry may help monitor and analyse postoperative total knee replacement mortality specific to our locality.
 
New knowledge added by this study
  • Preoperative range of motion may be predictive of mortality in primary total knee replacement.
Implications for clinical practice or policy
  • Proper preoperative optimisation of general health and counselling is necessary before primary total knee replacement.
 
 
Introduction
More than 2000 primary total knee replacements (TKR) are performed in Hong Kong each year and more than 10 000 patients are on the waiting list for TKR at public hospitals. With an ever-increasing waiting list, joint replacement centres with high surgery volume have been set up in public hospitals. More such centres are planned in the future to tackle the ageing population and rising demand. As one of the most popular elective ‘ultra-major’ surgeries, how safe is primary TKR?
 
According to various knee replacement registries, 30-day mortality of TKR ranges from 0.2% to 0.4%, 90-day mortality 0.4% to 0.7%, and 1-year mortality 1% to 2%.1 2 3 4 5 6 7 8 Risk factors for post-TKR mortality include age at operation, male sex, too high or low body mass index, American Society of Anesthesiologists (ASA) class 3 to 4, presence of co-morbidities, and simultaneous bilateral surgery.1 2 3 4 6 7 8 9 10 11 12 There are a lack of similar data for the Asian population, however, and the risk of mortality in a high-volume hospital has not been described locally. The aims of the study were to review the mortality of primary TKR in Hong Kong and to identify risk factors of post-TKR mortality in a high-volume hospital.
 
Methods
Data retrieval
All primary TKR performed in public hospitals (Hospital Authority) and all primary TKR at the authors’ institute (Yan Chai Hospital, YCH) from October 2011 to September 2014 were reviewed. Data retrieval for all public hospitals was performed with the Clinical Data Analysis and Reporting System. Procedure code for retrieval was “81.54 TOTAL KNEE REPLACEMENT”. Data of patients at our institute were retrieved additionally with Clinical Management System of the Hospital Authority. The medical records of all deceased cases before September 2015 were reviewed.
 
Data analyses
The primary outcome measures were 30-day, 90-day, and 1-year mortality. Correlation coefficient between 30-day, 90-day, and 1-year mortality and annual surgery volume of all public hospitals was calculated with Pearson test. From data of YCH, comparisons were made between the mortality of unilateral TKR and simultaneous bilateral TKR. Case-control analysis was performed for possible risk factors of primary TKR total mortality. A control group included non-mortality cases of all simultaneous bilateral TKR in the same period and all unilateral primary TKR performed from October 2012 to March 2013. The latter period was chosen to allow a 1-year ‘run-in’ time for the newly established joint replacement centre that commenced operation in October 2011. All bilateral cases were used due to their relative scarcity. Chi squared test and Fisher’s exact test were used for univariate analysis, and multiple logistic regression was used for multivariate analysis. Final model for multiple logistic regression was identified by backward elimination. A P value of <0.05 was considered statistically significant.
 
Results
There were 6588 primary TKR in 15 public hospitals and 1184 primary TKR at YCH (1095 unilateral and 89 bilateral). The 30-day, 90-day, and 1-year mortality was 0% (n=0), 0.08% (n=1), and 0.34% (n=4) for YCH and 0.1% (n=8), 0.2% (n=16), and 0.7% (n=48) for all public hospitals (YCH inclusive), respectively (Table 1). There was no correlation between hospital surgery volume and 30-day, 90-day, or 1-year mortality among the 15 public hospitals (R=0.151, P=0.578; R=0.031, P=0.910; R=0.032, P=0.972, respectively). For cases at YCH, the mean follow-up time was 12.8 (range, 4-38) months, the mean operation-to-death interval was 21 (1-35) months, and the mean age at death was 78 (70-87) years. Main causes of death were malignancy (50%) and pneumonia (21%) [Table 2]. Significant predictors of total mortality identified by univariate analysis included age at operation, preoperative range of motion (ROM), and ASA class 3; the former two were also confirmed by the final model of multivariable analysis (Table 3). The mean age at operation was 76 versus 68 years for mortality and non-mortality cases while the mean preoperative ROM was 95 versus 108 degrees, respectively. Body mass index, co-morbidities, deep vein thrombosis (DVT) prophylaxis, and postoperative DVT did not differ significantly between the two groups. Preoperative Western Ontario and McMaster Universities Arthritis Index (WOMAC), Knee Society score (KSS), and function score (FS) were also not significantly different. There was no significant difference in 30-day, 90-day, or 1-year mortality for bilateral TKR versus unilateral TKR (Table 1).
 

Table 1. Comparison of mortality rates
 

Table 2. Summary of mortality cases in Yan Chai Hospital from October 2011 to September 2014
 

Table 3. Predictors of all-cause mortality in patients with primary total knee replacement in Yan Chai Hospital
 
Discussion
Mortality rate
The 30-day, 90-day, and 1-year mortality in Hong Kong public hospitals was 0.1%, 0.2%, and 0.7%, respectively. These compared favourably with data of large national joint registries of other countries: 0.2% to 0.4%, 0.4% to 0.7%, and 1% to 2%, respectively.1 2 3 4 5 6 7 8 There is no definitive explanation for such findings but several possibilities exist. First, TKR is still mostly considered a ‘risky’ and major operation in Hong Kong such that the popularity of such surgery remains low compared with other countries. In 2013, the incidence of primary TKR was around 4 per 10 000 population in Hong Kong (estimated from data of the present study) compared with 12 in the United Kingdom, 14 in Sweden, and 19 in Australia.13 14 15 Lower operation incidence implies stricter selection criteria for operation. Second, the mortality of the general population of Hong Kong is known to be among the lowest in the world16; our findings may partly reflect the low mortality of the general population. Third, easy access to medical treatment in Hong Kong might facilitate timely intervention of early complications, hence reducing postoperative mortality. Whatever the explanation, the lower mortality indicates that primary TKR in Hong Kong are safe and conform to international standards.
 
One-year mortality following primary TKR in Hong Kong was lower than the mortality of the general population of the same age16 (Table 1). Similar findings have been shown by other studies.17 It has been suggested that strict selection criteria for operation meant that those selected were of better health than the general population. It was also hypothesised that pain relief and restored function would have a positive effect on a patient’s overall health, hence a lower mortality in the long term. Nevertheless, 1-year may be too short a period for the latter effect to be obvious.
 
Mortality risk factors
In the present study, older age at operation was identified as a significant risk factor. This is consistent with findings in other studies.2 3 4 6 7 8 9 11 18 Some studies have reported higher 30-day,2 3 4 higher 90-day,6 7 and even higher total mortality in the long term.9 11 With an ageing population and higher life expectancy, there will be more patients with older age in future who undergo TKR. To date, there is no consensus on an age limit for the procedure. It is agreed that patients in their 80s or even 90s could still benefit from the surgery18 provided the associated higher mortality is well explained and accepted.
 
The presence of co-morbidities was not a significant predictor of mortality in the present study. Rather, the poor control or the severity of co-morbidities in terms of ASA class 3 was found by univariate analysis to be a significant factor. There is evidence that patients with only specific co-morbidities such as cardiovascular disease will have higher mortality.1 4 6 7 8 19 In addition, higher 30-day mortality,3 90-day mortality,6 and total mortality8 9 have been associated with higher ASA class. The lack of significance of ASA class 3 in multivariate analysis in our study suggests an underlying confounding factor. Analysis by t test showed that the age of patients with ASA class 3 was significantly older (72 vs 67 years, P<0.001). Thus in the present study, ASA class was confounded by age at surgery.
 
Preoperative ROM was also found to be a significant factor by univariate and multivariate analyses in the present study. This might be a novel finding. The exact explanation for such an association requires exploration by further study. One possibility is that preoperative ROM predicts postoperative ROM20 that in turn affects postoperative ambulation and function. As mentioned above, it was hypothesised that restored ambulation and function can have a positive effect on a patient’s overall health, hence a lower mortality. There are studies which reported an association between mortality and postoperative knee function. The latter was in terms of preoperative ambulatory status,8 postoperative ambulatory status, and postoperative WOMAC pain score.11 No knee score in the present study was found to be a significant predictor of mortality, however. One explanation could be that FS, WOMAC, and a large portion of KSS are patient-reported outcomes whereas ROM is an objective measurement; the more objective the measurement, the better it might be in predicting a secondary outcome such as mortality.
 
Although bilateral TKR has been found by several studies to have a higher mortality rate,12 21 22 it was not a significant predictor in the present study. Our institute performed bilateral TKR in selected patients with mild and well-controlled co-morbidities and younger age. Also, the fast-track rehabilitation protocol was used with an average length of hospital stay of 9.6 days (authors’ unpublished data). The results of analysis might reflect the equivalent safety of bilateral TKR with careful patient selection and fast-track rehabilitation. Many studies have demonstrated equal mortality for bilateral TKR with careful patient selection and a fast-track protocol.23 24
 
The present study has some limitations. First, due to inconsistent documentation across all public hospitals, data for case-control analysis for predictors of mortality were obtained from patients at our institute only. The smaller sample size limited the power of analysis of the present study. Second, since 70% of the mortality of our institute occurred more than 1 year after surgery and the mean operation-to-death interval was 21 months, analysis for predictors of mortality was performed on total mortality rather than 30-day, 90-day, or 1-year mortality. The very low early mortality in our institute and in Hong Kong means that a more powerful analysis of mortalities within 1 year may require a much larger sample size. This calls for a citywide joint replacement registry in which there is unified and detailed documentation of preoperative patient parameters, operative details, and postoperative outcome measurements. Such registries have already been established nationwide for 11 years in the United Kingdom13 and for 40 years in Sweden.14 Third, data for other known significant predictors of all-cause mortality, such as smoking and alcoholism, were not analysed. These factors might have confounded the present study. Since these factors are not known to be associated with age or preoperative ROM, the influence of these potential confounders on the conclusion of the present study should be insignificant. Lastly, the period chosen for selection of the control group did not fully match the death cases. This may have introduced confounding factors or made the groups incomparable. Since there was no change in the indications for surgery, surgical practice or rehabilitation protocol during the study period, and the sampled control should be representative of the target population.
 
Conclusions
Mortality after primary TKR was low in public hospitals in Hong Kong. Patients of older age or poorer general health in terms of poor ROM or ASA class 3 should be in optimal health before surgery and counselled about the higher mortality rate. The role of a pre-admission clinic and fast-track rehabilitation in contributing to the lower mortality in our institute should be further explored. A citywide joint replacement registry may help monitor and analyse post-TKR mortality specific to our locality.
 
Declaration
All authors have disclosed no conflicts of interest.
 
References
1. Hunt LP, Ben-Shlomo Y, Clark EM, et al. 45-Day mortality after 467,779 knee replacements for osteoarthritis from the National Joint Registry for England and Wales: an observational study. Lancet 2014;384:1429-36. Crossref
2. Lie SA, Pratt N, Ryan P, et al. Duration of the increase in early postoperative mortality after elective hip and knee replacement. J Bone Joint Surg Am 2010;92:58-63. Crossref
3. Belmont PJ Jr, Goodman GP, Waterman BR, Bader JO, Schoenfeld AJ. Thirty-day postoperative complications and mortality following total knee arthroplasty: incidence and risk factors among a national sample of 15,321 patients. J Bone Joint Surg Am 2014;96:20-6. Crossref
4. Parvizi J, Sullivan TA, Trousdale RT, Lewallen DG. Thirty-day mortality after total knee arthroplasty. J Bone Joint Surg Am 2001;83-A:1157-61.
5. Pedersen AB, Mehnert F, Sorensen HT, Emmeluth C, Overgaard S, Johnsen SP. The risk of venous thromboembolism, myocardial infarction, stroke, major bleeding and death in patients undergoing total hip and knee replacement: a 15-year retrospective cohort study of routine clinical practice. Bone Joint J 2014;96-B:479-85. Crossref
6. Singh JA, Lewallen DG. Ninety-day mortality in patients undergoing elective total hip or total knee arthroplasty. J Arthroplasty 2012;27:1417-1422.e1. Crossref
7. Gill GS, Mills D, Joshi AB. Mortality following primary total knee arthroplasty. J Bone Joint Surg Am 2003;85-A:432-5.
8. Jämsen E, Puolakka T, Eskelinen A, et al. Predictors of mortality following primary hip and knee replacement in the aged. A single-center analysis of 1,998 primary hip and knee replacements for primary osteoarthritis. Acta Orthop 2013;84:44-53. Crossref
9. Clement ND, Jenkins PJ, Brenkel IJ, Walmsley P. Predictors of mortality after total knee replacement: a ten-year survivorship analysis. J Bone Joint Surg Br 2012;94:200-4. Crossref
10. Thornqvist C, Gislason GH, Køber L, Jensen PF, Torp-Pedersen C, Andersson C. Body mass index and risk of perioperative cardiovascular adverse events and mortality in 34,744 Danish patients undergoing hip or knee replacement. Acta Orthop 2014;85:456-62. Crossref
11. Lizaur-Utrilla A, Gonzalez-Parreño S, Miralles-Muñoz FA, Lopez-Prats FA. Ten-year mortality risk predictors after primary total knee arthroplasty for osteoarthritis. Knee Surg Sports Traumatol Arthrosc 2015;23:1848-55. Crossref
12. Restrepo C, Parvizi J, Dietrich T, Einhorn TA. Safety of simultaneous bilateral total knee arthroplasty. A meta-analysis. J Bone Joint Surg Am 2007;89:1220-6. Crossref
13. 11th Annual Report. National Joint Registry for England, Wales and Northern Ireland. UK: National Joint Registry; 2014: 73-121.
14. Annual Report 2013. The Swedish Knee Arthroplasty Register; 2013: 2-55.
15. Australian Orthopaedic Association National Joint Replacement Registry. Annual Report. Adelaide: Australian Orthopaedic Association; 2014: 126-207.
16. The mortality trend in Hong Kong, 1981 to 2013. Hong Kong Monthly Digest of Statistics; 2014: 4-10.
17. Lovald ST, Ong KL, Lau EC, Schmier JK, Bozic KJ, Kurtz SM. Mortality, cost, and health outcomes of total knee arthroplasty in Medicare patients. J Arthroplasty 2013;28:449-54. Crossref
18. Miric A, Inacio MC, Kelly MP, Namba RS. Can total knee arthroplasty be safely performed among nonagenarians? An evaluation of morbidity and mortality within a total joint replacement registry. J Arthroplasty 2014;29:1635-8. Crossref
19. Robertsson O, Stefánsdóttir A, Lidgren L, Ranstam J. Increased long-term mortality in patients less than 55 years old who have undergone knee replacement for osteoarthritis: results from the Swedish Knee Arthroplasty Register. J Bone Joint Surg Br 2007;89:599-603. Crossref
20. Parsley BS, Engh GA, Dwyer KA. Preoperative flexion. Does it influence postoperative flexion after posterior-cruciate-retaining total knee arthroplasty? Clin Orthop Relat Res 1991;(275):204-10.
21. Hu J, Liu Y, Lv Z, Li X, Qin X, Fan W. Mortality and morbidity associated with simultaneous bilateral or staged bilateral total knee arthroplasty: a meta-analysis. Arch Orthop Trauma Surg 2011;131:1291-8. Crossref
22. Fu D, Li G, Chen K, Zeng H, Zhang X, Cai Z. Comparison of clinical outcome between simultaneous-bilateral and staged-bilateral total knee arthroplasty: a systematic review of retrospective studies. J Arthroplasty 2013;28:1141-7. Crossref
23. Kim YH, Choi YW, Kim JS. Simultaneous bilateral sequential total knee replacement is as safe as unilateral total knee replacement. J Bone Joint Surg Br 2009;91:64-8. Crossref
24. Powell RS, Pulido P, Tuason MS, Colwell CW Jr, Ezzet KA. Bilateral vs unilateral total knee arthroplasty: a patient-based comparison of pain levels and recovery of ambulatory skills. J Arthroplasty 2006;21:642-9. Crossref

Acceptability of the combined oral contraceptive pill among Hong Kong women

Hong Kong Med J 2016 Jun;22(3):231–6 | Epub 11 Apr 2016
DOI: 10.12809/hkmj154672
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
ORIGINAL ARTICLE
Acceptability of the combined oral contraceptive pill among Hong Kong women
Sue ST Lo, MD, FRCOG; Susan YS Fan, MB, BS, MRCOG
The Family Planning Association of Hong Kong, 10/F, 130 Hennessy Road, Wanchai, Hong Kong
 
Corresponding author: Dr Sue ST Lo (stlo@famplan.org.hk)
 
 Full paper in PDF
Abstract
Objective: To evaluate the motivators and barriers to the use of the combined oral contraceptive pill among Hong Kong women.
 
Methods: The Family Planning Association of Hong Kong commissioned the ESDlife to launch an online survey and invited its female members aged 18 to 45 years who had used contraceptives in the past 12 months to participate in this survey. The online survey was posted on the ESDlife website between April 2015 and May 2015. Measurements included contraceptive choice, and motivators and barriers to the use of a combined oral contraceptive pill.
 
Results: A total of 1295 eligible women with a median age of 32 years participated in this survey. In the past 12 months, 76.1% of them used a male condom, 20.9% practised coitus interruptus, 16.2% avoided coitus during the unsafe period, and 12.6% took a combined oral contraceptive pill. These women chose a combined oral contraceptive for convenience, effectiveness, and menstrual regulation, though 60.9% had stopped the pills because they were worried about side-effects, experienced side-effects, or consistently forgot to take the pills. Some women had never tried a combined oral contraceptive pill because they feared side-effects, they were satisfied with their current contraceptive method, or pill-taking was inconvenient.
 
Conclusions: The combined oral contraceptive pill is underutilised by Hong Kong women compared with those in many western countries. A considerable proportion of respondents expressed concern about actual or anticipated side-effects. This suggests that there remains a great need for doctors to dispel the underlying myths and misconceptions about the combined oral contraceptive pill.
 
 
New knowledge added by this study
  • Some women chose a combined oral contraceptive (COC) pill for convenience, effectiveness, and menstrual regulation.
  • Some women had never tried a COC pill because they feared its side-effects, were satisfied with their current contraceptive method, or pill-taking was inconvenient.
  • Some women stopped taking their COC pill because they feared its side-effects, experienced side-effects, or consistently forgot to take pills.
Implications for clinical practice or policy
  • During contraceptive counselling, doctors should educate women and dispel the myths and misconceptions about COC pills.
  • Doctors should explain the side-effects of the COC pill, its absolute risk, and the underlying health conditions that might increase the risk of complications as well as the non-contraceptive benefits of COC thoroughly so that women can make an informed decision and use it safely.
  • To help women stay on the pill, doctors should inform women that different pills have slightly different side-effect profiles and they can switch to another formulation if they experience any problem with their current COC. Improving accessibility by allowing walk-in consultations for problems with the COC pill gives women additional support.
 
 
Introduction
According to the Family Planning Knowledge, Attitude and Practice in Hong Kong Survey 2012 among Hong Kong couples,1 the male condom was the most popular contraceptive. The proportion of couples who used a male condom doubled from 32.2% in 1987 to 69.6% in 2012. Combined oral contraceptive (COC) pill was the second most common form of contraception, though the proportion of women using a COC pill declined from 20.3% in 1987 to 10.8% in 2012. The failure rate of the male condom when used correctly is 6 times higher than that for the COC pill.2 Although the low-dose COC pill has a low incidence of complications, high efficacy, and many non-contraceptive benefits, relatively few women use it in Hong Kong. The report of the United Nations world contraceptive patterns 2013 estimated that the prevalence of pill use in Hong Kong women aged 15 to 49 years was 6.7%, which is much lower than other countries with similar development, wealth, and culture such as Australia (30.0%), Canada (21.0%), Singapore (10.0%), the UK (28.0%), and the US (16.3%).3 Unlike these countries, the COC pill is not a prescription drug in Hong Kong. Women can buy a low-dose COC pill that contains either 30-µg or 20-µg ethinylestradiol and one of the progestogens: levonorgestrel, gestodene, desogestrel, or drospirenone at any of the large-chain personal health and beauty retailers or pharmacy stores. All pills have similar efficacy. Their failure rate is 0.3% within the first year of perfect use.2 Low-dose pills are safer, better tolerated, and have equal or higher efficacy than high-dose pills that contain 50-µg ethinylestradiol.
 
With 70% of couples in Hong Kong using the male condom,1 the demand for abortion due to failed contraception cannot be ignored. It was shown that 77.4% of women who underwent an abortion were using contraception during the index pregnancy and 51.2% of them were using a male condom.1 The number of legal abortions in Hong Kong has reduced from 25 363 in 1995 to 10 359 in 2014 (personal communication, Department of Health), though the number of abortions carried out across the border is unknown. According to the results from the serial 5-yearly territory-wide family planning survey,1 the proportion of married women who went to China for their last abortion increased from 24.3% in 1992 to 47.2% in 2012. Given the limited resources assigned to abortion in public hospitals, women have to resort to the more expensive legal abortion service in private hospitals or the Family Planning Association of Hong Kong (FPAHK). The FPAHK performs 3000 medical and surgical first-trimester abortions each year and has reached its full service capacity. There is a need to further reduce unplanned pregnancies and abortion in Hong Kong. One plausible solution is to encourage more women to use more effective contraception such as the combined hormonal contraceptive pill, progestogen-only contraceptives, intrauterine contraceptive device, or sterilisation. The failure rate of these effective contraceptives when used correctly is <1% in the first year of use.2
 
Studies have shown that identifying women’s perspective can help doctors understand their motive to choose one contraceptive over another.4 One study identified personal choices, local factors, women’s perceived safety, effectiveness, and convenience of the method as determinants of contraceptive choice.5 Among the effective contraceptives available in Hong Kong, the COC pill is the most accepted. We performed this survey to determine the motivators and barriers to COC pill use.
 
Methods
The Family Planning Association of Hong Kong invited ESDlife to host the survey that was open to its female members aged between 18 and 45 years. The questionnaire was designed by the investigators. ESDlife is an online lifestyle media in Hong Kong. It is a joint venture between the Hong Kong SAR Government and a commercial firm that began in 2000 with the aim of providing e-government and e-commerce services. With the establishment of the Government’s own website in 2008, all government services have migrated to the official website and ESDlife remains a solely commercial portal. As of 2 January 2015, it had 297 152 members of whom 64.4% were female. Among the female members, 89.0% were within our target age range: 32.3% were 30-34 years old, 23.3% were 35-39 years old, 19.3% were 25-29 years old, 10.3% were 40-45 years old, and 3.8% were 18-24 years old.
 
ESDlife sent out 100 000 invitations randomly to its female members aged between 18 and 45 years on 21 April 2015 and invited them to participate in this online survey between 21 April 2015 and 20 May 2015. There were 16 questions that explored the basic demographic characteristics of respondents (6), their contraceptive choice (3), and their motivators and barriers to COC use (7). Invited members entered the survey via a link and those who had not used any contraception in the previous 12 months were screened out by the first question. Only eligible subjects could proceed with the survey. They could stop at any question and the questionnaire would be voided. To encourage participation, a $50 supermarket coupon was given to every 10th respondent via ESDlife. This study was reviewed and approved by the Health Services Subcommittee and Ethics Panel of the FPAHK.
 
Data analyses were accomplished using the Statistical Package for the Social Sciences (Windows version 22.0; SPSS Inc, Chicago [IL], US). Descriptive statistics were presented. Bivariate Chi squared test was performed to analyse the demographic characteristics that predicted COC pill use.
 
Results
During the survey period, only completed questionnaires were captured by the system so the number of incomplete questionnaires was unknown. A total of 1566 women completed the survey within the 1-month period, 271 were screened out by Question 1 because they had not used regular contraception in the past 12 months and 1295 questionnaires were analysed. The response rate was 1.57%. The median age of the respondents was 32 years (interquartile range, 29-36 years). Half of them (50.7%) had a university education, 20.5% had a post-secondary education (diploma or associate degree), and 28.3% had a secondary education. The majority (65.5%) were married, 29.0% were unmarried, 3.3% were cohabiting, 2.1% had separated or divorced, and 0.2% were widowed. Over half of the respondents were nulliparous (56.7%) and had no plan for pregnancy (52.3%). They usually purchased contraceptives from a chain of personal health and beauty retailers (52.8%), convenience store and supermarket (43.9%), or pharmacy (23.6%). They usually sought contraceptive information from an online health website (46.5%), online forum (40.1%), gynaecologists (27.8%), or family planning clinic (21.6%). A summary of the socio-demographic characteristics is shown in Table 1.
 

Table 1. Socio-demographic characteristics (n=1295)
 
Among the 1295 respondents, 453 (35.0%) had used more than one type of contraceptive in the previous 12 months. The contraceptive choices of the whole group were: male condom (76.1%), coitus interruptus (20.9%), safe period (16.2%), and COC pill (12.6%) [Table 1]. The contraceptive choices of the 986 male condom users were further analysed to estimate their risk of unplanned pregnancy. Among them, 598 (60.6%) used a male condom alone, 295 (29.9%) also used other less effective contraceptives such as a female condom, safe period, and coitus interruptus but whether they used them all together during coitus or switched between these contraceptives was unknown. Therefore, these condom users were indisputably at risk for unplanned pregnancy because they did not use other effective contraceptives with the male condom.
 
In this study sample, 842 (65.0%) women had never tried a COC pill. The main reasons were fear of side-effects (72.1%), satisfied with their current contraceptive (32.1%), and pill-taking was inconvenient for them (18.5%) [Table 2]. Among 453 women who had tried a COC pill, the median age they started use was 24 years (interquartile range, 20-28 years). Use of COC pill was associated with older age (mean ± standard deviation: users and non-users was 33.4 ± 5.8 and 32.4 ± 5.5 years, respectively; t test, P=0.003), not planning to get pregnant (P=0.002), and university education (P=0.004). There was no association with relationship status (P=0.968) or parity (p=0.427). These women preferred the COC pill because of convenience (47.7%), effectiveness (44.8%), menstrual regulation (33.6%), recommendation by their doctor (24.7%), reduced burden to partner (17.0%), for relief of dysmenorrhoea (14.1%), and improvement of acne (12.6%) [Table 3]. They chose a COC pill based on the dosage of hormones, type of hormones, and price. Among the 453 ever-users, 177 (39.1%) had been taking a COC pill in the previous 12 months. Use had stopped in 276 because they feared side-effects (39.1%); they experienced side-effects such as nausea, vomiting, breast tenderness, oedema, or weight gain (27.9%); they consistently forgot to take pills (19.9%); their doctor told them to stop (14.1%); or they were having less frequent coitus (12.3%) (Table 4).
 

Table 2. Reasons for never tried combined oral contraceptives (n=842)
 

Table 3. Reasons for using combined oral contraceptives (n=453)
 

Table 4. Reasons for cessation of combined oral contraceptives (n=276)
 
Discussion
The pattern of contraceptive use in this study sample was similar to that in the 2012 territory-wide survey.1 Male condom was the most popular contraceptive, used by 76.1% of couples in our study. The proportion of women using a COC pill in our study was also similar to that in the 2012 survey. Our survey has provided some information about the characteristics of women who chose to take the COC pill, such as older age, university education, and no plan for future pregnancy. A similar age profile and education attainment were identified in a national survey conducted in the US,6 in which parity and relationship status were also characteristics associated with COC pill use.
 
Fear of side-effects was the major reason cited by both subgroups of women who stopped or had never tried a COC pill. Studies carried out in both developed and developing countries have also shown that the experience of side-effects as well as the fear of side-effects are major reasons for discontinuation.7 8 9 10 It appeared that fear of side-effects was a unique barrier across different countries and cultures. Minor side-effects such as breast tenderness, fluid retention, nausea, and vomiting were transient and usually subsided after one to two cycles. Major health hazards such as myocardial infarction, stroke, thromboembolism, breast cancer, and cervical cancer are rare. Two meta-analyses showed a 2-fold increase in myocardial infarction and stroke in low-dose COC pill users compared with non-users.11 12 The risk of venous thromboembolism was increased by 3- to 5-fold depending on the type of progestogen used.13 Since the baseline incidence of these vascular events in women of reproductive age is very low (myocardial infarction: 0.2 per 100 000 at age 30-34 years to 2.0 at age 40-44 years14; stroke: 1 per 100 000 at age 30-34 years to 1.6 at age 40-44 years14; thromboembolism: 2 per 10 000 women at reproductive age15), the absolute risk of such vascular complications is very small. Breast cancer risk with a low-dose COC pill is also small. A large meta-analysis of case-control studies from 25 countries showed a modest increase in breast cancer risk with the COC pill (relative risk=1.24; 95% confidence interval [CI], 1.15-1.33).16 The risk of cervical cancer depends on the duration of use. Women who used a COC pill for less than 5 years have no increased risk of cervical cancer. The odds ratio for cervical cancer after using COC for 5 to 9 years was 2.82 (95% CI, 1.46-5.42) and 4.03 (95% CI, 2.09-8.02) for 10 years or longer.17 Cervical cancer is largely preventable by regular cervical smears, safe sex, as well as avoidance of smoking. The overall morbidity and mortality associated with the low-dose COC pill are low and most healthy women can use it without major concerns.
 
The lack of access to consultation services has exacerbated concern about side-effects, both for women who experience them and for those who fear them.9 At our clinics, women are counselled about the common side-effects and complications of the COC pill. This prevents them from panicking when minor side-effects occur. They are also told to stop taking the COC pill immediately and consult a doctor if they develop signs and symptoms of a major complication. Such counselling helps women establish realistic expectations and they are able to use COC safely. An information sheet detailing side-effects and complications, warning signs and symptoms for major complications, commonly used drugs that interact with COC pill, and missed pill management is given to all users. When first prescribed, we usually provide two packs and then review acceptability after 2 months. Women are advised that different COC pills vary slightly in their side-effect profile and they can change to another formulation if they have problems. We also offer walk-in clinics for any woman who wishes to get contraceptive advice from nurses. The above COC pill delivery mode conforms to the World Health Organization recommendations.18
 
Apart from side-effects and complications, women should be informed of the non-contraceptive benefits of the COC pill, such as menstrual regulation and relief of dysmenorrhoea; reduced risk for endometrial, ovarian, and colorectal cancers; lower incidence of gynaecological diseases such as endometriosis, pelvic inflammatory disease, ectopic pregnancy; and improved acne and bone health. All such information should be shared with women to help them establish an impartial perspective on the risks and benefits of the COC pill.
 
The main limitation of this survey is the very low response rate, albeit not unexpected with online survey. There was also selection bias as members of an exclusive group were invited to participate. Those who participated in the survey prompted self-selection bias as they might be systematically different from those who chose not to respond. When we planned the study, we had explored other alternatives such as face-to-face interview, phone interview, or online survey for the general public. Nonetheless, the first would be too expensive and in the last two alternatives, we would be unable to verify respondent’s age or gender. We settled with this arrangement as it was the most convenient means to reach our target group since ESDlife only allowed female members aged 18 to 45 years to participate. The demographic statistics provided by ESDlife revealed that the education attainment and income reported by its female members were better than the population average. The contraceptive choice in this group matched that of the population study and the sample size was not small. Although the results obtained cannot be generalised to the local population, we believe they provide useful insight into the reasons why women do or do not use the COC pill. The other limitation is the number of questions we could ask was limited by the budget. If we had a larger budget to include more questions, we would have explored the type of COC pill used, total duration of use, and the switch pattern in women who used more than one contraceptive in the previous 12 months. Lastly, there was a discrepancy in the number of women who were using a COC pill in the past 12 months. For “Question 15. Are you still on COC in the past 12 months?”, 177 responded positively. In response to Question 7, however, only 163 chose COC pill as one of the contraceptives they had used in the past 12 months. Some women might have omitted COC when they selected their contraceptives from the list provided in Question 7.
 
Conclusions
The COC pill remains underutilised in Hong Kong compared with many western countries. The male condom is the most popular contraceptive and the proportion of women using a COC pill is one sixth of that of women who use a male condom. A considerable proportion of respondents expressed concerns about actual or anticipated side-effects. Doctors should focus on this area during contraceptive counselling and help dispel the underlying myths and misconceptions surrounding COC pill use. Studies have shown that minor side-effects are transient, major complications are rare in healthy women, and there are many non-contraceptive benefits of the COC pill. These facts should be emphasised during COC counselling to help women balance the risks and benefits of the COC pill and make an informed choice about contraception.
 
Declaration
Sponsorship was provided by Pfizer Corporation Hong Kong Limited to cover all costs incurred with ESDlife and incentives for participants. The company was not involved in the study design, execution, data interpretation, or manuscript preparation.
 
References
1. Family Planning Knowledge, Attitude and Practice in Hong Kong Survey 2012. Available from: http://www.famplan.org.hk/fpahk/en/template1.asp?style=template1.asp&content=info/research.asp. Accessed 6 Aug 2015.
2. Trussell J. Contraceptive failure in the United States. Contraception 2011;83:397-404. Crossref
3. United Nations. Department of Economic and Social Affairs. Population Division. World contraceptive patterns 2013. Available from: http://www.un.org/en/development/desa/population/publications/pdf/family/worldContraceptivePatternsWallChart2013.pdf. Accessed 6 Aug 2015.
4. Heise L. Beyond acceptability: reorienting research on contraceptive choice. In: Ravindran TS, Berer M, Cottingham J, editors. Beyond acceptability: users’ perspectives on contraception. London: Reproductive Health Matters; 1997: 6-14.
5. User preferences for contraceptive methods in India, Korea, the Philippines, and Turkey. World Health Organization Task Force on Psychosocial Research in Family Planning and Task Force on Service Research in Family Planning. Stud Fam Plann 1980;11:267-73.
6. Hall KS, Trussell J. Types of combined oral contraceptives used by US women. Contraception 2012;86:659-65. Crossref
7. Ali M, Cleland J. Contraceptive discontinuation in six developing countries: a cause-specific analysis. Int Fam Plan Perspect 1995;21:92-7. Crossref
8. Sanders SA, Graham CA, Bass JL, Bancroft J. A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation. Contraception 2001;64:51-8. Crossref
9. D’Antona Ade O, Chelekis JA, D’Antona MF, Siqueira AD. Contraceptive discontinuation and non-use in Santarém, Brazilian Amazon. Cad Saude Publica 2009;25:2021-32. Crossref
10. Larsson G, Blohm F, Sundell G, Andersch B, Milsom I. A longitudinal study of birth control and pregnancy outcome among women in a Swedish population. Contraception 1997;56:9-16. Crossref
11. Baillargeon JP, McClish DK, Essah PA, Nestler JE. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 2005;90:3863-70. Crossref
12. Khader YS, Rice J, John L, Abueita O. Oral contraceptives use and the risk of myocardial infarction: a meta-analysis. Contraception 2003;68:11-7. Crossref
13. Faculty of Sexual and Reproductive Healthcare Statement. Venous thromboembolism and hormonal contraception. November 2014. Available from: http://www.fsrh.org/pdfs/FSRHStatementVTEandHormonalContraception.pdf. Accessed 6 Aug 2015.
14. Farley TM, Meirik O, Collins J. Cardiovascular disease and combined oral contraceptives: reviewing the evidence and balancing risks. Human Reprod Update 1999;5:721-35. Crossref
15. European Medicines Agency. Benefits of combined hormonal contraceptives (CHCs) continue to outweigh risks. Product information updated to help women make informed decisions about their choice of contraception. London, UK: EMA, 2014. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Combined_hormonal_contraceptives/human_referral_prac_000016.jsp&mid=WC0b01ac05805c516f. Accessed 6 Aug 2015.
16. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713-27. Crossref
17. Moreno V, Bosch FX, Muñoz N, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 2002;359:1085-92. Crossref
18. World Health Organization. Family Planning: A Global Handbook for Providers. 2011 edition. Available from: https://www.fphandbook.org/sites/default/files/chap_1_eng.pdf. Accessed 6 Aug 2015.

Effect of non-invasive prenatal testing as a contingent approach on the indications for invasive prenatal diagnosis and prenatal detection rate of Down’s syndrome

Hong Kong Med J 2016 Jun;22(3):223–30 | Epub 6 May 2016
DOI: 10.12809/hkmj154730
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
ORIGINAL ARTICLE    CME
Effect of non-invasive prenatal testing as a contingent approach on the indications for invasive prenatal diagnosis and prenatal detection rate of Down’s syndrome
KO Kou, MRCOG, FHKAM (Obstetrics and Gynaecology)1; CF Poon, MSc Health Care (Nursing), RDMS (OB/GYN & FE)1; SL Kwok, RNM, Master of Nursing (Clinical Leadership)1; Kelvin YK Chan, BSc, PhD2; Mary HY Tang, FRCOG, FHKAM (Obstetrics and Gynaecology)2; Anita SY Kan, MRCOG, FHKAM (Obstetrics and Gynaecology)2; KY Leung, MD, FHKAM (Obstetrics and Gynaecology)1
1 Department of Obstetrics and Gynaecology, Queen Elizabeth Hospital, Jordan, Hong Kong
2 Prenatal Diagnostic Laboratory, Tsan Yuk Hospital and Department of Obstetrics and Gynaecology, Queen Mary Hospital, Hong Kong
 
Corresponding author: Dr KY Leung (leungky1@ha.org.hk)
 
 Full paper in PDF
Abstract
Introduction: In Hong Kong, universal combined first-trimester screening for Down’s syndrome was started as a ‘free service’ in July 2010. Non-invasive prenatal testing was available as a self-financed item in August 2011. This study aimed to determine whether the introduction of non-invasive prenatal testing as a contingent approach influenced the indications for invasive prenatal diagnosis and the consequent prenatal detection of Down’s syndrome.
 
Methods: This historical cohort study was conducted at the Prenatal Diagnosis Clinic of Queen Elizabeth Hospital in Hong Kong. We compared the indications for invasive prenatal diagnosis and prenatal detection of Down’s syndrome in singleton pregnancies 1 year before and 2 years following the availability of non-invasive prenatal testing as a contingent test after a positive aneuploidy test. All pregnant women who attended our hospital for counselling about universal Down’s syndrome screening between August 2010 and July 2013 were recruited.
 
Results: A total of 16 098 women were counselled. After the introduction of non-invasive prenatal testing, the invasive prenatal diagnosis rate for a positive aneuploidy screening reduced from 77.7% in 2010-11 to 68.8% in 2012-13. The new combined conventional plus non-invasive prenatal testing strategy was associated with a lower false-positive rate (6.9% in 2010-11 vs 5.2% in 2011-12 and 4.9% in 2012-13). There was no significant increase in invasive prenatal diagnosis for structural anomalies over the years. There was no significant trend in the overall prenatal detection rate of Down’s syndrome (100% 1 year before vs 89.1% 2 years after introduction of non-invasive prenatal testing). Four (2.6%) of 156 women who underwent non-invasive prenatal testing for a screen-positive result had a high-risk result for trisomy 21, which was subsequently confirmed by invasive prenatal diagnosis. There were no false-negative cases.
 
Conclusion: The introduction of non-invasive prenatal testing as a contingent approach reduced the invasive prenatal diagnosis rate for a positive aneuploidy screening without affecting the invasive prenatal diagnosis rate for structural anomalies or the overall detection rate of fetal Down’s syndrome.
 
New knowledge added by this study
  • Introduction of non-invasive prenatal testing (NIPT) decreased overall invasive prenatal diagnosis (IPD) rate for a positive aneuploidy screening without affecting the IPD rate for structural anomalies.
  • NIPT as a contingent approach does not affect the overall detection rate of fetal Down’s syndrome.
Implications for clinical practice or policy
  • NIPT provides a safe contingent approach for a positive aneuploidy screening. This is particularly relevant in centres with a high false-positive rate following conventional screening for Down’s syndrome.
  • Extending the indications of NIPT from high-risk to intermediate- or low-risk women with a view to increasing the prenatal detection rate of Down’s syndrome requires further evaluation.
 
 
Introduction
Over the last 30 years, there has been a shift in clinical practice away from performing an invasive prenatal diagnosis (IPD) on the basis of maternal age to a non-invasive screening method1 2 3 4 5 with improving performance.6 7 8 9 10 11 12 Initially, the introduction of second-trimester screening (STS) resulted in an overall increase in the number of IPD tests, mainly amniocentesis, for women aged <35 years with screen-positive result.1 The later implementation of combined first-trimester screening (cFTS) caused a mild and gradual decrease in the number of IPD and amniocentesis, but an increase in the number or proportion of chorionic villus sampling (CVS) tests.1 2 3 The recent introduction of non-invasive prenatal testing (NIPT) has resulted in a rapid decrease in the number of invasive tests including amniocentesis and CVS within a short period of time.5 13 14 Such non-invasive testing has a higher sensitivity (95.5-100% vs 85-90%) and a lower false-positive rate (0.002-0.2% vs 3-5%) than traditional non-invasive screening methods for Down’s syndrome,6 7 8 9 10 11 12 and is well accepted by women5 and physicians.15
 
Although not as a free service, NIPT has been available in Hong Kong since August 2011. In our previously published study,16 we showed that the introduction of NIPT as a contingent test resulted in a significant decrease in IPD by 16.3% and 25.6% in the first and second year, respectively. It remained unclear, however, whether this change in practice affected the overall prenatal detection rate of Down’s syndrome and whether the indication for IPD because of a scan abnormality was increased. In the present study, using the same study population as before, we aimed to review all the indications for IPD and to determine any alteration in the overall prenatal detection of Down’s syndrome before and after the introduction of NIPT as a contingent approach.
 
Methods
This historical cohort study was conducted at the Prenatal Diagnosis Clinic of Queen Elizabeth Hospital, Hong Kong. All pregnant women who attended our hospital for counselling on prenatal testing for Down’s syndrome between August 2010 and July 2013 were recruited. The utilisation of conventional screening, NIPT, and IPD for Down’s syndrome and other aneuploidies in all singleton pregnancies were included. Our hospital is one of the largest referral public hospitals in Hong Kong with around 6000 deliveries a year. This study was approved by the Research Ethics Committee of Kowloon Central/Kowloon East Cluster, Hong Kong. Informed consent was not required for this retrospective study.
 
Since 1 July 2010, universal prenatal screening for Down’s syndrome with cFTS between 11 weeks and 13 weeks and 6 days or STS has been offered to all pregnant women after adequate counselling. Combined first-trimester screening includes fetal nuchal translucency (NT) measurement, and free beta–human chorionic gonadotrophin and pregnancy-associated plasma protein-A assessment. The gestational age is determined by an ultrasound examination (crown rump length in the first or head biometry in the second trimester) shortly after the first antenatal visit.
 
All NT measurements were performed by trained midwives and doctors who were Fetal Medicine Foundation–certified or accredited as maternal fetal medicine (MFM) subspecialists. In our hospital, MFM team doctors counselled screen-positive (risk ≥1 in 250 in cFTS) women about different options including IPD with CVS or amniocentesis, or no further prenatal invasive testing. After August 2011, the option of self-financed NIPT was also discussed at the request of patients.
 
Most commercial NIPT was based on massively parallel sequencing with ‘shotgun’ counting of all cell-free DNA sequences while others involve ‘targeted’ counting of specific DNA sequences. A usual NIPT report includes the risk for trisomies 21, 18, and 13. Sex chromosomal or other abnormalities are also reported if identified on NIPT. If NIPT demonstrated a high risk for trisomy 21, 18 or 13, confirmatory IPD was required. After undergoing NIPT in the private sector, the woman would be followed up, counselled by doctors, rescanned for any structural fetal anomaly and offered an option of invasive testing, regardless of the results of NIPT, at no charge. We advised women with fetal NT ≥3.5 mm or structural abnormalities to undergo IPD rather than NIPT given their higher risk of atypical chromosome abnormalities that might not be picked up by the latter.17 In addition, IPD would be offered (a) if first-trimester or routine mid-trimester anomaly scan showed an abnormality, (b) for genetic diseases like thalassaemia, (c) if there was a positive family history, or (d) rarely, if there was maternal anxiety after adequate counselling.
 
Chromosome analysis was mainly performed by the prenatal diagnostic laboratory of Tsan Yuk Hospital and a small proportion at Prince of Wales Hospital, Hong Kong. These two laboratories are accredited by professional bodies in providing prenatal diagnostic tests and serve the local obstetric units. Analyses included G-banding chromosome analyses and quantitative fluorescence polymerase chain reaction for rapid aneuploidy detection. All pregnancy outcomes were traced by reviewing hospital records or phone contact in women who delivered outside this hospital.
 
We determined the number of fetuses and newborns with Down’s syndrome prenatally or postnatally, the rate of different prenatal tests for Down’s syndrome, and the number of IPD that were needed to diagnose one fetus with Down’s syndrome. We also reviewed the indications for IPD and classified them as one of the following priorities: high risk for trisomy 21, 18, 13 or other aneuploidy on NIPT, increased NT (≥3.5 mm), structural anomalies on ultrasound, parental carrier of or previous pregnancies with abnormal karyotype, positive aneuploidy screening, maternal age ≥35 years, or others. If NT was increased and cFTS trisomy 21 risk was high, increased NT would be selected as the sole indication for IPD.
 
Statistical analyses
With the use of descriptive statistics and Chi squared test for linear trend, the rates of conventional screening, NIPT, IPD, and prenatally diagnosed Down’s syndrome were compared 1 year before and 2 years after NIPT introduction. All statistical analyses were performed using the Statistical Package for the Social Sciences (Windows version 21.0; SPSS Inc, Chicago [IL], US).
 
Results
A total of 16 098 women with singleton pregnancies were counselled on prenatal testing for Down’s syndrome. Although the total proportion of women who underwent screening remained around 97% from 2010 to 2013, cFTS increased from 84.4% in 2010-11 to 90.5% in 2012-13 and STS decreased from 12.1% to 7.1% in the same period (P<0.001) [Table 1]. With a sharp increase in the use of NIPT in the screen-positive group (0%, 0.8%, and 1.9% in 2010-11, 2011-12, 2012-13, respectively; P<0.001), the rate of IPD and CVS dropped from 7.6% and 4.2% in 2010-11 to 6.0% and 2.5% in 2012-13, respectively while the amniocentesis rate fluctuated. The actual number of IPD remained similar over the years though the rate declined, probably because of an increasing number of screenings from 4288 in 2010-11 to 5618 in 2012-13 (Table 1).
 

Table 1. Trend analysis for number of a variety of tests in women who attended prenatal diagnosis and counselling clinic from August 2010 to July 2013
 
Indications for invasive prenatal diagnosis
There was a significant decrease in IPD for positive aneuploidy screening from 77.7% in 2010-11 to 68.8% in 2012-13 (P=0.005). There was no significant increase in IPD for structural anomalies over the years (Table 2).
 

Table 2. Trend analysis for number of invasive prenatal diagnosis performed from August 2010 to July 2013 with various clinical indications and subgroup analysis for screen-positive results and maternal age ≥35 years
 
Prenatal detection of Down’s syndrome
There was no significant trend in the overall prenatal diagnosis/detection rate of Down’s syndrome before and after the availability of NIPT (Table 3). The number of IPD required to diagnose one case of Down’s syndrome decreased from 28 to 16 over the same period of time, though the trend was not significant, probably because of the small sample size (Table 3). There were nine newborn infants with Down’s syndrome over the 3 years. In two cases, women declined IPD despite a positive Down’s syndrome screening result. In another two cases that were included in the 45 diagnosed prenatally, women chose to continue their pregnancy after IPD of Down’s syndrome. The remaining five cases were screened negative and diagnosed postnatally (Fig).
 

Table 3. Trend analysis for number and prenatal detection rate of Down’s syndrome, and number of invasive prenatal diagnosis required to diagnose one DS case
 

Figure. Number of fetuses and newborns with DS diagnosed prenatally or postnatally according to different screening tests
 
Performance of non-invasive prenatal testing
Four (2.6%) of 156 women who underwent NIPT for a screen-positive result (cFTS or STS being 1 in 3, 1 in 25, 1 in 45 and 1 in 230) were considered at high risk for trisomy 21 (increased amount of chromosome 21 DNA molecules in a maternal sample compared with that of a euploid reference sample); all results were confirmed on subsequent IPD. One woman who had a positive aneuploidy screening but a low-risk NIPT result underwent IPD and had normal fetal karyotype. There were no false-negative results and all babies were confirmed normal after delivery by routine clinical examination.
 
Performance of conventional screening
The overall screen-positive and false-positive rates were 6.8% and 6.5% respectively, and were similar over the 3-year period (Table 1).
 
With an increasing number of NIPT as secondary screening performed for positive cFTS/STS, the false-positive rate of screening decreased from 6.9% in 2010-11 to 5.2% in 2011-12 and 4.9% in 2012-13. In 2012-13, with 107 NIPT performed for a positive cFTS or STS, the false-positive rate decreased by 29.0% from 6.9% to 4.9%.
 
The cFTS risk of the five cases of Down’s syndrome not diagnosed prenatally was 1 in 300, 690, 770, 7300, and 7300. In other words, the risk of three out of these five cases was below 1 in 1000. All five women were younger than 35 years. Among those screened negative, four cases of Down’s syndrome were diagnosed prenatally by IPD performed for fetal anomaly (Fig). In one of these four cases, mid-trimester scan showed subtle sonographic signs including absent nasal bone and persistent left superior vena cava.
 
Discussion
As shown in other studies5 14 and our previous study,16 the introduction of NIPT was accompanied by a decrease in IPD rate. In the present study, we have further shown that the introduction of NIPT reduced the IPD rate for positive aneuploidy screening without affecting the prenatal detection of Down’s syndrome. Consistent with previous studies,5 13 14 there was a rapid uptake of NIPT, probably because of its non-invasive nature and high sensitivity and specificity for common aneuploidies.6 A local study showed that NIPT results could reduce women’s uncertainty associated with risk probability–based results from conventional screening.18 Women are willing to pay for a test that has a lower false-positive rate.19
 
We could not exclude the possibility that the reduction in IPD rate might be partially related to an increase in the proportion of cFTS with a lower false-positive rate than STS.3 Nevertheless, we observed no significant increase in IPD performed for structural anomalies despite a concern about missing atypical chromosomal abnormalities with NIPT alone.17 20 21
 
The benefit of reducing the IPD rate is particularly relevant to our screening programme as the overall screen-positive rate of our conventional screening programme was 6.8%, which is higher than the published figures of 3.3% to 5.9%.4 22 23 24 25 26 With increasing use of NIPT as secondary screening for a positive result of cFTS/STS, the false-positive rate was reduced. The improvement was encouraging even before full implementation of the strategy using NIPT as a secondary screening tool.
 
Assuming 1.8% reduction in IPD (7.6% in 2010-11 – mean of 5.7% in 2011-12 and 6.0% in 2012-13; Table 1) as in our present study, an annual delivery rate of 50 000 in Hong Kong, and 1% miscarriage rate associated with IPD, we estimate that around 900 IPDs or nine miscarriages can be potentially avoided if this contingent approach is adopted widely. This reduction in IPD-related miscarriage could be further improved as theoretically about 98% of the IPD for positive aneuploidy screening could be avoided if NIPT was used by all screen-positive women.27 Nonetheless, 1.8% ([1020-736]/16 098) of IPD (Table 2) were still required for other indications including increased NT or structural anomalies, even if all screen-positive women opted for NIPT. Alternatively, the screen-positive rate could be reduced by changing the cut-off value from 1 in 250 to 1 in 150,2 improving the quality assurance of measurement of NT (www.fetalmedicine.com) and laboratory assays of serum markers, algorithms in calculation of trisomy 21 risk, and adding sonographic markers.4 28
 
The prenatal detection rate of Down’s syndrome in the present study was similar to the published results of 83% to 93%.4 22 23 24 25 26 In contrast to cFTS and STS that have been used in primary screening and resulted in a reduction in the number of live births with Down’s syndrome,1 4 introduction of NIPT did not improve the detection rate of our screening programme. This is expected as NIPT is currently not routinely used for primary screening. Nevertheless, NIPT did not decrease the detection rate of Down’s syndrome as there was no false-negative rate for NIPT in the present small study. There was concern about missing atypical abnormalities with NIPT alone.17 20 21 Further studies are required.
 
In keeping with international guidelines,29 30 31 32 we suggest offering NIPT as an option to women with positive aneuploidy screening alone without increased NT or structural abnormalities to avoid an unnecessary IPD and its associated miscarriage risk. We also recommend improving the prenatal detection rate of a screening programme for Down’s syndrome by adjusting the cut-off value for cFTS, for example, from 1 in 250 to 1 in 1000, rather than offering it to all women as a primary screening.33 In our unit, the detection rate would be improved from 91.4% to 96.6% as cFTS risk of three of our five missed cases of Down’s syndrome were above 1 in 1000. As such, NIPT would be offered to 16.9% of women, including 6.8% with cFTS risk ≥1 in 250 and 10.1% with risk >1 in 1000 but <1 in 250. Offering an additional option of NIPT to women with advanced maternal age only did not improve the detection rate based on the results of the present study, probably because all five missed cases were younger than 35 years and sample size was small. Careful analysis with accurate assumptions, including the uptake rate of cFTS, and NIPT, the number of IPD avoided, cut-off value for cFTS, decreasing charges of NIPT with time,34 and other issues is required to determine the cost-effectiveness of incorporating NIPT into the current screening programme for Down’s syndrome.20 35 Major governing or professional bodies recommend NIPT in the context of informed consent, education, and pre- and post-test counselling.29 30 31 32 36 In our previous study,37 we showed that Chinese women who underwent NIPT recognised the limitations, but did not understand the complicated aspects. We suggest giving more information by health care professionals, preferably trained midwives, so that patients can make an informed choice.37
 
The limitations of the present study included its retrospective nature, single-centre, and small sample size. The actual performance of NIPT could not be examined as not all eligible subjects were tested. Availability and payment methods for NIPT and other prenatal testing, cut-off level of cFTS, and women’s preferences differ in different places. Thus, generalisation of the results of the present study should be done with caution.
 
Conclusion
The introduction of NIPT as a contingent approach reduced the IPD rate for positive aneuploidy screening without increasing the IPD rate for scan abnormalities or affecting the overall prenatal detection rate of Down’s syndrome. This fall in IPD rate was particularly relevant in our centre with a high false-positive rate after cFTS.
 
Acknowledgements
We would like to thank the prenatal diagnostic laboratory of Tsan Yuk Hospital and Prince of Wales Hospital, Hong Kong for performing the chromosome analysis.
 
Declaration
All authors have disclosed no conflicts of interest.
 
References
1. Cheffins T, Chan A, Haan EA, et al. The impact of maternal serum screening on the birth prevalence of Down’s syndrome and the use of amniocentesis and chorionic villus sampling in South Australia. BJOG 2000;107:1453-9. Crossref
2. Morgan S, Delbarre A, Ward P. Impact of introducing a national policy for prenatal Down syndrome screening on the diagnostic invasive procedure rate in England. Ultrasound Obstet Gynecol 2013;41:526-9. Crossref
3. Muller PR, Cocciolone R, Haan EA, et al. Trends in state/population-based Down syndrome screening and invasive prenatal testing with the introduction of first-trimester combined Down syndrome screening, South Australia, 1995-2005. Am J Obstet Gynecol 2007;196:315.e1-7; discussion 285-6.
4. Ekelund CK, Jørgensen FS, Petersen OB, Sundberg K, Tabor A; Danish Fetal Medicine Research Group. Impact of a new national screening policy for Down’s syndrome in Denmark: population based cohort study. BMJ 2008;337:a2547. Crossref
5. Chetty S, Garabedian MJ, Norton ME. Uptake of noninvasive prenatal testing (NIPT) in women following positive aneuploidy screening. Prenat Diagn 2013;33:542-6. Crossref
6. Norton ME, Brar H, Weiss J, et al. Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012;207:137.e1-8. Crossref
7. Palomaki GE, Kloza EM, Lambert-Messerlian GM, et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med 2011;13:913-20. Crossref
8. Bianchi DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert AJ, Rava RP; MatErnal BLood IS Source to Accurately diagnose fetal aneuploidy (MELISSA) Study Group. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 2012;119:890-901. Crossref
9. Evans MI, Wright DA, Pergament E, Cuckle HS, Nicolaides KH. Digital PCR for noninvasive detection of aneuploidy: power analysis equations for feasibility. Fetal Diagn Ther 2012;31:244-7. Crossref
10. Malone FD, Canick JA, Ball RH, et al. First-trimester or second-trimester screening, or both, for Down’s syndrome. N Engl J Med 2005;353:2001-11. Crossref
11. Wald NJ. Prenatal screening for open neural tube defects and Down syndrome: three decades of progress. Prenat Diagn 2010;30:619-21. Crossref
12. Rozenberg P, Bussières L, Chevret S, et al. Screening for Down syndrome using first-trimester combined screening followed by second-trimester ultrasound examination in an unselected population. Am J Obstet Gynecol 2006;195:1379-87. Crossref
13. Larion S, Romary L, Mlynarczyk M, Abuhamad AZ, Warsof SL. Changes in prenatal testing trends after introduction of noninvasive prenatal testing. Obstet Gynecol 2014;123 Suppl 1:62S-63S. Crossref
14. Larion S, Warsof SL, Romary L, Mlynarczyk M, Peleg D, Abuhamad AZ. Uptake of noninvasive prenatal testing at a large academic referral center. Am J Obstet Gynecol 2014;211:651.e1-7. Crossref
15. Musci TJ, Fairbrother G, Batey A, Bruursema J, Struble C, Song K. Non-invasive prenatal testing with cell-free DNA: US physician attitudes toward implementation in clinical practice. Prenat Diagn 2013;33:424-8. Crossref
16. Poon CF, Tse WC, Kou KO, Leung KY. Uptake of noninvasive prenatal testing in Chinese women following positive Down syndrome screening. Fetal Diagn Ther 2015;37:141-7. Crossref
17. Petersen OB, Vogel I, Ekelund C, Hyett J, Tabor A; Danish Fetal Medicine Study Group; Danish Clinical Genetics Study Group. Potential diagnostic consequences of applying non-invasive prenatal testing: population-based study from a country with existing first-trimester screening. Ultrasound Obstet Gynecol 2014;43:265-71. Crossref
18. Yi H, Hallowell N, Griffiths S, Yeung Leung T. Motivations for undertaking DNA sequencing-based non-invasive prenatal testing for fetal aneuploidy: a qualitative study with early adopter patients in Hong Kong. PLoS One 2013;8:e81794. Crossref
19. Lo TK, Lai FK, Leung WC, et al. Screening options for Down syndrome: how women choose in real clinical setting. Prenat Diagn 2009;29:852-6. Crossref
20. van Landingham S, Bienstock J, Wood Denne E, Hueppchen N. Beyond the first trimester screen: can we predict who will choose invasive testing? Genet Med 2011;13:539-44. Crossref
21. Benn P, Borell A, Chiu R, et al. Position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenat Diagn 2013;33:622-9. Crossref
22. Hadlow NC, Hewitt BG, Dickinson JE, Jacoby P, Bower C. Community-based screening for Down’s Syndrome in the first trimester using ultrasound and maternal serum biochemistry. BJOG 2005;112:1561-4. Crossref
23. O’Leary P, Breheny N, Dickinson JE, et al. First-trimester combined screening for Down syndrome and other fetal anomalies. Obstet Gynecol 2006;107:869-76. Crossref
24. Soergel P, Pruggmayer M, Schwerdtfeger R, Muhlhaus K, Scharf A. Screening for trisomy 21 with maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a regional experience from Germany. Fetal Diagn Ther 2006;21:264-8. Crossref
25. Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience. BJOG 2003;110:281-6. Crossref
26. Stenhouse EJ, Crossley JA, Aitken DA, Brogan K, Cameron AD, Connor JM. First-trimester combined ultrasound and biochemical screening for Down syndrome in routine clinical practice. Prenat Diagn 2004;24:774-80. Crossref
27. Chiu RW, Akolekar R, Zheng YW, et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ 2011;342:c7401. Crossref
28. Nicolaides KH. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn 2011;31:7-15. Crossref
29. American College of Obstetricians and Gynecologists Committee on Genetics. Committee Opinion No. 545: Noninvasive prenatal testing for fetal aneuploidy. Obstet Gynecol 2012;120:1532-4. Crossref
30. Gregg AR, Gross SJ, Best RG, et al. ACMG statement on noninvasive prenatal screening for fetal aneuploidy. Genet Med 2013;15:395-8. Crossref
31. Soothill PW, Lo YM. Non-invasive prenatal testing for chromosomal abnormality using maternal plasma DNA, Scientific Impact Paper No. 15. London, Royal College of Obstetricians and Gynaecologists; 2014.
32. Benn P, Borrell A, Chiu R, et al. Position Statement from the Chromosome Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. April 2015. Available from: https://www.ispdhome.org/docs/ISPD/Society%20Statements/PositionStatement_Current_8Apr2015.pdf. Accessed 8 Oct 2015.
33. Benn P, Curnow KJ, Chapman S, Michalopoulos SN, Hornberger J, Rabinowitz M. An economic analysis of cell-free DNA non-invasive prenatal testing in the US general pregnancy population. PLoS One 2015;10:e0132313. Crossref
34. Shengmou L, Min C, Chenhong W, et al. Effects, safety and cost-benefit analysis of Down syndrome screening in first trimester [in Chinese]. Zhonghua Fu Chan Ke Za Zhi 2014;49:325-30.
35. Stoll K, Lutgendorf M, Knutzen D, Nielsen PE. Questioning the costs and benefits of non-invasive prenatal testing. J Matern Fetal Neonatal Med 2014;27:633-4. Crossref
36. Devers PL, Cronister A, Ormond KE, Facio F, Brasington CK, Flodman P. Noninvasive prenatal testing/noninvasive prenatal diagnosis: the position of the National Society of Genetic Counselors. J Genet Couns 2013;22:291-5. Crossref
37. Kou KO, Poon CF, Tse WC, Mak SL, Leung KY. Knowledge and future preference of Chinese omen in a major public hospital in Hong Kong after undergoing non-invasive prenatal testing for positive aneuploidy screening: a questionnaire survey. BMC Pregnancy Childbirth 2015;15:199. Crossref

A prospective randomised controlled trial of octylcyanoacrylate tissue adhesive and standard suture for wound closure following breast surgery

Hong Kong Med J 2016 Jun;22(3):216–22 | Epub 22 Apr 2016
DOI: 10.12809/hkmj154513
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
ORIGINAL ARTICLE
A prospective randomised controlled trial of octylcyanoacrylate tissue adhesive and standard suture for wound closure following breast surgery
Clement TH Chen, FCSHK, FHKAM (Surgery)1; Catherine LY Choi, FCSHK, FHKAM (Surgery)2; Dacita TK Suen, FCSHK, FHKAM (Surgery)1; Ava Kwong, FCSHK, FHKAM (Surgery)1
1 Department of Surgery, Queen Mary Hospital and Tung Wah Hospital, Hong Kong
2 Private practice, Hong Kong
 
Corresponding authors: Dr Clement TH Chen (chenthc@ha.org.hk), Dr Ava Kwong (avakwong@hku.hk)
 
 Full paper in PDF
Abstract
Introduction: Several studies have demonstrated that octylcyanoacrylate tissue adhesive provides an equivalent cosmetic outcome as standard suture for wound closure. This study aimed to compare octylcyanoacrylate tissue adhesive with standard suture for wound closure following breast surgery.
 
Methods: A prospective randomised controlled trial was conducted in a public hospital in Hong Kong. A total of 70 female patients, who underwent elective excision of clinically benign breast lump between February 2009 and November 2011, were randomised to have wound closure using either octylcyanoacrylate tissue adhesive or standard wound suture following breast surgery. Wound complications and cosmetic outcome were measured.
 
Results: Octylcyanoacrylate tissue adhesive achieved wound closure in significantly less time than standard suturing (mean, 80.6 seconds vs 344.6 seconds; P<0.001). There was no statistical difference in wound condition or cosmetic outcome although number of clinic visits, ease of self-showering, and comfort of dressing significantly favoured octylcyanoacrylate tissue adhesive.
 
Conclusions: Octylcyanoacrylate tissue adhesive may be offered as an option for wound closure following breast surgery.
 
 
New knowledge added by this study
  • Use of octylcyanoacrylate (OCA) tissue adhesive in wound closure following breast surgery is feasible.
Implications for clinical practice or policy
  • OCA may be offered as an option for wound closure following breast surgery.
 
 
Introduction
In Hong Kong, thousands of patients undergo breast surgery every year for both benign and malignant conditions.1 Patients expect a good cosmetic outcome and satisfactory postoperative wound management. This is in addition to the expectation of a cure, or in the case of breast cancer, complete removal of lesions with optimal survival.
 
Several studies have demonstrated that octylcyanoacrylate (OCA) tissue adhesive provides an equivalent cosmetic outcome to wound suturing in repair of lacerations,2 3 head and neck surgery,4 plastic surgery,5 and breast surgery.6 7 The OCA tissue adhesives are supplied as monomers in a liquid form. They polymerise on contact with tissue anions, forming a strong bond that holds the opposed wound edges together. The OCA tissue adhesive usually sloughs off with time. The wound epithelises within 5 to 10 days and the adhesive does not require removal.
 
In-vitro studies have shown that OCA provides an effective antimicrobial barrier for the first 72 hours after application.8 It is approved by the US Food and Drug Administration as a topical skin adhesive that protects the wound from bacteria. It also facilitates postoperative wound care as patients are allowed to shower immediately. There is no need for suturing, staple removal, or dressings. Higher patient satisfaction following skin closure with OCA tissue adhesive compared with sutures has been observed.6 Studies also show faster wound closure with OCA.9
 
This study aimed to assess the outcome of elective breast surgical incision repair with OCA tissue adhesive compared with standard wound suture (SWS). We compared the cosmetic outcome, complication rates, and patient satisfaction score for breast incisions in elective surgery closed with OCA tissue adhesive versus SWS.
 
Methods
The study was in compliance with the Declaration of Helsinki and ICH-GCP (International Conference on Harmonisation, Good Clinical Practice). It was reviewed and approved by the institutional review boards.
 
Based on a randomised trial of OCA versus SWS in breast surgery,5 patient satisfaction in an OCA group has been reported to be significantly higher than that of a SWS group. To detect a difference with a power of 90% and α=0.05, 35 patients were needed for each arm.
 
A total of 70 female patients, who underwent elective excision of clinically benign breast lump between February 2009 and November 2011 in this randomised controlled trial, were randomly allocated to have wound closure using either OCA or SWS with a continuous monofilament subcuticular method. They were seen on the morning of the surgery, consented, and randomly allocated to a study arm. Each randomisation number was computer-generated, sealed in an envelope, and kept in a secure designated place. At the time of wound closure, the surgeon would call a third-party nurse to open the sealed envelope that would determine the method to be used for wound closure. The surgery was performed by specialists or surgical trainees under a specialist’s supervision. Two evaluation forms were administered to collect information on wound condition and cosmetic grading by different parties.
 
Postoperatively, the wound condition was examined by a surgeon who was not involved in the study. An evaluation form was completed to note any indication of (1) wound infection, (2) dehiscence, (3) oozing, and (4) discharge on day 0-1 (early postoperative period) and day 10-14 (first follow-up).
 
The cosmetic grading of the surgical wound was checked on day 30 and 180 by an evaluator (surgeons not involved in the study or the above evaluations) who looked for any sign of (1) step-off borders (edges not on same plane), (2) contour irregularities (wrinkled skin near wound), (3) margin separation (gap between sides), (4) edge inversion (wound not properly everted), and (5) excessive distortion (swelling/oedema/infection); and (6) evaluated the overall appearance of the wound.
 
Patient evaluation of whether the appearance of the wound was “good” or “bad” over a score of 1 (very bad) to 10 (very good) on day 30 and day 180 was also recorded.
 
Patients were also asked five questions about self-care of the wound at the day-30 visit. Questions were answered and rated on a 5-point Likert scale (very good, good, neutral, bad, very bad) regarding (1) pain, (2) ease of caring, (3) self-showering, (4) frequency of hospital/clinic visits for wound cleansing, and (5) comfort level of wound dressing.
 
Statistical analyses
Data were summarised with descriptive statistics. Means and standard deviations (for numeric variables) and numbers and percentages (for categorical variables) were calculated where appropriate. We checked the normality of the data and found that it did not follow the normal distribution. Therefore the Wilcoxon rank sum test and Fisher’s exact test were applied to determine any significant difference between the OCA and SWS groups. All statistical analyses were done using the Statistical Package for the Social Sciences (Windows version 16.0; SPSS Inc, Chicago [IL], US) and R version 3.0.2 (the R Foundation). All statistical tests were two-sided and statistical significance was considered at P<0.05.
 
Results
A total of 70 patients, half of whom were randomised to receive OCA or SWS, were entered into this study. One patient from the suture group was lost to follow-up and excluded from subsequent analysis, leaving a total number of 69 patients (35 for OCA group and 34 for SWS group).
 
Demographic characteristics
The demographics of the two groups were comparable. There was no statistical difference in terms of age, tumour size, co-morbidity including diabetes, pathology, laterality and location of the lesion, or the rank of the surgeon involved (Table 1).
 

Table 1. Surgical and demographic characteristics of study participants
 
Use of OCA was associated with significantly less time to complete the wound closure process compared with suture (mean, 80.6 seconds vs 344.6 seconds; P<0.001; Table 1). With similar length of surgical wound, OCA required 7.1 times less time to close the wound than suture (P<0.001).
 
Wound conditions in early postoperative period (day 0-1) and at first follow-up (day 10-14)
The occurrence of adverse wound condition is shown in Table 2. There was no unfavourable condition noticed upon first-day follow-up. Wound complications on day 10-14 all occurred in the OCA group.
 

Table 2. Breast cancer patients with wound complications after wound closure by either OCA (n=35) or standard suture (n=34) on early postoperative period (day 0-1) and upon first follow-up (day 10-14)
 
Cosmetic grading by an evaluator and patients on day 30 and 180
Table 3 summarises the incidence of any wound cosmetic problem on day 30 and 180. Cosmetic problems were found only on day 30, and were not confined to any one group. One patient from the suture group felt that the overall appearance of the surgical wound on day 30 was bad but subsequently commented it was “good” on day 180. No bad comments were received from any patient who had undergone wound closure with OCA.
 

Table 3. Breast cancer patients with cosmetic problems with surgical wound closure by either OCA (n=35) or standard suture (n=34), graded by an evaluator on day 30 and day 180
 
For the patient’s view of cosmetic outcome, a higher score was given to wounds closed by sutures compared with OCA on both day 30 and 180, although the standard deviations were larger in the OCA group, and the differences were not statistically significant (Table 4). Higher scores were given on day 180 compared with day 30 in both groups.
 

Table 4. Cosmetic grading by breast cancer patients of wounds closed by either OCA or standard suture on day 30 and day 180
 
Patients’ opinion of different kinds of wound management 30 days after surgery
The actual number of hospital or clinic visits was recorded. Patients in the OCA group required fewer visits than those in the suture group (16 OCA vs 18 sutures, 1.19 ± 2.66 vs 2.50 ± 4.57; P=0.063). A higher percentage of patients in the OCA group felt “very good” on ‘self-showering’ (OCA vs suture, 66.7% vs 21.2%; P<0.001), ‘frequency of hospital/clinic visits for wound cleansing’ (OCA vs suture, 66.7% vs 25.0%; P=0.001), and ‘comfort level of wound dressing’ (OCA vs suture, 58.8% vs 18.2%; P=0.003) [Table 5]. More patients in the suture group rated “good”, instead of “very good” for these three categories. The same applied for ‘ease of caring’ although statistical significance was not reached. For patients who commented “bad” or “very bad”, the percentages were generally higher from the OCA group. There was no significant difference between the two groups for reports about pain (P=0.564).
 

Table 5. Patient opinion of different kinds of surgical wound management 30 days following breast cancer surgery
 
Discussion
Tissue adhesive material has long been used in wound closure in western countries, and offers the advantages of faster closure, need for less postoperative wound care, and higher patient satisfaction.
 
In this study among Chinese women, we demonstrated that time required for wound closure was much less in the OCA group compared with the SWS group (P<0.001). Although the difference was significant, time required for wound closure was not a significant concern for the surgeon.
 
There were three instances of postoperative complications in the OCA group. In two patients, the surgery was performed by a trainee under supervision, and in one by a specialist. One patient required secondary suturing 3 weeks later. The other two were treated conservatively with antibiotics. We postulate that there is a learning curve for closure with OCA, thus technical skill and experience of the surgeon may play a role.
 
For cosmetic outcome, the score was comparable in both groups, although slightly higher in the SWS group. Nonetheless, the difference was less than 1 point on a scale of 10. The standard deviation in the OCA group was wider (OCA 2.17 vs SWS 1.36) at day 30 but was not statistically significant.
 
For wound problems, margin separation occurred on postoperative day 30 in five patients in the OCA group compared with two in the SWS group. There was no statistical difference in cosmetic problem grading between the two study groups. It should be noted that tissue adhesive wound repair is a manual skill, just like suturing, and requires practice and careful application. Factors such as wound oozing or discharge may hinder proper functioning of the tissue adhesive.
 
The skin of patients of Chinese or Asian descent is more prone to keloid scarring and pigmentation, thus the effect of using tissue adhesives may differ to that of a western population. A previous study did not show any difference in the rate of hypertrophic scar formation.10 In our study, there was no hypertrophic scar or keloid formation in either group.
 
There was a significant difference in preference in terms of self-showering, frequency of hospital/clinic visits, and comfort level of dressing between OCA and SWS groups. These factors affect patients since they impact on daily activities and saving of time. On the other hand, there was no statistical difference in degree of pain, although the Phi value was very small, thus a larger sample size may be required to detect any difference. The sample size for all other values was adequate.
 
In terms of cost, a study in Hong Kong has shown that tissue adhesive is more expensive than SWS,11 but may be more cost-effective from a social viewpoint in terms of superior cosmetic outcome and overall patient satisfaction.
 
Strengths and weaknesses of this study
First, this was a prospective randomised study confined to closure of benign breast lump wounds and thus not necessarily applicable to all surgical wounds. We did not determine the number of eligible patients for the study, or note how many of them refused to take part. This may have led to self-selection bias. Second, the operation was performed by different surgeons of different seniority, and may have led to varying levels of surgical technique. This was not shown to be statistically significant but the sample size was not designed to reflect this. Lastly, during wound evaluation, the surgeon might not have been totally blind to the type of closure if sutures or stitch marks were visible. This may be a cause of blinding bias. The use of a scoring scale is also a subjective evaluation, and may be influenced by the patient’s mood and other factors.
 
Conclusions
The use of OCA should be discussed and offered to patients as an option for wound closure in breast surgery. It achieves faster wound closure, is not inferior to standard wound closure, has a higher comfort level, and requires less frequent clinic visits. Understanding cost-effectiveness is essential in medical care, thus OCA should be offered as an option to be provided as a self-financed item in the public sector where it is now widely available.
 
Acknowledgements
We thank Mr Jack Chau and Miss Fidelia Wong for performing the early statistical analysis, and Mr Ling-hiu Fung and Mr Wing-pan Luk of the Hong Kong Sanatorium & Hospital for the later review and re-running of the statistical analysis methods. We also thank Ethicon, Johnson and Johnson Company for providing the OCA study material.
 
Declaration
Johnson and Johnson provided the study material. No other conflict of interests was declared by authors.
 
References
1. Top ten cancers in 2013. Hong Kong Cancer Registry. Available from: http://www3.ha.org.hk/cancereg/statistics.html. Accessed Jan 2016.
2. Singer AJ, Quinn JV, Clark RE, Hollander JE; TraumaSeal Study Group. Closure of lacerations and incisions with octylcyanoacrylate: a multicenter randomized controlled trial. Surgery 2002;131:270-6. Crossref
3. Chow A, Marshall H, Zacharakis E, Paraskeva P, Purkayastha S. Use of tissue glue for surgical incision closure: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Surg 2010;211:114-25. Crossref
4. Maw JL, Quinn JV, Wells GA, et al. A prospective comparison of octylcyanoacrylate tissue adhesive and suture for the closure of head and neck incisions. J Otolaryngol 1997;26:26-30.
5. Toriumi DM, O’Grady K, Desai D, Bagal A. Use of octyl-2-cyanoacrylate for skin closure in facial plastic surgery. Plast Reconstr Surg 1998;102:2209-19. Crossref
6. Gennari R, Rotmensz N, Ballardini B, et al. A prospective, randomized, controlled clinical trial of tissue adhesive (2-octylcyanoacrylate) versus standard wound closure in breast surgery. Surgery 2004;136:593-9. Crossref
7. Nipshagen MD, Hage JJ, Beekman WH. Use of 2-octylcyanoacrylate skin adhesive (Dermabond) for wound closure following reduction mammaplasty: a prospective, randomized intervention study. Plast Reconstr Surg 2008;122:10-8. Crossref
8. Quinn JV, Osmond MH, Yurack JA, Moir PJ. N-2-butylcyanoacrylate: risk of bacterial contamination with an appraisal of its antimicrobial effects. J Emerg Med 1995;13:581-5. Crossref
9. Soni A, Narula R, Kumar A, Parmar M, Sahore M, Chandel M. Comparing cyanoacrylate tissue adhesive and conventional subcuticular skin sutures for maxillofacial incisions—a prospective randomized trial considering closure time, wound morbidity, and cosmetic outcome. J Oral Maxillofac Surg 2013;71:2152.e1-8. Crossref
10. Wilson AD, Mercer N. Dermabond tissue adhesive versus Steri-Strips in unilateral cleft lip repair: an audit of infection and hypertrophic scar rates. Cleft Palate Craniofac J 2008;45:614-9. Crossref
11. Wong EM, Rainer TH, Ng YC, Chan MS, Lopez V. Cost-effectiveness of Dermabond versus sutures for lacerated wound closure: a randomised controlled trial. Hong Kong Med J 2011;17 Suppl 6:4-8.

Is pain from mammography reduced by the use of a radiolucent MammoPad? Local experience in Hong Kong

Hong Kong Med J 2016 Jun;22(3):210–5 | Epub 22 Apr 2016
DOI: 10.12809/hkmj154602
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
ORIGINAL ARTICLE
Is pain from mammography reduced by the use of a radiolucent MammoPad? Local experience in Hong Kong
Helen HL Chan, FHKCR, FHKAM (Radiology)1; Gladys Lo, FHKCR, FHKAM (Radiology)1; Polly SY Cheung, FCSHK, FHKAM (Surgery)2
1 Department of Diagnostic and Interventional Radiology, Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong
2 Private practice, Hong Kong
 
Corresponding author: Dr Helen HL Chan (chanhlh@yahoo.com)
 
 Full paper in PDF
Abstract
Introduction: Screening mammogram can decrease the mortality of breast cancer. Studies show that women avoid mammogram because of fear of pain, diagnosis, and radiation. This study aimed to evaluate the effectiveness of a radiolucent pad (MammoPad; Hologic Inc, Bedford [MA], US) during screening mammogram to reduce pain in Chinese patients and the possibility of glandular dose reduction.
 
Methods: This case series was conducted in a private hospital in Hong Kong. Between November 2011 and January 2012, a total of 100 Chinese patients were recruited to our study. Left mammogram was performed without MammoPad and served as a control. Right mammogram was performed with the radiolucent MammoPad. All patients were then requested to complete a simple questionnaire. The degree of pain and discomfort was rated on a 0-10 numeric analogue scale. Significant reduction in discomfort was defined as a decrease of 10% or more.
 
Results: Of the 100 patients enrolled in this study, 66.3% of women reported at least a 10% reduction in the level of discomfort with the use of MammoPad. No statistical differences between age, breast size, and the level of discomfort were found.
 
Conclusion: The use of MammoPad significantly reduced the level of discomfort experienced during mammography. Radiation dose was also reduced.
 
 
New knowledge added by this study
  • Pain and discomfort associated with mammography is reduced with the use of MammoPad.
  • The glandular dose for mammography is also reduced.
Implications for clinical practice or policy
  • MammoPad is now used in all our patients. There are fewer complaints about pain during mammography.
 
 
Introduction
Screening mammography is the only known scientifically proven method that can decrease the mortality of breast cancer.1 2 Although most women are informed of the importance of mammography, a significant number avoid this screening procedure. The three most common reasons given are fear of pain, fear of the mammogram results, and fear of radiation.
 
Among these three reasons, pain and discomfort appear to be the most common, especially in those with a poor experience.3 Although most pain occurs during breast compression, reducing compression by the technician had no significant effect on the discomfort of mammography. Studies have quoted different methods to relieve patient anxiety and to reduce pain and discomfort during the procedure. These included a thorough explanation of the procedure,4 topical application of 4% lidocaine gel to the skin of the chest before mammography,5 self-controlled breast compression during mammography,6 and the use of a radiolucent pad (MammoPad; Hologic Inc, Bedford [MA], US) during mammography.7 8 Oral acetaminophen and ibuprofen were shown to be of no significant effect in relieving discomfort during mammography. Poulos and Rickard9 reported that decreasing the compression force did not significantly reduce discomfort.
 
Asian patients might have more fibroglandular tissue in their breasts that thus appear to have a higher density on screening mammogram. Whether or not they experience more discomfort during mammography is unknown. MammoPad is a soft, compressible cushion that provides a softer and warmer surface for taking mammography. We believe it may improve compliance with mammography among Asian patients. We performed a prospective study to evaluate the effectiveness of MammoPad used during screening mammogram to reduce pain in Asian patients. The possibility of glandular dose reduction was also assessed.
 
Methods
Between November 2011 and January 2012, a total of 100 patients were recruited to our study. The inclusion criteria included Chinese women who were asymptomatic and referred for routine breast screening. Patients prescribed regular oral contraceptive pills and those with a family history of breast cancer were also included in our study. There was no age limitation. The included participants were 32 to 70 years old, with a mean age of 49.7 (± standard deviation, 7.3) years. Women with known breast cancer, who presented with breast lump or had prior breast surgery, were excluded. After obtaining informed consent, screening mammogram was performed with the standard craniocaudal (CC) and mediolateral oblique (MLO) views. For each patient, the left breast was imaged without MammoPad and served as a control. The MammoPad was then placed on the surface of the digital detector of the mammographic equipment (Inspiration/Novation, Siemens, Germany) and the right mammogram was performed (Figs 1 and 2). The level of compression was determined by the experienced mammographic technician. On completion of the procedure, all patients were requested to complete a simple questionnaire (Appendix). The degree of pain and discomfort (including coldness and hardness of the mammogram compression device) was assessed by a 0-10 numeric analogue scale. Three patients refused to participate in the study.
 
Declaration
All authors have disclosed no conflicts of interest.
 

Figure 1. Image quality between the right and left mammogram in dense breast
(a) The right mammogram is performed with a pad and (b) the left mammogram is performed without a pad and serve as the control. No significant change in image quality is shown between the right and left mammogram in dense breast
 

Figure 2. The use of MammoPad on the mammographic equipment
 

Appendix. Patient assessment questionnaire for mammogram using MammoPad
 
The image quality of the mammograms with and without MammoPad was assessed by two experienced radiologists who had mammographic training (one radiologist had >20 years of and another radiologist >10 years of mammography reading experience). The two radiologists were blinded as to which side of the mammogram was performed with and without MammoPad. Since the MammoPad was radiolucent, its presence was not evident on the mammogram.
 
The mammographic assessment was divided into five categories:
(1) Symmetrical on both sides with satisfactory diagnostic image quality;
(2) Quality of right mammogram image slightly better than the left mammogram but with diagnostic accuracy unaffected;
(3) Quality of left mammogram image slightly better than the right mammogram but with diagnostic accuracy unaffected;
(4) Quality of right mammogram image much better than the left mammogram, affected the diagnostic accuracy, and required repeated mammogram; and
(5) Quality of left mammogram image much better than the right mammogram, affected the diagnostic accuracy, and required repeated mammogram.
 
Any disagreement about the findings was resolved through consensus between the radiologists.
 
Statistical analysis
Significant reduction in discomfort of the mammography was defined as a decrease in discomfort by 10% or more. The mean differences in continuous variables between the mammograms with and without a pad were tested by paired sample t test. The differences in the percentage of comfort between groups in density, size, and age were tested by Chi squared test. A two-tailed P value of <0.05 was considered statistically significant.
 
Results
Image quality
Among the mammograms compared, 92% of the images from the two groups with or without MammoPad had comparable image quality (Fig 1). Only 4% of images from the group without MammoPad were found to have better image quality. Another 4% of the images from the group with MammoPad were noted to have better image quality. In the 4% of image groups with image quality differences (either right side better than the left side or vice versa), two radiologists did not consider diagnostic accuracy to be affected. The patients with image quality differences of the right and left side had follow-up mammograms without MammoPad performed 1 year later. There was no mammographic evidence of malignancy in these patients.
 
For pain and discomfort reduction
The Table shows the comparisons in pain reduction and other measures between the mammograms with and without a pad. Using paired sample t test, the mean (± standard deviation) scores for pain (5.7 ± 2.5 vs 4.2 ± 1.8), coldness (4.0 ± 2.2 vs 2.2 ± 2.1), hardness (3.6 ± 2.4 vs 2.0 ± 2.1), and overall feeling (4.1 ± 2.3 vs 2.6 ± 2.1) were significantly higher in the group without MammoPad than the group with MammoPad (all P<0.001). The thickness was higher in the group with MammoPad when compared with the group without MammoPad in both the CC view (57.8 ± 13.8 mm vs 53.1 ± 13.0 mm; P<0.001) and MLO view (54.2 ± 16.6 mm vs 50.9 ± 16.4 mm; P=0.019).
 

Table. Comparison of pain and discomfort score, compression force, and dose parameters for mammograms with and without MammoPad
 
Among the 100 patients, 90 of them had previously undergone mammography of whom 64 (71.1%) reported the mammogram with a pad to be ‘more comfortable’ or ‘much more comfortable’ than prior studies without a pad. Only 26 (28.9%) patients reported that the level of discomfort for mammogram with MammoPad was the same as prior studies. There was no association between patient age and comfort during mammography (Chi squared value=5.81, degrees of freedom [df]=8, P=0.664; Fig 3). Patients with less breast density were more likely to report ‘much more comfortable’ than those patients with high breast density (Chi squared value=10.3 [df=2], P=0.006; Fig 4). There was no statistically significant association between breast size and comfort during mammography (Chi squared value=4.68 [df=4], P=0.322; Fig 5). All patients preferred using MammoPad in future mammography.
 

Figure 3. Association between age and comfort during mammography
There was no statistical significance between age and comfort during mammography (P=0.664)
 

Figure 4. Comparison of patients with less breast density and those with high breast density
Patients with less breast density were more likely to report ‘much more comfortable’ than patients with high breast density (P=0.006)
 

Figure 5. Association between breast size and comfort during mammography
There was no statistical significance between the breast size and the comfort during mammography (P=0.322)
 
For dosage reduction
The mean glandular dose was higher in the group without MammoPad than the group with MammoPad in both views (1.11 ± 0.44 mGy vs 1.06 ± 0.38 mGy for CC view, and 1.08 ± 0.43 mGy vs 1.01 ± 0.36 mGy for MLO view). For the group with MammoPad, there was a 4.5% decrease in dose for the CC view and 6.5% decrease in dose for the MLO view. The statistical significance was P=0.01 and 0.001, respectively (Table).
 
For compression force
There was no statistically significant difference in the mean compression force in the two groups in the CC view (80.1 ± 27.1 N vs 77.2 ± 29.3 N; P=0.094). Reduced compression force in the MammoPad group was noticed in the MLO view (82.0 ± 37.7 N vs 86.0 ± 38.5 N; P=0.037) [Table].
 
Discussion
Breast cancer is the third leading cause of cancer death among females in Hong Kong, after colorectal and lung cancers.10 In 2013, a total of 596 women died from breast cancer, accounting for 10.5% of all cancer deaths in females.10 Screening mammogram is proven to be effective in the early detection of breast cancer. Unfortunately, the utilisation of screening mammogram in Hong Kong is limited, partly because there is no government-subsidised mammographic screening programme. Another important factor is the discomfort experienced during mammography.
 
Various studies have attempted to reduce the pain and discomfort associated with mammography. The most promising method to date appears to be the radiolucent MammoPad. Tabar et al7 reported that two thirds of women experienced a significant reduction in pain when the radiolucent cushions were used during mammography. Markle et al8 reported that use of a radiolucent cushion reduced discomfort during screening mammogram in 73.5% of patients.
 
In our study, we confirmed that the image quality of the mammograms was unaffected by the presence of the MammoPad. After review by the radiologists, diagnostic accuracy was considered unaffected in the 4% image groups with image quality differences (either right side better than the left or vice versa). The difference in image quality was probably secondary to asymmetrical fibroglandular tissue thickness in both breasts. In all, 66.3% of our patients reported at least a 10% reduction in the level of discomfort with the use of MammoPad. This finding was comparable with the study performed by Tabar et al.7 In addition, there was no obvious correlation between age, breast size, and level of discomfort. Reduced compression force in the group with MammoPad was noticed in the MLO view, but not in the CC view.
 
Unlike the study performed by Dibble et al,11 we encountered no problem with inadequate positioning for the mammograms. This may have been because our technicians were well-trained in the use of the MammoPad prior to study commencement. No mammograms required repetition.
 
With the use of MammoPad, Markle et al8 also reported a 4% decreased dose in the CC view, but not the MLO view. In our study, there was a 4.5% decrease in dose for the CC view and 6.5% decrease in dose for the MLO view. These data were statistically significant (P<0.05). With the use of the MammoPad, the compression on breast tissue may be more evenly distributed and account for the dose reduction.
 
Although the improved comfort while using the MammoPad and the dose reduction during mammography are encouraging, our study has several limitations. First, there might have been patient selection bias. This study was performed in a private hospital on Hong Kong Island. There were no similar data available from public hospitals elsewhere in Hong Kong so comparison was not possible. In view of the small sample size, the results might not be representative of the whole screening population. As a result, there might have been an inherent patient selection bias. This selection bias might be minimised if a larger and representative sample could be obtained. Second, since there is no routine breast cancer screening programme in Hong Kong, patients in this study were self-selected and might be more motivated to undergo mammogram or be more informed about such procedure. This might in turn affect the pain and discomfort perception and subsequent scores. In addition, the scoring system for pain, coldness, and hardness was a 0-10 numeric analogue scale system, which is a subjective scoring system. Patient anxiety may result in a higher pain score, and thus, a potential measurement bias might exist. A thorough explanation before performing the mammogram might help to reduce this bias.
 
The MammoPad was a single-use device with obvious hygienic and safety advantages. In the United States, the MammoPad can be recycled, although this cannot be achieved in our unit at present. We might explore the possibility of recycling the device in future to decrease the environmental impact.
 
Conclusion
The use of MammoPad significantly reduced the level of discomfort during mammography. This should improve compliance with initial and follow-up mammography. In addition, we demonstrated radiation dose reduction in both CC and MLO mammograms, which is another important benefit of using MammoPad. We recommend the use of MammoPad for screening mammography in all our patients.
 
Acknowledgements
The authors thank Betty ML Hung and Carmen KM Lam for their assistance in preparation of the questionnaires and data analysis.
 
References
1. Weedon-Fekjær H, Romundstad PR, Vatten LJ. Modern mammography screening and breast cancer mortality: population study. BMJ 2014;348:g3701. Crossref
2. Broeders M, Moss S, Nyström L, et al. The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. J Med Screen 2012;19 Suppl 1:14-25. Crossref
3. Elwood M, McNoe B, Smith T, Bandaranayake M, Doyle TC. Once is enough—why some women do not continue to participate in a breast cancer screening programme. N Z Med J 1998;111:180-3.
4. Shrestha S, Poulos A. The effect of verbal information on the experience of discomfort in mammography. Radiography 2001;7:271-7. Crossref
5. Lambertz CK, Johnson CJ, Montgomery PG, et al. Premedication to reduce discomfort during screening mammography. Radiology 2008;248:765-72. Crossref
6. Kornguth PJ, Rimer BK, Conaway MR, et al. Impact of patient-controlled compression on the mammography experience. Radiology 1993;186:99-102. Crossref
7. Tabar L, Lebovic GS, Hermann GD, Kaufman CS, Alexander C, Sayre J. Clinical assessment of a radiolucent cushion for mammography. Acta Radiol 2004;45:154-8. Crossref
8. Markle L, Roux S, Sayre JW. Reduction of discomfort during mammography utilizing a radiolucent cushioning pad. Breast J 2004;10:345-9. Crossref
9. Poulos A, Rickard M. Compression in mammography and the perception of discomfort. Australas Radiol 1997;41:247-52. Crossref
10. Hong Kong Cancer Registry. Top ten cancers in 2013. Available from: http://www3.ha.org.hk/cancereg/Statistics.html. Accessed Mar 2016.
11. Dibble SL, Israel J, Nussey B, Sayre JW, Brenner RJ, Sickles EA. Mammography with breast cushions. Womens Health Issues 2005;15:55-63. Crossref

Comparison of clinical and pathological characteristics between screen-detected and self-detected breast cancers: a Hong Kong study

Hong Kong Med J 2016 Jun;22(3):202–9  |  Epub 29 Mar 2016
DOI: 10.12809/hkmj154575
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
ORIGINAL ARTICLE
Comparison of clinical and pathological characteristics between screen-detected and self-detected breast cancers: a Hong Kong study
Silvia SS Lau, MPH (HK), MSc1; Polly SY Cheung, FCSHK, FHKAM (Surgery)2; TT Wong, FCSHK, FHKAM (Surgery)2; Michael KG Ma, FRCS (Eng), FHKAM (Surgery)2; WH Kwan, FHKCR, FHKAM (Radiology)3
1 Medical Physics & Research Department, Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong
2 Breast Care Centre, Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong
3 Department of Radiotherapy, Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong
 
Corresponding author: Dr Silvia SS Lau (silvialauss@yahoo.com.hk)
 
 Full paper in PDF
Abstract
Introduction: Breast cancer is the leading cause of death of Hong Kong women with increasing incidence. This study aimed to determine any prognostic differences between screen-detected and self-detected cases of breast cancer in a cohort of Hong Kong patients.
 
Methods: This was a case series with internal comparison carried out in a private hospital in Hong Kong. Approximately 3000 cases of Chinese patients diagnosed with ductal carcinoma in situ or invasive breast cancer were reviewed.
 
Results: The screen-detected group showed better pathological characteristics than the self-detected group. Number of lymph nodes involved, invasive tumour size, and tumour grade were more favourable in the screen-detected group. There was also a lower proportion of patients with pure invasive ductal carcinoma and mastectomy in the screen-detected group.
 
Conclusion: This study provides indirect evidence that women in the local population may gain clinical benefit from regular breast cancer screening. The findings need to be validated in a representative population of Hong Kong women.
 
New knowledge added by this study
  • It is possible that in the Hong Kong local population, breast cancer detected by screening mammogram or ultrasound has more favourable pathological characteristics than self-detected tumours.
Implications for clinical practice or policy
  • Further large-scale clinical trials to evaluate the cost-effectiveness and clinical efficacy of breast cancer screening in the Hong Kong local population should be conducted. Change in prevalence of breast cancer in the female population of Hong Kong and advances in breast imaging technology may have altered the cost-benefit ratio of breast cancer screening.
 
 
Introduction
Breast cancer is the second leading cause of death due to cancer in the world with an age-standardised incidence rate of 43.1 per 100 000 population in 2012.1 Gøtzsche and Nielsen2 showed that early detection of breast cancer can reduce mortality. The benefit of mammographic screening in terms of lives saved is greater than the harm caused by overdiagnosis; according to Duffy et al,3 2 to 2.5 lives are saved for every overdiagnosed case.
 
Breast cancer is also a significant health problem in Hong Kong. It is the third leading cause of death due to cancer and the most common cancer of women.4 The crude incidence rate of breast cancer in Hong Kong increased from 57 per 100 000 in 2000 to 91.7 per 100 000 in 2012.4
 
Despite this, Hong Kong does not have a universal breast cancer screening programme for the whole population. Women who wish to be screened must arrange and pay for it. As the incidence of breast cancer in Hong Kong is low compared with western populations, there is concern about the cost-effectiveness of a universal screening programme. The incremental cost-effectiveness ratio for mammography examination is relatively higher than in the United States.5
 
In view of the controversy there is a need for further studies in Hong Kong to provide local data on the efficacy of breast cancer screening by mammogram. This will enable policy makers, doctors, and patients to decide on the most cost-effective method of early breast cancer detection.
 
This study aimed to investigate whether there are any prognostic differences between screen-detected (mammography, ultrasound examination of breasts, or clinical examination) and self-detected breast cancers in a cohort of Hong Kong breast cancer patients and to determine whether there is any benefit of detection by screening.
 
Methods
Background of database used
A retrospective study was conducted at the Hong Kong Sanatorium & Hospital (HKSH), a private hospital in Hong Kong where the Breast Care Centre provides a comprehensive breast screening programme and breast cancer consultation services for patients. Since 2003, all breast cancer cases in the hospital have been discussed at a weekly multidisciplinary breast conference. Over 50% of cases are referred from public hospitals spread across the whole territory.
 
Clinical history, and information about diagnosis, neoadjuvant chemotherapy, surgical treatment, postoperative pathology, and treatment recommendations for each patient are recorded in a structured datasheet before the conference. The Chairman of the conference validates data by checking the data logic during case presentation and, if necessary, clarifying details with the doctor-in-charge. A research assistant again checked data validity and logic by computer for cases selected for analysis. Frequency tables, scatter plots, and cross-tabulation tables were generated for each required variable to ensure completeness and to determine whether any data deviated from usual clinical practice.
 
Subjects
All Chinese females confirmed to have in-situ or invasive breast cancer from or referred to HKSH between 2003 and 2010 were included in this study. For analysis of trends of prognostic factors, only patients between 2004 and 2010 were included as the sample size for year 2003 was small after dividing data into subsets by year and prognostic factors.
 
Ethics
The use of the database for data analysis for health care research purposes was approved by the Research Ethics Committee of HKSH.
 
Epidemiological analysis
Patients were classified into two groups, screen-detected or self-detected tumour, before the outcomes were reviewed. The screen-detected group included screening mammogram, screening ultrasonogram, or clinical examination. The self-detected group included self-examination or presence of symptoms at presentation. Such information was recorded on the datasheet that was anonymised. Demographic data of patients were retrieved and significant prognostic factors according to St Gallen’s risk categorisation were analysed.
 
Data analysis
The Statistical Package for the Social Sciences (Windows version 18.0; SPSS Inc, Chicago [IL], US) was used for analysis. Descriptive statistics were used to summarise demographics, as well as pathological and clinical characteristics of patients. Univariate logistic regression was used to determine odds ratio (OR) of screening status for different pathological characteristics. Association between type of surgery and screening status, tumour size, and age was determined by univariate logistic regression. In order to know how effective the models were in predicting the type of surgery, Hosmer-Lemeshow goodness-of-fit test was used, in which the null hypothesis was no significant difference between observed and predicted values of dependent variable. Multivariate analysis was performed on the type of surgery, which was dichotomous having breast-conserving surgery (BCS) as reference group with adjustment of confounding factors that included detection mode, lymph node status, tumour size, tumour grade, tumour stage, oestrogen receptors (ER), progesterone receptors (PR), HER2 score, and age. Nagelkerke’s R2 was used to show explanatory power of model.
 
Data for invasive tumour size were plotted against screening status to gain an overview of changes between 2004 and 2010.
 
Results
Data from 2763 Chinese women out of 3373 cases confirmed to have in-situ or invasive breast cancer between 2003 and 2010 were analysed. Of the 610 cases excluded from analysis, 210 were due to unknown histology, 258 with unknown report type, and 142 with unknown first-detection method. Of the patients included, 75.7% were in the self-detected group and 24.3% in the screen-detected group. The mean age of patients was 50.2 (range, 24-92) years, with the highest number in both groups aged 40 to 49 years (Table 1). There was also a significant proportion of younger patients (<40 years) in the self-detected group (16.6%). The screen-detected group had a statistically significant higher age at first live birth, though the difference in mean age was only 1 year.
 

Table 1. Comparison of patient characteristics between self-detected and screen-detected groups by Chi squared test
 
Pathological characteristics of self-detected and screen-detected groups are shown in Table 1. There was a significant difference in ER, but no demonstrable significant difference in PR or HER2 status. Approximately 4% of patients in both groups did not undergo surgery for a variety of reasons, thus only limited information was available from biopsy specimens about pathological characteristics.
 
The odds of having 0 lymph nodes, smaller tumour size, or ER/PR positivity were all higher in the screen-detected group. Results were not statistically significant for HER2 positivity although it showed higher odds in the self-detected group (Table 2).
 

Table 2. Univariate analysis by logistic regression for all cases
 
Table 3 shows that after adjustment for potential confounding factors, patients with screen-detected cancers were less likely to require mastectomy (OR=0.658, P=0.004). Statistically significant factors associated with a higher risk of mastectomy included: positive lymph node, tumour grading higher than 1, tumour size of >2 cm, older age, and positive HER2 score. The Hosmer-Lemeshow test had a P value of 0.88, meaning the goodness of fit of the model was satisfactory at the 5% significance level.
 

Table 3. Logistic regression for type of surgery (breast-conserving surgery vs mastectomy)
 
The Figure shows the trend in differences between groups for invasive tumour size between 2004 and 2010. In the screen-detected group, there was an increasing proportion of invasive tumours detected when ≤2 cm and a decreasing trend for detection of tumour of >2 to 5 cm. There was, however, no significant difference between groups for trend of histology, lymph node involvement, tumour grade, type of surgery, ER positivity, or HER2 positivity.
 

Figure. Trend of invasive tumour size of screen-detected and self-detected groups
 
Discussion
Although the incidence of breast cancer in Hong Kong is half that of the United Kingdom, the screen-detected group showed a pattern of breast cancer diagnosis at an earlier stage compared with the self-detected group. This is consistent with the findings of similar studies in other countries, such as Singapore.6 This study may provide evidence that supports the benefits of regular screening to detect breast cancer lesions at an early stage in Hong Kong women. This will facilitate less invasive surgery and a possibly better overall clinical outcome. Breast cancer screening programmes have been established in many countries around the world. In order to bring Hong Kong in line with world health care standards, more research that will result in established and unified guidelines for the local population is required.
 
Pathological risk factors
Significant prognostic factors in the St Gallen’s risk categorisation, including number of lymph nodes with disease, size of primary tumour, and histological grade between the self-detected and screen-detected groups were analysed. These prognostic factors were chosen because they have been verified as significant in the local population.7
 
In this study, screen-detected breast tumours were of smaller size, at a lower stage and grade, and with less lymph node involvement. Screen-detected breast cancers in the Hong Kong population may thus carry a better prognosis than self-detected ones. This can serve as evidence that fulfils most of the Wilson and Jungner criteria for a screening evaluation programme8 and also supports breast cancer screening in Hong Kong. Some of the criteria for breast cancer screening that have been fulfilled include: an important health problem (it is the second leading cause of death from cancer in Hong Kong), acceptable treatment is well established, facilities for diagnosis and treatment are widely available, natural history of the disease is well understood, and effective treatment is available for early-stage disease. Findings of this study suggested that breast tumours detected on screening have a better prognosis. The cost-benefit balance was not addressed, however, nor screening/case-finding policies.
 
In the screen-detected group, a higher percentage of tumours were ER positive. It was revealed that ER and PR are significant prognostic factors within the first 10 years following diagnosis.9 It is known that HER2 positivity shows poorer prognosis8 but there was no significant difference in HER2 status between screen-detected and self-detected groups.
 
Trends
By observing the trend in size of invasive tumour at first presentation, the stable pattern in the self-detected group suggests that tumour detection by the general population has not improved. On the contrary, an increasing detection of tumours of ≤2 cm in the screen-detected group is an evidence of the improved efficacy of screening using new technology such as mammogram or sonogram. There remains room for improvement in the application of radiology. Apart from magnetic resonance imaging, digital mammography may be more efficacious in women younger than 50 years.9 This may change future trends in early diagnosis.
 
Hormonal receptor and HER2 status
Unlike tumour size and number of lymph nodes involved, both of which are increased in breast tumours detected at a later stage with a consequent poorer prognosis, prognostic factors such as status of ER/PR and HER2 are intrinsic characteristics of tumours. They should not differ whether or not a tumour is detected at an earlier stage. Therefore no statistically significant difference in these intrinsic characteristics was expected between screen-detected and self-detected tumours. Nonetheless, in this study, tumours in the screen-detected group were more likely to be positive for ER, and this may carry some prognostic implication. Further studies may be required to investigate whether tumours detected at an earlier stage show differences in intrinsic factors.
 
Surgical treatment
When choosing between BCS and mastectomy, detection mode, number of positive lymph nodes, invasive tumour size, grading, staging, ER, PR, HER2 score, and age were potential significant factors. With adjustment of these factors, detection mode may be an independent factor that affects choice of surgery. Screen-detected patients tended to have BCS when the effect of number of positive lymph nodes, tumour size, grading, HER2 score, and age was excluded. Such surgery is less invasive than mastectomy and is associated with better cosmetic outcome, and may have an important impact on the psychological health and coping ability of patients recovering from breast cancer. Breast cancer screening may lead to less invasive treatment with better rehabilitation outcome.
 
Potential biases
Many studies have claimed longer survival in patients with breast cancer detected by screening mammogram. Nonetheless, this may be due to lead-time bias: survival time appears longer because diagnosis is earlier than in patients where tumour has been self-detected or become symptomatic. In addition, there is selection bias since women with a family history of breast cancer or who are better informed are more likely to submit to breast cancer screening.
 
Cost-effectiveness
A local study suggested that population-based breast cancer screening by mammography may not be cost-effective in Hong Kong women.5 This balance between cost and benefit may be altered by the rising incidence of breast cancer in Hong Kong and the availability of advanced breast imaging technology that is associated with fewer false-positive diagnoses. There may also be a broader range of screening options, hence cost will be lowered. Therefore, the incremental cost-effectiveness ratio may be lowered.
 
Recommendations
A prospective randomised controlled trial would be the most effective study design to evaluate the effectiveness of mammogram screening. This would require a huge amount of resources, however. In addition, education level and household income, which are risk factors for breast cancer, may affect a woman’s decision to undergo a mammogram. These confounding factors should be considered when determining the effect of mammogram examination on development of breast cancer. Postmenopausal hormone replacement therapy also affects the density of breast tissue that may hinder the effectiveness of mammography for breast cancer screening.10
 
The lack of a population-based breast cancer screening programme in Hong Kong should prompt study of the attitude of Hong Kong women towards breast cancer screening. Quantitative surveys or qualitative interviews such as focus groups could help determine their opinion of mammogram screening, what proportion of women perform regular self-examination or undergo clinical breast examinations and regular mammogram examinations and how often, and whether age is a contributing factor. Trend study may also be meaningful if a particular age-group shows an increasing or decreasing trend for any of the examinations. Understanding level of knowledge about risk factors for breast cancer can also guide appropriate education about breast cancer prevention.
 
Limitations of this study
The major strength of this study is the large number of cases in the database, which is one of the most comprehensive breast cancer databases available in Hong Kong in terms of surgical and pathological characteristics. This provides valuable information about the characteristics of breast cancers detected by oneself and through screening, thus allowing a better understanding of the potential benefits of screening by mammogram or ultrasound examination.
 
This study has limitations. First, it was not a randomised controlled trial. The presence of confounding factors such as living standard, household income, and education level could not be totally excluded. There were also more self-detected than screen-detected patients in this study, thus data might skew towards self-detected cases. It is ethically difficult to randomise women to a control group of education and regular breast self-examination, or an intervention group of regular breast cancer screening by imaging.
 
Second, data were derived from a single private hospital and findings may not be representative of the Hong Kong population in general. Self-selection bias, especially for attending a private hospital, is also possible. Nonetheless, this is probably one of the largest breast cancer databases in Hong Kong, thus one of the best available sources of information options at present.
 
Third, secondary data that had been used in this study may not be in a format that met the research question. Some information required may not be available from secondary data. Only 2198 (79.6%) patients were included in the multivariate logistic regression. Other medical and non-medical factors that could have affected the choice of surgery in individual patients might be related to the practice of screening. Data on parity of women and breastfeeding experience, which may be of interest/relevance, were also not available. Also, the potential benefits and harm of screening were not thoroughly examined due to the unavailability of data for survival, mortality, and side-effects. For this study, a long period of time was required to examine the data and filter out required variables for analyses as there were more than 200 variables in the database. Information bias also exists as complete blinding of the analysts was not possible.
 
Conclusion
This study suggests that in the local Hong Kong population, breast cancers detected by screening mammogram or ultrasound tend to be of smaller size, lower stage, lower grade and with less lymph node involvement, and consequent better prognosis. Although this may not be considered conclusive evidence to support regular screening imaging of Hong Kong women on a population-wide basis, it provides indirect evidence that women in our local population may gain clinical benefit from such a programme.
 
Acknowledgements
 
This article is adapted from a dissertation submitted in partial fulfilment of the requirements for the Master of Public Health at the University of Hong Kong, Hong Kong Special Administrative Region, China. The dissertation was awarded distinction in 2012. Part of the material in this article was presented in the Hong Kong Sanatorium & Hospital Li Shu Pui Symposium 2012 in Hong Kong.
 
The first author would like to acknowledge Dr Joseph Wu, Assistant Professor, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, for his supervision of the project leading to completion of the dissertation for the Master of Public Health course. The authors would also like to thank Dr Andrew Ho, Senior Research Assistant, who is statistical advisor of the project. Finally, the authors would like to express sincere appreciation to staff of Information Technology Department of Hong Kong Sanatorium & Hospital, who helped retrieve all necessary data for the study.
 
Declaration
All authors have disclosed no conflicts of interest.
 
References
1. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Accessed Dec 2015.
2. Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2011;(1):CD001877. Crossref
3. Duffy SW, Tabar L, Olsen AH, et al. Absolute numbers of lives saved and overdiagnosis in breast cancer screening, from a randomized trial and from the Breast Screening Programme in England. J Med Screen 2010;17:25-30. Crossref
4. Hong Kong Cancer Registry. Female breast cancer in Hong Kong. Available from: http://www3.ha.org.hk/cancereg/breast_2012.pdf. Accessed Jan 2016.
5. Wong IO, Kuntz KM, Cowling BJ, Lam CL, Leung GM. Cost-effectiveness analysis of mammography screening in Hong Kong Chinese using state-transition Markov modelling. Hong Kong Med J 2010;16(Suppl 3):38S-41S.
6. Chuwa EW, Yeo AW, Koong HN, et al. Early detection of breast cancer through population-based mammographic screening in Asian women: a comparison study between screen-detected and symptomatic breast cancers. Breast J 2009;15:133-9. Crossref
7. Yau TK, Soong IS, Chan K, et al. Evaluation of the prognostic value of 2005 St. Gallen risk categories for operated breast cancers in Hong Kong. Breast 2008;17:58-63. Crossref
8. Wilson JM, Jungner G. Principles and practice of screening for disease. Public Health Papers. No. 34. Geneva: World Health Organization; 1968.
9. Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat 2008;107:309-30. Crossref
10. Cox B, Ballard-Barbash R, Broeders M, et al. Recording of hormone therapy and breast density in breast screening programs: summary and recommendations of the International Cancer Screening Network. Breast Cancer Res Treat 2010;124:793-800. Crossref

Evaluation of biological, psychosocial, and interventional predictors for success of a smoking cessation programme in Hong Kong

Hong Kong Med J 2016 Apr;22(2):158–64 | Epub 20 Nov 2015
DOI: 10.12809/hkmj154549
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
ORIGINAL ARTICLE
Evaluation of biological, psychosocial, and interventional predictors for success of a smoking cessation programme in Hong Kong
KS Ho, FHKAM (Family Medicine), FHKAM (Medicine); Bandai WC Choi, MSocSc; Helen CH Chan, MSocSc, MPH; KW Ching, MB, BS, FHKAM (Family Medicine)
Integrated Centre for Smoking Cessation, Tung Wah Group of Hospitals; (c/o) 17/F Tung Sun Commercial, 194-200 Lockhart Road, Wanchai, Hong Kong
 
Corresponding author: Dr KS Ho (rayhoks@yahoo.com.hk)
 
 Full paper in PDF
Abstract
Introduction: Predictors for smoking cessation have been identified in different studies but some of the predictors have been variable and inconsistent. In this study, we reviewed all the potential variables including medication, counselling, and others not commonly studied to identify the robust predictors of smoking cessation.
 
Methods: This historical cohort study was conducted in smoking cessation clinics in Hong Kong. Subjects who volunteered to come for free treatment between January 2010 and December 2011 were reviewed. Those under the age of 18 years, or who were mentally unstable or cognitively impaired were excluded. Counselling and quit-smoking medications were provided to the participants. The outcome measure was self-reported 7-day point prevalence abstinence rate at week 26.
 
Results: Univariate analysis showed that the following were significant predictors of quitting: (1) psychosocial variables such as feeling stressed, feeling depressed, confidence in quitting, difficulty in quitting, importance of quitting, Smoking Self-Efficacy Questionnaire score; (2) smoking-related variables such as number of cigarettes smoked per day, Fagerström Test for Nicotine Dependence score, number of high-risk situations encountered; (3) health-related variable of having mental illness; (4) basic demographics such as age, marital status, and household income; and (5) interventional variables such as counselling and pharmacotherapy. Multiple logistic regression showed that the independent predictors were age, having mental illness, daily cigarette consumption, Fagerström Test for Nicotine Dependence score, reasons for quitting, confidence in quitting, depressed mood, external self-efficacy, intervention with counselling and medications.
 
Conclusions: This clinic-based local study offers a different perspective on the predictors of quitting. It reminds us to adopt a holistic approach to deal with nicotine withdrawal, to enhance external self-efficacy to resist temptation and social influences, to provide adequate counselling, and to help smokers to cope with mood problems.
 
New knowledge added by this study
  • A more holistic list of predictors of smoking cessation were included in this local clinic-based study, and differed from many other studies by population survey. Household income, marital status, gender, years of smoking, smoking cohabitant, perceived health, anxious mood, perceived importance, and difficulty in quitting were no longer predictors. Many of these are not modifiable. It is more important to enhance self-efficacy and to use counselling and medication to counter mood problems.
Implications for clinical practice or policy
  • In clinical practice, we should adopt a holistic approach to smoking cessation by providing more intensive counselling, managing withdrawal symptoms with medication, strengthening external self-efficacy to resist external temptation, and screening for mood problems.
 
 
Introduction
Smoking has long been identified as a major global public health issue. It is the leading cause of preventable death worldwide and kills about 6 million people each year.1 Although Hong Kong has the lowest smoking prevalence among the major cities of China, at 11.1% as reported in 2010, it still accounts for about 5700 deaths annually, approximately one fifth of all deaths per year. In 1998, there were 1324 passive smoking–related deaths reported.2 3
 
According to the evidence-based MPOWER measures introduced by the World Health Organization4 to reduce the demand for tobacco, to provide smoking cessation services and cessation support in the public health care system, governments around the world have put more emphasis on smoking cessation programmes to reduce the tobacco-related health risks.5 On 1 January 2007, the Hong Kong Special Administrative Region (SAR) Government enacted the Smoking (Public Health) Ordinance and on 25 February 2009, tobacco tax was increased by 50%. In 2009, the Tung Wah Group of Hospitals (TWGHs) was commissioned by the Hong Kong SAR Government to provide a community-based smoking cessation service in Hong Kong.
 
The Integrated Centre on Smoking Cessation (ICSC) of the TWGHs was set up in different districts of Hong Kong, namely Shatin, Kwun Tong, Sheung Shui, Tuen Mun, Mongkok, Wanchai, Cheung Sha Wan, and Tsuen Wan to provide a free smoking cessation service to Hong Kong citizens. An integrated model of counselling and pharmacotherapy was adopted.6 7
 
Identification of predictors and determinants of success in smoking cessation is crucial for smoking cessation service.8 Over the last decade, health care professionals have endeavoured to identify the predictors and characteristics of successful quitters.9 Overseas studies have identified the following: old age, high socio-economic status,10 11 12 male gender, younger age at smoking initiation, previous quit attempts, being married, fewer depressive symptoms, fewer anxiety symptoms, lower prior tobacco consumption, lower score of Fagerström Test for Nicotine Dependence (FTND), no cohabitating smoker, and high cessation-related motivation/confidence.8 10 11 12 13 14 Nonetheless, many studies have shown that these predictors are not always consistent.11 15 This may be due to different methodologies and environments in different studies. Some studies were population surveys based on individual recall and did not include interventions. In this study, we analysed all potential variables and interventions. With a more comprehensive list of variables, we hoped to identify some robust independent predictors of successful quitters.
 
Methods
Study setting
Clients who attended an ICSC in different districts in Hong Kong from 1 January 2010 to 31 December 2011 were recruited via smoking cessation hotlines, referral from health care professionals, or self-referral.
 
All clients received counselling, and pharmacotherapy was prescribed if the client agreed. An average of four face-to-face counselling sessions were conducted over the first 8-week intensive treatment phase by registered social workers who were all trained in tobacco cessation counselling. Phone follow-up and counselling were also offered during this treatment phase and between 9 and 12 weeks. The stage of change theory and motivational interviewing techniques were adopted.16 17 18 Clients were followed up by telephone at week 26 and week 52 to ascertain abstinence from smoking. The medications provided by ICSC included nicotine replacement therapy (NRT) and non-NRT. The former included nicotine patches, gum, lozenges, and inhalers. Oral medications included varenicline and bupropion. Medications were prescribed according to the clients’ personal preference and clinical conditions following a thorough explanation by counsellors or medical officers. For example, NRT gum would not be given to a client with dentures and a patch would not be given to a client with skin allergy.
 
Study design, participants, and data collection
This was a historical cohort study. All cases commenced treatment between 1 January 2010 and 31 December 2011. The inclusion criteria of the study were adults aged 18 years or above. Clients who were mentally unstable or cognitively impaired were excluded.
 
A structured questionnaire was used to collect the following information: (i) socio-demographic variables: age, gender, marital status, education, monthly household income, number of people living together; (ii) health-related variables: perceived health, cessation advice by nurse, cessation advice by doctor, cessation advice by any medical professional, severe/chronic illness, mental illness; (iii) smoking-related variables: age started smoking, years of smoking, cohabitation with another smoker, number of cigarettes smoked per day, FTND score,19 previous quit attempt, number of previous quit attempts, time of last attempt, reason to quit, high-risk situation; (iv) psychosocial variables: self-perceived stress, self-perceived depression, perceived importance, difficulty and confidence in quitting (from a scale of 0-100), perceived source of social support, Smoking Self-Efficacy Questionnaire (SEQ-12)20 21; and (v) intervention variables. Consent was obtained and confidentiality was assured. The questionnaire was self-administered and illiterate clients were given help as appropriate. Completed forms were validated by the counsellors.
 
Outcome measure
The outcome measure was self-reported 7-day point prevalence abstinence rate at week 26. Clients who were not able to be followed up or with an absent response for smoking status were considered to have not quitted.
 
Statistical analyses
Data management and analysis was performed using the Statistical Package for the Social Sciences (Windows version 22.0; SPSS Inc, Chicago [IL], US). Univariate logistic regression was used for all studied predictors. All predictors with a reported P value of <0.10 were then included in multiple logistic regression analysis. Backward elimination was used in the multivariate analysis to identify independent predictors of abstinence as well as to calculate the adjusted odds ratio (AOR) and 95% confidence interval. All statistical analyses were two-tailed tests and a P value of <0.05 was considered statistically significant.
 
Results
Demographics
A total of 4045 clients who attended the ICSC during 1 January 2010 to 31 December 2011 were reviewed and 3853 cases who met the inclusion criteria were analysed. The gender ratio of male-to-female was approximately 7:3. Their age ranged from 18 to 89 years with a mean of 42 years; mean duration of smoking of this cohort was 20 years, and mean cigarette consumption was 18 cigarettes per day (Table 1).
 

Table 1. Demographics and smoking-related characteristics of subjects (n=3853)
 
Univariate logistic regression
The abstinence rate at week 26 was 35.1% (1353/3853). Univariate analysis of basic demographic data revealed that successful quitting was related to older age, being married, and higher household income (Table 2). Mental illness was significantly related to failure to quit but chronic illness was not, for examples, hypertension, diabetes, and chronic obstructive pulmonary disease.
 

Table 2. Univariate logistic regression analysis of socio-demographic and health-related variables (n=3853)
 
Analysis of smoking-related variables showed that successful quitting was related to longer years of smoking, not cohabiting with a smoker, lower daily cigarette consumption, and lower FTND score. Successful quitters were more likely to report “prove my ability to quit smoking” and “avoid discrimination as a smoker”. A higher number of high-risk situations in quitting were negatively related to quit rate. Significant individual high-risk situations included “under time pressure”, “arguing with others”, “depressed or frustrated”, “drinking alcohol or coffee”, “difficulty in sleeping”, and “bored” (Table 3).
 

Table 3. Univariate logistic regression analysis of smoking-related variables (n=3853)
 
The following psychosocial variables were correlated to quitting: not feeling stressed, not feeling depressed, high perceived importance of quitting, low perceived difficulty in quitting, high confidence in quitting, perceived support from spouse, and high SEQ-12 score (Table 4). All interventional variables were significant predictors of smoking abstinence: number of face-to-face counselling sessions, over-the-phone counselling, and use of medication.
 

Table 4. Univariate logistic regression analysis of psychosocial and interventional variables (n=3853)
 
Multiple logistic regression
All items reported P<0.10 in the univariate logistic regression analysis were included in the multiple logistic model with backward elimination. Only subjects with complete data in all fields of the included items were analysed (n=2714). As shown in Table 5, independent predictors of smoking abstinence at week 26 were older age, quitting based on “prove my ability to quit smoking”, high confidence in quitting, high external self-efficacy, more counselling sessions (both office and phone contact), and use of medication. The following characteristics were predictive of failure to quit: history of mental illness, high daily cigarette consumption, high FTND score, and feeling depressed.
 

Table 5. Multiple logistic regression (n=2714)
 
Discussion
This is the first comprehensive study of predictors of success for smoking cessation in a local smoking cessation service. Age, mental health, cigarette consumption, FTND score, reasons to quit, confidence in quitting, depressive mood, self-efficacy, sessions of office counselling, phone counselling, and medication treatment were identified as predictors among clients who volunteered to quit smoking.
 
In the univariate logistic analysis, most of the predictors were consistent with other studies. In many studies of predictors,15 22 results for gender, number of previous attempts, education level and social status, years of smoking, and history of depression have been inconsistent. In our study, a more comprehensive list of potential predictors from five domains (namely, demographics, health-related, smoking-related, psychosocial, and interventional variables) was included. After multiple logistic regression analysis, many commonly reported determinants/predictors were excluded. They included perceived health, marital status, cohabitation with a smoker, household income, gender, years of smoking, perceived importance of quitting or difficulty in quitting, feeling anxious, and internal self-efficacy in quitting.
 
The effect of age appeared to be consistent with the results of local23 24 and some international studies11 12 13 that older age was an independent predictor.25 Results for the predictive power of male gender have been controversial: some studies have reported it as a predictor of cessation success,8 10 26 while others have found it to have no significant effect or a negative effect.12 27 28 Our study could not confirm these findings. In addition, the role of marital status, education, household income, and number of cohabitants were shown not to be predictive, contrary to some overseas studies.29 30 Nonetheless, consistent with many studies, cigarette consumption and FTND score were negatively correlated with quit rate.8 27 31
 
Extensive research indicates that individual motivation, especially intrinsic motivation, is predictive of the long-term cessation result.8 In our study, two robust reasons to quit that could significantly predict abstinence were “prove my ability to quit smoking” and “avoid discrimination as a smoker”. This seemed to correspond to the “self-control” and “social influence” factors of Reasons for Quitting scale.32 In Hong Kong, smoking in some designated areas and public places is forbidden. This may precipitate the “avoid discrimination as a smoker” response. In service provision, operational initiatives and promotion strategies may be tailored to these two areas when motivating smokers to quit.
 
Perceived depressive mood (AOR=0.77) and history of mental illness (AOR=0.67) greatly enervated the success rate of quitting in our participants. Similar results have been reported in western countries as well as in Asia.8 33 34 35 This reinforces the importance of implementing appropriate mental health screening and referral in smoking cessation clinics. Presence of a chronic illness was not shown to be predictive although this may have been due to our relatively small sample size for this group of clients or because ours was a cohort of smokers who were motivated to quit. The effect of chronic illness may thus be attenuated. Studies have also shown that not all chronic diseases have the same impact on smoking cessation.36 37
 
The link between self-efficacy and successful quitting has long been established.22 38 Both external and internal self-efficacy in SEQ-12 scales have been found to be predictive in smoking cessation in western countries.21 In our study, after adjusting all potential predictors, a high degree of confidence and external self-efficacy were predictive of cessation, while the predictive ability of total and internal sub-score of SEQ-12 faded after adjustment. This is consistent with a previous Hong Kong study.20 Manifestation of cultural differences in self-efficacy during smoking cessation warranted further investigation. According to the results in the current study, smoking cessation counselling should focus more on helping clients to develop techniques to resist external temptation and to enhance external self-efficacy.
 
Consistent with overseas reviews of smoking cessation counselling,15 39 our study indicated that the number of sessions of face-to-face counselling or phone support were strong predictors (AOR=1.15 and 1.12, respectively). Both kinds of medication (NRT and non-NRT) were also associated with successful smoking cessation. Most previous predictor studies have not included these parameters, however.
 
There are some limitations in our study. Since this was a retrospective case review study of smokers who were motivated to quit, the results cannot be generalised to the whole smoking population. In addition, in the process of multiple logistic regression, only 2714 clients instead of all study subjects were analysed. Interventional variables such as office counselling, phone counselling, and medication modality were not randomly allocated. Patient compliance with medication was not evaluated, thus information on the use of medication may be biased. Another potential confounding factor was a small amount of missing data for some predictors. The effect of job nature and different chronic illnesses was not included in this study because of insufficient data; only chronic disease as a group was analysed. Self-reported 7-day point prevalence abstinence rate was not biochemically validated although previous study has shown that self-reported abstinence does not differ much to abstinence according to biochemical validation.40
 
Conclusions
This local study has identified a number of predictors of smoking abstinence at week 26 in clients who volunteered to seek treatment from a smoking cessation clinic. Most large-scale overseas studies have been based on a population survey. This was a large-scale comprehensive study performed in a real-life smoking cessation programme in Hong Kong. As such, it offers a better understanding of the determinants of successful quitting. Although some predictors have not been addressed and need further study, this study highlights the need for a holistic approach to the management of nicotine withdrawal, and to enhance external self-efficacy and motivation, to provide an adequate number of counselling sessions and to help smokers cope with mood problems.
 
References
1. WHO Report on the global tobacco epidemic. Geneva: World Health Organization; 2013.
2. Lam TH, Ho SY, Hedley AJ, Mak KH, Peto R. Mortality and smoking in Hong Kong: case-control study of all adult deaths in 1998. BMJ 2001;323:361. Crossref
3. Hong Kong Council on Smoking and Health: Annual Report 2011-2012. Hong Kong: Hong Kong Council on Smoking and Health; 2012.
4. WHO Report on the global tobacco epidemic, 2008: The MPOWER Package. Geneva: World Health Organization; 2008.
5. Wang L, Kong L, Wu F, Bai Y, Burton R. Preventing chronic diseases in China. Lancet 2005;366:1821-4. Crossref
6. 2008 PHS Guideline Update Panel, Liaisons, and Staff. Treating tobacco use and dependence: 2008 update U.S. Public Health Service Clinical Practice Guideline executive summary. Respir Care 2008;53:1217-22.
7. Reducing tobacco use: a report of the Surgeon General—executive summary. Nicotine Tob Res 2000;2:379-95. CrossRef
8. Caponnetto P, Polosa R. Common predictors of smoking cessation in clinical practice. Respir Med 2008;102:1182-92. Crossref
9. Prochaska JO, DiClemente CC, Velicer WF, Ginpil S, Norcross JC. Predicting change in smoking status for self-changers. Addict Behav 1985;10:395-406. Crossref
10. Hymowitz N, Cummings KM, Hyland A, Lynn WR, Pechacek TF, Hartwell TD. Predictors of smoking cessation in a cohort of adult smokers followed for five years. Tob Control 1997;6 Suppl 2:S57-62. Crossref
11. Monsó E, Campbell J, Tønnesen P, Gustavsson G, Morera J. Sociodemographic predictors of success in smoking intervention. Tob Control 2001;10:165-9. Crossref
12. Osler M, Prescott E. Psychosocial, behavioural, and health determinants of successful smoking cessation: a longitudinal study of Danish adults. Tob Control 1998;7:262-7. Crossref
13. Hyland A, Borland R, Li Q, et al. Individual-level predictors of cessation behaviours among participants in the International Tobacco Control (ITC) Four Country Survey. Tob Control 2006;15 Suppl 3:iii83-94. Crossref
14. Haas AL, Muñoz RF, Humfleet GL, Reus VI, Hall SM. Influences of mood, depression history, and treatment modality on outcomes in smoking cessation. J Consult Clin Psychol 2004;72:563-70. Crossref
15. Iliceto P, Fino E, Pasquariello S, D’Angelo Di Paola ME, Enea D. Predictors of success in smoking cessation among Italian adults motivated to quit. J Subst Abuse Treat 2013;44:534-40. Crossref
16. Miller WR, Rollnick S. Talking oneself into change: motivational interviewing, stages of change, and therapeutic process. J Cogn Psychother 2004;18:299-308. Crossref
17. DiClemente CC, Prochaska JO. Toward a comprehensive, transtheoretical model of change: stages of change and addictive behaviors. In: Miller WR, Heather N, editors. Treating addictive behaviors. 2nd ed. New York: Plenum Press; 1998: 3-24.
18. Lai DT, Cahill K, Qin Y, Tang JL. Motivational interviewing for smoking cessation. Cochrane Database Syst Rev 2010;(1):CD006936. Crossref
19. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991;86:1119-27. Crossref
20. Leung DY, Chan SS, Lau CP, Wong V, Lam TH. An evaluation of the psychometric properties of the Smoking Self-Efficacy Questionnaire (SEQ-12) among Chinese cardiac patients who smoke. Nicotine Tob Res 2008;10:1311-8. Crossref
21. Etter JF, Bergman MM, Humair JP, Perneger TV. Development and validation of a scale measuring self-efficacy of current and former smokers. Addiction 2000;95:901-13. Crossref
22. Li L, Borland R, Yong HH, et al. Predictors of smoking cessation among adult smokers in Malaysia and Thailand: findings from the International Tobacco Control Southeast Asia Survey. Nicotine Tob Res 2010;12 Suppl:S34-44. Crossref
23. Yu DK, Wu KK, Abdullah AS, et al. Smoking cessation among Hong Kong Chinese smokers attending hospital as outpatients: impact of doctors’ advice, successful quitting and intention to quit. Asia Pac J Public Health 2004;16:115-20. Crossref
24. Abdullah AS, Yam HK. Intention to quit smoking, attempts to quit, and successful quitting among Hong Kong Chinese smokers: population prevalence and predictors. Am J Health Promot 2005;19:346-54. Crossref
25. Fiore MC, Novotny TE, Pierce JP, Hatziandreu EJ, Patel KM, Davis RM. Trends in cigarette smoking in the United States. The changing influence of gender and race. JAMA 1989;261:49-55. Crossref
26. Piper ME, Cook JW, Schlam TR, et al. Gender, race, and education differences in abstinence rates among participants in two randomized smoking cessation trials. Nicotine Tob Res 2010;12:647-57. Crossref
27. Vangeli E, Stapleton J, Smit ES, Borland R, West R. Predictors of attempts to stop smoking and their success in adult general population samples: a systematic review. Addiction 2011;106:2110-21. Crossref
28. Bjornson W, Rand C, Connett JE, et al. Gender differences in smoking cessation after 3 years in the Lung Health Study. Am J Public Health 1995;85:223-30. Crossref
29. Kim YJ. Predictors for successful smoking cessation in Korean adults. Asian Nurs Res (Korean Soc Nurs Sci) 2014;8:1-7. Crossref
30. Chandola T, Head J, Bartley M. Socio-demographic predictors of quitting smoking: how important are household factors? Addiction 2004;99:770-7. Crossref
31. Abdullah AS, Ho LM, Kwan YH, Cheung WL, McGhee SM, Chan WH. Promoting smoking cessation among the elderly: what are the predictors of intention to quit and successful quitting? J Aging Health 2006;18:552-64. Crossref
32. Curry S, Wagner EH, Grothaus LC. Intrinsic and extrinsic motivation for smoking cessation. J Consult Clin Psychol 1990;58:310-6. Crossref
33. Kim SK, Park JH, Lee JJ, et al. Smoking in elderly Koreans: prevalence and factors associated with smoking cessation. Arch Gerontol Geriatr 2013;56:214-9. Crossref
34. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: A population-based prevalence study. JAMA 2000;284:2606-10. Crossref
35. Covey LS, Glassman AH, Stetner F. Depression and depressive symptoms in smoking cessation. Compr Psychiatry 1990;31:350-4. Crossref
36. Salive ME, Cornoni-Huntley J, LaCroix AZ, Ostfeld AM, Wallace RB, Hennekens CH. Predictors of smoking cessation and relapse in older adults. Am J Public Health 1992;82:1268-71. Crossref
37. Freund KM, D’Agostino RB, Belanger AJ, Kannel WB, Stokes J 3rd. Predictors of smoking cessation: The Framingham Study. Am J Epidemiol 1992;15:957-64.
38. Gwaltney CJ, Metrik J, Kahler CW, Shiffman S. Self-efficacy and smoking cessation: a meta-analysis. Psychol Addict Behav 2009;23:56-66. Crossref
39. Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. Am J Prev Med 2008;35:158-76.
40. Patrick DL, Cheadle A, Thompson DC, Diehr P, Koepsell T, Kinne S. The validity of self-reported smoking, a review and meta-analysis. Am J Public Health 1994;84:1086-93. Crossref

Pages